المؤلفون: Alfonso, Paola, Baena Aristizábal, Yolima, Caro Salas, Carlos Elías, Cepeda Herrera, Milena Cristina, Cetina Barrera, Gloria Rocío, Cortázar Hernández, Tania Milena, Díaz Rojas, Liseth, Forero Rubio, Luisa, Hurtado Medina, Sandra, Jiménez Ariza, Mauricio, Jordana, Francisco, Lozano Álvarez, María Constanza, Martín Reyes, Liliana Astrid, Mier Giraldo, Helen Jhoana, Mora Huertas, Ángela Cristina, Mora Huertas, Claudia Elizabeth, Olaya Osorio, María del Pilar, Pérez Damonte, Silvia H., Perico Franco, Litta Samari, Plazas Bonilla, Clara Eugenia, Reyes Barrios, Luis Humberto, Reyes Goyeneche, Constanza, Rodríguez, Sylvia, Rojas Carrillo, Jhon Wylmer, Rosas Pérez, Jaiver Eduardo, Sarmiento Romero, Sonia Carolina, Rosa Vallejo Díaz, Bibiana Margarita, Valencia Islas, Norma Angélica, Yañez Villamizar, Felix Alonso

المساهمون: Universidad Nacional de Colombia - Departamento de Farmacia - Facultad de Ciencias, Universidad Nacional de Colombia. Sede Bogotá

مصطلحات موضوعية: 610 - Medicina y salud::615 - Farmacología y terapéutica, ARTICULOS DE TOCADOR, COSMETICOS, Toilet preparations, Cosmetics, Evaluación de calidad, Productos cosmeticos, Regulación en la industria cosmetica, Fundamentos fisiológicos, Fundamentos inmunologicos, Fundamentos en toxicología, Evaluación toxicológica, Gestión del riesgo, Gestión documental

وصف الملف: 104 páginas; application/pdf

العلاقة: 2022; Diplomado en Evaluación de la Seguridad de Productos Cosméticos (Safety Assessor Training); Organización de las Naciones Unidas para el Desarrollo Industrial. (2021). Guía para exportar ingredientes naturales para cosméticos a la Unión Europea y Suiza: un paso a paso. GQSP Colombia - Programa de Calidad para la Cadena de Químicos. https://gqspcolombia.org/wp-content/uploads/2021/12Test/ Guia_exportar-ingredientes-naturales_Suiza_UE.pdf; Organización de las Naciones Unidas para el Desarrollo Industrial. (2021). Requisitos de calidad y sostenibilidad para ingredientes naturales en Suiza y la Unión Europea. GQSP Colombia - Programa de Calidad para la Cadena de Químicos. https://gqspcolombia.org/wp-content/uploads/2021/12/Requisitos-de-calidadTest-y-sostenibilidad-IN.pdf; Rados, C. (2006). FDA Law Enforcement: Critical to Product Safety FDA Consumer magazine. The Centennial Edition; January-February 2006. U. S. Food and Drug Administration. https://www.fda.gov/files/FDA-Law-Enforcement--Critical-to-Product-Safety.pdfTest; Acuerdo por el que se determinan las sustancias prohibidas y restringidas en la elaboración de productos de perfumería y belleza [Secretaría de Salud, Estados Unidos Mexicanos]. 21 de mayo de 2010. Diario Oficial de la Federación. https:// dof.gob.mx/nota_detalle.php?codigo=5143790&fecha=21/05/2010#gsc.tab=0; Agência Nacional de Vigilância Sanitária. (2012). Guia para Avaliação de Segurança de Produtos Cosméticos (2.ª ed.). https://www.gov.br/anvisa/pt-brTest/ centraisdeconteudo/publicacoes/cosmeticos/manuais-e-guias/guia-para-avaliacao-de-seguranca-de-produtos-cosmeticos.pdf/view; Association of Southeast Asian Nations. (2022). Guidelines for safety evaluation of cosmetic products. https://www.hsa.gov.sg/docs/default-source/hprgTest/ cosmetic-products/guidance/guidelines-for-the-safety-assessment-of-a-cosmetic-product.pdf; Comieco. (2008). Reglamento Técnico Centroamericano RTCA 71.01.35:06. Productos cosméticos. Registros e inscripción sanitaria de productos cosméticos. Ministerio de Economía (Mineco), Consejo Nacional de Ciencia y Tecnología (conacyt), Ministerio de Fomento, Industria y Comercio (mific), Secretaría de Industria y Comercio (sic), Ministerio de Economía, Industria y Comercio (meic).; Cosmetics Europe. (2004). Guidelines for The Safety Assessment of a Cosmetic Product. https://www.cosmeticseurope.eu/files/3714/6407/8024/Guidelines_for_the_Safety_Assessment_of_a_Cosmetic_Product_-_2004.pdfTest; Decisión 833 de 2018 [Comunidad Andina de Naciones]. Armonización de Legislaciones en materia de Productos Cosméticos. 26 de noviembre de 2018. Gaceta oficial del Acuerdo de Cartagena. Año xxxv – Número 3450.; Decreto 239 de 2003 [Ministerio de Salud de Chile]. Reglamento del sistema nacional de control de cosméticos. 20 de junio de 2003.; Decreto 679 de 2016 [Presidencia de la República de Colombia]. Protección al consumidor – Bien defectuoso. 27 de abril de 2016.; Disposición número DI-2019-2196-APN-ANMAT. Anexo 1 Guía referencial para la evaluación de seguridad de productos cosméticos, higiene personal y perfumes [Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, República Argentina]. 12 de marzo de 2019. https://www.boletinoficialTest. gob.ar/detalleAviso/primera/203264/20190314; Food and Drug Administration. (2021). Cosmetics Recalls & Alerts. U.S. Food and Drug Administration. https://www.fda.gov/cosmeticsTest/ cosmetics-compliance-enforcement/cosmetics-recalls-alerts; Food and Drug Administration. (2022). Regulations Related to Cosmetics from Title 21 of the Code of Federal Regulations (21 CFR). U.S. Food and Drug Administration. https://www.fda.gov/cosmetics/cosmetics-laws-regulationsTest/ regulations-related-cosmetics-title-21-code-federal-regulations-21-cfr; Health Canada. (2008). Health Environments and Consumer Safety Branch; guidance document Classification of Products at the Cosmetic-Drug Interface. Minister of Health Canada. https://www.canada.ca/content/dam/hc-sc/migration/hc-scTest/ cps-spc/alt_formats/hecs-sesc/pdf/pubs/indust/cosmet_drug_guide-drogue_ref/ cosmet_drug_guide-drogue_ref-eng.pdf; Listado de Productos Cosméticos y sus Requerimientos Técnicos [Administración Nacional de Medicamentos, Alimentos y Tecnología Médica]. 9 de diciembre de 2014. http://www.anmat.gov.ar/comunicados/Listado_cosmeticos_10-12-14.pdfTest; Resolución 2108 de 2019 [Comunidad Andina de Naciones]. Reglamento de la Decisión 833: Armonización de Legislaciones en materia de Productos Cosméticos. 14 de noviembre de 2019. Gaceta oficial del Acuerdo de Cartagena. Año xxxvi – Número 3813.; Organización de las Naciones Unidas para el Desarrollo Industrial. (2018). Recomendaciones para el desarrollo de estudios de estabilidad de productos cosméticos. Programa Safe+. https://www.unido.org/sites/default/files/files/2019-02/ONUDI_Gu%C3%ADa%20de%20Estabilidad_FINAL%20Test(003).pdf; Organización de las Naciones Unidas para el Desarrollo Industrial. (2018). Documento de Recomendaciones para el soporte de las proclamas de productos cosméticos. Programa Safe+. https://www.unido.org/sites/default/files/files/2018-04Test/ Guia-de-Proclamas-web.pdf; Personal Care Products Council. (2014). Safety Evaluation Guidelines. https://access-archive.personalcarecouncil.orgTest; Regulation (EC) No 1223/2009 [European Parliament, European Council]. On cosmetic products. 30 de noviembre de 2009. https://eur-lex.europa.euTest/ legal-content/EN/TXT/?uri=CELEX%3A02009R1223-20220301; Scientific Committee on Consumer Safety. (2019). Guidance on the Safety assessment of Nanomaterials in cosmetics. https://health.ec.europa.eu/systemTest/ files/2020-10/sccs_o_233_0.pdf; Scientific Committee on Consumer Safety. (2021). The SCCS notes of guidance for the testing of cosmetic ingredients and their safety evaluation (11.a revisión). https://ec.europa.eu/health/system/files/2021-04/sccs_o_250_0.pdfTest; Agencia Española de Medicamentos y Productos Sanitarios (aemps) y Asociación Nacional de Perfumería y Cosmética (stanpa). (2021). Cosméticos microbiológicamente seguros: Guía para producir materias primas y productos cosméticos seguros desde el punto de vista microbiológico y de la conservación. https://www.aempsTest. gob.es/publicaciones/publica/docs/cosmeticos_seguros-para_ninos_peque.pdf; Cosmetic Ingredient Review. (2022). The Cosmetic Ingredient Review (cir). http://www.cir-safety.orgTest/; European Chemicals Agency. (2022). Agencia Europea de Sustancias Químicas echa. https://echa.europa.eu/es/homeTest; European Commission. (2019). Glossary of common ingredient names. https://eur-lexTest. europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32019D0701&qid=1646063328988; European Commission. (2020). European Commission database for information on cosmetic substances and ingredients – Cosing. http://ec.europa.eu/consumersTest/ cosmetics/cosing/; Food and Drug Administration. (2022). Color Additives Permitted for Use in Cosmetics – cfr Code of Federal Regulations Title 21. U. S. Food and Drug Administration. http://www.fda.gov/Cosmetics/Labeling/IngredientNamesTest/ ucm109084.htm; Food and Drug Administration. (2022). Cosmetics Labeling. Food and Drug Administration. https://www.fda.gov/cosmetics/cosmetics-labelingTest/; Food and Drug Administration. (2022). Part 352. Sunscreens active ingredientes – cfr Code of Federal Regulations Title 21. Food and Drug administration. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearchTest. cfm?CFRPart=352; Food and Drug Administration. (2022). Prohibited & Restricted Ingredients in Cosmetics. U.S. Food and Drug Administration. https://www.fda.gov/cosmeticsTest/ cosmetics-laws-regulations/prohibited-restricted-ingredients-cosmetics; Halla, N., Fernandes, I. P., Heleno, S. A., Costa, P., Boucherit-Otmani, Z., Boucherit, K., Rodrigues, A. E., Ferreira, I. C. y Barreiro, M. F. (2018). Cosmetics Preservation: A Review on Present Strategies. Molecules, 23(7), 1571. https://doiTest. org/10.3390/molecules23071571; International Council for Harmonisation. (2020). ich Q3E: Guideline for Extractables and Leachables (E&L) (Final Concept Paper). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.; International Fragrance Association. (2022). Lista de transparencia de la ifra. https://ifrafragrance.org/priorities/ingredients/ifra-transparency-listTest; Murat, P., Puttaswamy, S., Ferret, P. J., Coslédan, S. y Simon, V. (2020). Identification of Potencial Extractables and Leachables in Cosmetc Plastic Packaging by Microchambers-Thermal Extraction and Pyrolysis-Gas Chromatography-Mass Spectrometry. Molecules, 25(9), 2115. https://doi.org/10.3390/molecules25092115Test.; Noh, I., Kim, N., Tran, H. N., Lee, J. y Lee, C. (2019). 3D printable hyaluronic acid-based hydrogel for its potential application as a bioink in tissue engineering. Biomaterials Research, 23, 3. https://doi.org/10.1186/s40824-018-0152-8Test; Ramírez, J., Parra, J. y Alvarez-Aldana, A. (2017). Análisis de técnicas de recuento de microorganismos. Mente Joven, 6, 1-8. https://revistas.unilibre.eduTest. co/index.php/mente_joven/article/view/3665; Sahu, S. (2019). Biotechnology for Sustainable Utilization of Bioresources. Daya Publishing House.; Scientific Committee on Consumer Safety. (2012). Opinión 1459-11 sccs: Fragrance allergens in cosmetic products; Scientific Committee on Consumer Safety. (2018). Opinión sccs 1589- 17: Skin Sensitisation Quantitative Risk Assessment for Fragrance Ingredients (QRA2).; Scientific Committee on Consumer Safety. (2022). sccs Opinions. http:// ec.europa.eu/health/scientific_committees/consumer_safety/opinions/index_en.htm; Unión Europea. (2022). Eurlex. https://eur-lex.europa.eu/homepageTest. html?locale=es; Bolzinger, M. A., Briançon, S., Pelletier, J. y Chevalier, Y. (2012). Penetration of drugs through skin, a complex rate-controlling membrane. Current Opinion in Colloid & Interface Science, 17(3), 156-165. https://doi.org/10.1016/jTest. cocis.2012.02.001; Haydont, V., Bernard, B. A. y Fortunel, N. O. (2019). Age-related evolutions of the dermis: Clinical signs, fibroblast and extracellular matrix dynamics. Mechanisms of Ageing and Development, 177, 150-156. https://doi.org/10.1016/jTest. mad.2018.03.006; Kabashima, K., Honda, T., Ginhoux, F. y Egawa, G. (2019). The immunological anatomy of the skin. Nature Reviews Immunology, 19, 19-30. https://doiTest. org/10.1038/s41577-018-0084-5; Klaassen, C. (2018). Casarett & Doull’s Toxicology: The Basic Science of Poisons (9.a ed.). McGraw-Hill Eduation; McKnight, G., Shah, J., Hargest, R. (2022). Physiology of the skin. Surgery, 40(1), 8-12. https://doi.org/10.1097/JDN.0b013e3182274a98Test; National Institutes of Health. (2018). Toxicology Risk Assessment. ToxTutor Home. https://www.oraulearning.org/topclass/media/a7ab6ff6-ccb2Test- 4f0c-80ca-7a56b7015f8a/06-001.html; Nosbaum, A., Vocanson, M., Rozieres, A., Henino, A. y Nicolas, J. F. (2009). Allergic and irritant contact dermatitis. European Journal of Dermatology, 19(4), 325-332. https://doi.org/10.1684/ejd.2009.0686Test; Oakley, A. M., Badri, T., Harris, B. W. (2022). Photosensitivity. StatPearls Publishing.; Taherali, F., Varum, F. y Basit. A. W. (2018). A slippery slope: On the origin, role and physiology of mucus. Advanced Drug Delivery Reviews. 124, 16-33. https://doi.org/10.1016/j.addr.2017.10.014Test; Zirwas, M. J. (2019). Contact dermatitis to cosmetics. Clinical Reviews in Allergy & Immunology, 56(1), 119-128. https://doi.org/10.1007/s12016-018-8717-9Test; European Commission y Joint Research Centre. (2019). eurl ecvam dataset on alternative methods to animal experimentation (db-alm). http://data.europaTest. eu/89h/b7597ada-148d-4560-9079-ab0a5539cad3; Lotz, C., Schmid, F. F., Rossi, A., Kurdyn, S., Kampik, D., De Wever, B., Walles, H. y Groeber, F. K. (2016). Alternative methods for the replacement of eye irritation testing. Alternatives to Animal Experimentation, 33(1), 55-67. https:// doi.org/10.14573/altex.1508241; Maxwell, G., MacKay, C., Cubberley, R., Davies, M., Gellatly, N., Glavin, S., Gouin, T., Jacquoilleot, S., Moore, C., Pendlington, R., Saib, O., Sheffield, D., Stark, R. y Summerfield, V. (2014). Applying the skin sensitisation adverse outcome pathway (aop) to quantitative risk assessment. Toxicol In Vitro, 28(1), 8-12. https://doi.org/10.1016/j.tiv.2013.10.013Test; Organisation for Economic Cooperation and Development. (2022). OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects. OECD iLibrary.; Pedrosa, T. D. N., Catarino, C. M., Pennacchi, P. C., Assis, S. R., Gimenes, F., Consolaro, M. E. L., Barros, S. B. M. y Maria-Engler, S. S. (2017). A new reconstructed human epidermis for in vitro skin irritation testing. Toxicology In Vitro, 42, 31-37. https://doi.org/10.1016/j.tiv.2017.03.010Test; Scientific Committee on Consumer Safety. (2021). SCCS Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation (11.a revisión).; Yang, C., Barlow, S. M., Muldoon, K. L., Vitcheva, V., Boobis, A. R., Felter, S. P., Arvidson, K. B., Keller, D., Cronin, M. T. D., Enoch, S., Worth, A. y Hollnagel, H. M. (2017). Thresholds of toxicological concern for cosmetics-related substances: New database, thresholds, and enrichment of chemical space. Food and Chemical Toxicology: an international journal published for the British Industrial Biological Research Association, 109, 170-193. https://doi.org/10.1016/j.fct.2017.08.043Test; Globally Harmonized System of Classification and Labelling of Chemicals. (2022). Sistema globalmente armonizado de clasificación y etiquetado de productos químicos. http://ghs-sga.com/etiquetado-de-productos-quimicosTest-y-fds/ fichas-de-seguridad/; International Cooperation on Cosmetic Regulation. (2011). Report for International Cooperation on Cosmetic Regulation. Principles of Cosmetic Product Safety Assessment. https://www.iccr-cosmetics.org/downloads/topics/2011-05_iccr_principles_of_cosmetic_product_safety_assessment.pdfTest; Li, H., Yuan, H., Middleton, A., Li, J., Nicol, B., Carmichael, P., Guo, J., Peng, S. y Zhang, Q. (2021). Next generation risk assessment (ngra): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (pbk) modelling: A case study of doxorubicin with dose metrics considerations. Toxicol In Vitro. 74, 105171. https://doi.org/10.1016/j.tiv.2021.105171Test; Reglamento (CE) n.o 1272/2008 [Parlamento Europeo, Consejo Europeo]. 16 de diciembre del 2008.; Reglamento (CE) n.o 1907/2006 [Parlamento Europeo, Consejo Europeo]. 18 de diciembre del 2006.; Stewart, S. E., Parker, M. D., Amézquita, A. y Pitt, T. (2016). Microbiological risk assessment for personal care products. International Journal of Cosmetic Sciences, 38(6), 634-645. https://doi.org/10.1111/ics.12338Test; Vtorushina, A. N., Larionovam E. V., Mezenceva, I. L. y Nikonova, E. D. (2017). Risk Assessment at the Cosmetic Product Manufacturer by Expert Judgment Method. IOP Conference Series: Earth and Environmental Science, 66, 012023. https://doi.org/10.1088/1755-1315/66/1/012023Test; Carmichael, P. L., Baltazar, M. T., Cable, S., Cochrane, S., Dent, M., Li, H., Middleton, A., Muller, I., Reynolds, G., Westmoreland, C. y White, A. (2022). Ready for regulatory use: nam and ngra for chemical safety assurance. ALTEX, 39(3), 359-366. https://doi.org/10.14573/altex.2204281Test; Danish Environmental Protection Agency. (2022). Endocrine Disruptor List. https://edlists.orgTest/; European Chemicals Agency. (2022). Endocrine disruptor assessment list. https://echa.europa.eu/es/ed-assessmentTest; Miller, M. R. y Poland, C. A. (2020). Nanotoxicology: The Need for a Human Touch? Small. 16(36), e2001516. https://doi.org/10.1002/smll.202001516Test; Toklu, H. Z., Antigua, A., Lewis, V., Reynolds, M. y Jones, J. (2019). Cosmetovigilance: A review of the current literature. Journal of Family Medicine and Primary Care, 8(5),1540-1545. https://doi.org/10.4103/jfmpc.jfmpc_447_18Test; Yilmaz, B., Terekeci, H., Sandal, S. y Kelestimur, F. (2020). Endocrine disrupting chemicals: exposure, effects on human health, mechanism of action, models for testing and strategies for prevention. Reviews in Endocrine and Metabolic Disorder, 21(1), 127-147. https://doi.org/10.1007/s11154-019-09521-zTest; https://repositorio.unal.edu.co/handle/unal/84072Test; Universidad Nacional de Colombia; Repositorio Institucional Universidad Nacional de Colombia; https://repositorio.unal.edu.coTest/

الإتاحة: https://doi.org/10.3390/molecules23071571Test
https://doi.org/10.3390/molecules25092115Test
https://doi.org/10.1186/s40824-018-0152-8Test
https://doi.org/10.1016/jTest
https://doi.org/10.1038/s41577-018-0084-5Test
https://doi.org/10.1097/JDN.0b013e3182274a98Test
https://doi.org/10.1684/ejd.2009.0686Test
https://doi.org/10.1016/j.addr.2017.10.014Test
https://doi.org/10.14573/altex.1508241Test
https://doi.org/10.1016/j.tiv.2013.10.013Test

المؤلفون: García Bustos, Manuel Arturo

المساهمون: Pinilla Roa, Análida Elizabeth, García Bustos, Manuel (0000-0002-7383-0756)

مصطلحات موضوعية: 610 - Medicina y salud::613 - Salud y seguridad personal, 610 - Medicina y salud::616 - Enfermedades, 610 - Medicina y salud::615 - Farmacología y terapéutica, 370 - Educación::374 - Educación de adultos, Prevention control, Prevención y control, Diabetes, Diabetes Mellitus Tipo 2, Educación, Herramientas Digitales, Prevención Secundaria, Prevención Primaria, Diabetes Mellitus Type 2, Education, Digital Tools, Secondary Prevention, Primary Prevention

وصف الملف: 106 páginas; application/pdf

العلاقة: Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ [Internet]. 2000;321(7258):412–9. Disponible en: http://dx.doi.org/10.1136/bmj.321.7258.41Test; Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int [Internet]. 2003;63(1):225–32. Disponible en: http://dx.doi.org/10.1046/j.1523-1755.2003.00712.xTest; American Diabetes Association. (2022). STANDARDS OF MEDICAL CARE IN DIABETES—2022. Diabetes Care, 45, 1-263. Disponible en: https://diabetesjournals.org/care/issue/45/Supplement_1https://ada.silverchair-cdn.com/ada/content_public/journal/care/issue/45/supplement_1/10/standards-of-care-2022-copyright-stamped-updated-01062022.pdf?Expires=1676169358&Signature=LtgGFYEtoPfWV4GxvhPaMT~vJfbs8v5upgSW-2fCvSq1YNgGxXMnGIjoifjuwlB9hNHM0DldrmNMobOgRt-e5b63swVJw6xCf0BWBXmsfZk8m0gVdU-1vL3jT2F11MTL2nzZAyNPF5nOHfyau8x~BWi1zvxO48yExEfvXCpI8q15tmDgOCV-qgGUdDJstw2qxhkga9Uy1GQuSZaSJmKHalxfcsIHaIcHr0z5bQyJjCGRT9YIxalpFMWgXx17sxLDFgfTWYLlwOrbZLAEV~omKmKFfPv3lQiGdnNCPo2wsw3kScLElZwoHl3jv-Gjv73qvEoRgOf22E-dX~AJvsdxaQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGATest; Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet [Internet]. 2018;391(10117):219–29. Disponible en: http://dx.doi.org/10.1016/s0140-6736Test(17)32409-1; Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab [Internet]. 2013;39(5):445-53. Disponible en: http://dx.doi.org/10.1016/j.diabet.2013.05.006Test; Brown HS 3rd, Wilson KJ, Pagán JA, Arcari CM, Martinez M, Smith K, et al. Cost-effectiveness analysis of a community health worker intervention for low-income Hispanic adults with diabetes. Prev Chronic Dis [Internet]. 2012;9(120074):E140. Disponible en: http://dx.doi.org/10.5888/pcd9.120074Test; Burger KNJ, Beulens JWJ, van der Schouw YT, Sluijs I, Spijkerman AMW, Sluik D, et al. Dietary fiber, carbohydrate quality and quantity, and mortality risk of individuals with diabetes mellitus. PLoS One [Internet]. 2012;7(8):e43127. Disponible en: http://dx.doi.org/10.1371/journal.pone.0043127Test; Bus SA, Lavery LA, Monteiro-Soares M, Rasmussen A, Raspovic A, Sacco ICN, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev [Internet]. 2020;36 Suppl 1(S1):e3269. Disponible en: http://dx.doi.org/10.1002/dmrr.3269Test; Cahn A, Akirov A, Raz I. Digital health technology and diabetes management: 数字化医疗技术与糖尿病管理. J Diabetes [Internet]. 2018;10(1):10–7. Disponible en: http://dx.doi.org/10.1111/1753-0407.12606Test; Carmena R, Ascaso JF, Redon J. Chronic kidney disease as a cardiovascular risk factor. J Hypertens [Internet]. 2020;38(11):2110–21. Disponible en: http://dx.doi.org/10.1097/HJH.0000000000002506Test; Muñoz O, García A, Arteaga J, Vallejo GS, Yabrudy YV, Gomez CL, et al. Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias en la población mayor de 18 años, Sistema General de Seguridad Social en Salud-Colombia, [Internet]. Ministerio de Salud. 2014 guía No. 27. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IETS/GPC-Dislipidemi-completa.pdfTest; Chatterjee S, Davies MJ, Heller S, Speight J, Snoek FJ, Khunti K. Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol [Internet]. 2018;6(2):130–42. Disponible en: http://dx.doi.org/10.1016/S2213-8587Test(17)30239-5; Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs [Internet]. 2013;73(4):327–39. Disponible en: http://dx.doi.org/10.1007/s40265-013-0023-5Test; Chiavaroli L, Viguiliouk E, Nishi SK, Blanco Mejia S, Rahelić D, Kahleová H, et al. DASH dietary pattern and cardiometabolic outcomes: An umbrella review of systematic reviews and meta-analyses. Nutrients [Internet]. 2019;11(2):338. Disponible en: http://dx.doi.org/10.3390/nu11020338Test; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet [Internet]. 2008;371(9607):117–25. Disponible en: http://dx.doi.org/10.1016/s0140-6736Test(08)60104-x; Church TS, Thompson AM, Katzmarzyk PT, Sui X, Johannsen N, Earnest CP, et al. Metabolic syndrome and diabetes, alone and in combination, as predictors of cardiovascular disease mortality among men. Diabetes Care [Internet]. 2009;32(7):1289–94. Disponible en: http://dx.doi.org/10.2337/dc08-1871Test; Cochran J, Conn VS. Meta-analysis of quality of life outcomes following diabetes self-management training. Diabetes Educ [Internet]. 2008;34(5):815–23. Disponible en: http://dx.doi.org/10.1177/0145721708323640Test; Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J [Internet]. 2020;41(2):255–323. Disponible en: http://dx.doi.org/10.1093/eurheartj/ehz486Test; Censo Nacional de Población y Vivienda 2019 [Internet]. Gov.co. Disponible en: https://sitios.dane.gov.co/cnpv/app/views/informacion/fichas/11.pdfTest; Davis J, Fischl AH, Beck J, Browning L, Carter A, Condon JE, et al. 2022 National Standards for Diabetes Self-Management Education and Support. Sci Diabetes Self Manag Care [Internet]. 2022;48(1):44-59. Disponible en: http://dx.doi.org/10.1177/26350106211072203Test; Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, Mohan V, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet [Internet]. 2017;390(10107):2050–62. Disponible en: http://dx.doi.org/10.1016/s0140-6736Test(17)32252-3; Dempsey PC, Larsen RN, Sethi P, Sacre JW, Straznicky NE, Cohen ND, et al. Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities. Diabetes Care [Internet]. 2016;39(6):964–72. Disponible en: http://dx.doi.org/10.2337/dc15-2336Test; The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care [Internet]. 1999;22(4):623–34. Disponible en: http://dx.doi.org/10.2337/diacare.22.4.623Test; Dong J-Y, Zhang Z-L, Wang P-Y, Qin L-Q. Effects of high-protein diets on body weight, glycaemic control, blood lipids and blood pressure in type 2 diabetes: meta-analysis of randomised controlled trials. Br J Nutr [Internet]. 2013;110(5):781–9. Disponible en: http://dx.doi.org/10.1017/S0007114513002055Test; Down S, Kirkland F. Injection technique in insulin therapy. Nurs Times [Internet]. 2012;108(10):18, 20–1. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22479839Test/; Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, et al. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern Med [Internet]. 2013;173(18):1682–92. Disponible en: http://dx.doi.org/10.1001/jamainternmed.2013.9051Test; Dunkler D, Kohl M, Heinze G, Teo KK, Rosengren A, Pogue J, et al. Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. Kidney Int [Internet]. 2015;87(4):784–91. Disponible en: http://dx.doi.org/10.1038/ki.2014.370Test; Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis: A systematic review and meta-analysis. JAMA [Internet]. 2015;313(6):603–15. Disponible en: http://dx.doi.org/10.1001/jama.2014.18574Test; Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin Olive oil or nuts. N Engl J Med [Internet]. 2018;378(25):e34. Disponible en: http://dx.doi.org/10.1056/NEJMoa1800389Test; Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK, MacLeod J, et al. Nutrition therapy for adults with diabetes or prediabetes: A consensus report. Diabetes Care [Internet]. 2019;42(5):731–54. Disponible en: http://dx.doi.org/10.2337/dci19-0014Test; Faruque LI, Wiebe N, Ehteshami-Afshar A, Liu Y, Dianati-Maleki N, Hemmelgarn BR, et al. Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials. CMAJ [Internet]. 2017;189(9):E341–64. Disponible en: http://dx.doi.org/10.1503/cmaj.150885Test; Franz MJ. Diabetes nutrition therapy: Effectiveness, macronutrients, eating patterns and weight management. Am J Med Sci [Internet]. 2016;351(4):374–9. Disponible en: http://dx.doi.org/10.1016/j.amjms.2016.02.001Test; Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet [Internet]. 2015;115(9):1447–63. Disponible en: http://dx.doi.org/10.1016/j.jand.2015.02.031Test; Funnell MM, Bootle S, Stuckey HL. The diabetes attitudes, wishes and needs second study. Clin Diabetes [Internet]. 2015;33(1):32–6. Disponible en: http://dx.doi.org/10.2337/diaclin.33.1.32Test; Gordon BA, Benson AC, Bird SR, Fraser SF. Resistance training improves metabolic health in type 2 diabetes: a systematic review. Diabetes Res Clin Pract [Internet]. 2009;83(2):157–75. Disponible en: http://dx.doi.org/10.1016/j.diabres.2008.11.024Test; Escalante Gutiérrez D, Lecca García L, Gamarra Sánchez J, Escalante Gutiérrez G. Amputación del miembro inferior por pie diabético en hospitales de la costa norte peruana 1990 - 2000: características clínico-epidemiológicas. Rev Peru Med Exp Salud Publica [Internet]. 2003;20(3):138–44. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342003000300005Test; Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary. Endocr Pract [Internet]. 2020;26(10):1196–224. Disponible en: http://dx.doi.org/10.4158/CS-2020-0490Test; Healy SJ, Black D, Harris C, Lorenz A, Dungan KM. Inpatient diabetes education is associated with less frequent hospital readmission among patients with poor glycemic control. Diabetes Care [Internet]. 2013;36(10):2960–7. Disponible en: http://dx.doi.org/10.2337/dc13-0108Test; Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol [Internet]. 2018;14(6):491–509. Disponible en: http://dx.doi.org/10.2217/fca-2018-0045Test; Hicks D, Kirkland F, Pledger J, Down S. Optimising injection technique in diabetes. The first UK injection technique recommendations 2010 [Internet]. Fit4diabetes.com. Disponible en: http://fit4diabetes.com/files/2613/3102/3031/FIT_Recommendations_Document.pdfTest; Hill MD. Stroke and diabetes mellitus. Handb Clin Neurol [Internet]. 2014;126:167–74. Disponible en: http://dx.doi.org/10.1016/B978-0-444-53480-4.00012-6Test; Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med [Internet]. 2008;359(15):1577–89. Disponible en: http://dx.doi.org/10.1056/NEJMoa0806470Test; Houmard JA, Tanner CJ, Slentz CA, Duscha BD, McCartney JS, Kraus WE. Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol [Internet]. 2004;96(1):101–6. Disponible en: http://dx.doi.org/10.1152/japplphysiol.00707.2003Test; Kanaley JA, Colberg SR, Corcoran MH, Malin SK, Rodriguez NR, Crespo CJ, et al. Exercise/physical activity in individuals with type 2 diabetes: A consensus statement from the American College of Sports Medicine. Med Sci Sports Exerc [Internet]. 2022;54(2):353–68. Disponible en: http://dx.doi.org/10.1249/MSS.0000000000002800Test; Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J [Internet]. 1985;110(5):1100–7. Disponible en: http://dx.doi.org/10.1016/0002-8703Test(85)90224-8; Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. VOLUME 3, ISSUE 1, JANUARY 2013;7-163.[Internet]. Kdigo.org. Disponible en: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdfTest; Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med [Internet]. 2002;346(6):393–403. Disponible en: http://dx.doi.org/10.1056/NEJMoa012512Test; Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Sato M, et al. Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. Diabetes Care [Internet]. 2009;32(5):959–65. Disponible en: http://dx.doi.org/10.2337/dc08-1716Test; Kriska AM, Rockette-Wagner B, Edelstein SL, Bray GA, Delahanty LM, Hoskin MA, et al. The impact of physical activity on the prevention of type 2 diabetes: Evidence and lessons learned from the Diabetes Prevention Program, a long-standing clinical trial incorporating subjective and objective activity measures. Diabetes Care [Internet]. 2021;44(1):43–9. Disponible en: http://dx.doi.org/10.2337/dc20-1129Test; Lazarte J, Hegele RA. Dyslipidemia management in adults with diabetes. Can J Diabetes [Internet]. 2020;44(1):53–60. Disponible en: http://dx.doi.org/10.1016/j.jcjd.2019.07.003Test; Lee AK, Warren B, Lee CJ, McEvoy JW, Matsushita K, Huang ES, et al. The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care [Internet]. 2018;41(1):104–11. Disponible en: http://dx.doi.org/10.2337/dc17-1669Test; Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care [Internet]. 2010;33(8):1872–94. Disponible en: http://dx.doi.org/10.2337/dc10-0843Test; Lindström J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care [Internet]. 2003;26(12):3230–6. Disponible en: http://dx.doi.org/10.2337/diacare.26.12.3230Test; Liu Y, Ye W, Chen Q, Zhang Y, Kuo C-H, Korivi M. Resistance exercise intensity is correlated with attenuation of HbA1c and insulin in patients with type 2 diabetes: A systematic review and meta-analysis. Int J Environ Res Public Health [Internet]. 2019;16(1):140. Disponible en: http://dx.doi.org/10.3390/ijerph16010140Test; Maddigan SL, Feeny DH, Johnson JA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res [Internet]. 2005;14(5):1311–20. Disponible en: http://dx.doi.org/10.1007/s11136-004-6640-4Test; Malave H, Castro M, Burkle J, Voros S, Dayspring T, Honigberg R, et al. Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol; McGrath K, Edi R. Diabetic kidney disease: Diagnosis, treatment, and prevention. Am Fam Physician. 2019;99(12):751–9. Disponible en:https://pubmed.ncbi.nlm.nih.gov/31194487Test/; Johanna A, Tolosa A, Lilian A. Análisis de situación de Salud(ASIS) Colombia, 2019. Gov.co. 2019; 15-264. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PSP/asis-2019-colombia.pdfTest; Miranda C, Da Ros R, Marfella R. Update on prevention of diabetic foot ulcer. Arch Med Sci Atheroscler Dis [Internet]. 2021;6(1):e123–31. Disponible en: http://dx.doi.org/10.5114/amsad.2021.107817Test; Monami M, Zannoni S, Gaias M, Nreu B, Marchionni N, Mannucci E. Effects of a short educational program for the prevention of foot ulcers in high-risk patients: A randomized controlled trial. Int J Endocrinol [Internet]. 2015;2015:615680. Disponible en: http://dx.doi.org/10.1155/2015/615680Test; Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS, et al. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med [Internet]. 2016;165(7):473. Disponible en: http://dx.doi.org/10.7326/m16-0273Test; Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med [Internet]. 1993;329(14):977–86. Disponible en: http://dx.doi.org/10.1056/NEJM199309303291401Test; Nathan DM, Cleary PA, Backlund J-YC, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med [Internet]. 2005;353(25):2643–53. Disponible en: http://dx.doi.org/10.1056/NEJMoa052187Test; Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care [Internet]. 2008;31(8):1473–8. Disponible en: http://dx.doi.org/10.2337/dc08-0545Test; Diabetes [Internet]. Who.int. [citado el 15 de enero de 2023]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/diabetesTest; Researchgate.net. [citado el 15 de enero de 2023]. Disponible en: https://www.researchgate.net/profile/Don-Nutbeam/publication/12979284_The_WHO_health_promotion_glossary/links/542022590cf203f155c2aa6e/The-WHO-health-promotion-glossary.pdfTest; Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation [Internet]. 2012;125(20):2469–78. Disponible en: http://dx.doi.org/10.1161/CIRCULATIONAHA.111.073684Test; Peña AP, Venegas BC, Obando JA. Educación en salud para promover autocuidado en personas con Diabetes tipo 2 durante su hospitalización. Univ Salud [Internet]. 2020;22(3):246–55. Disponible en: http://dx.doi.org/10.22267/rus.202203.197Test; Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J [Internet]. 2016;37(29):2315–81. Disponible en: http://dx.doi.org/10.1093/eurheartj/ehw106Test; Pinilla AE, Sánchez AL, Mejía A, Barrera M del P. Actividades de prevención del pie diabético en pacientes de consulta externa de primer nivel. Rev Salud Pública (Bogotá) [Internet]. 2011;13(2):262-73. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0124-00642011000200008&lng=es&nrm=is&tlng=esTest; Pinilla AE, Barrera M del P, Sánchez AL, Mejía A. Factores de riesgo en diabetes mellitus y pie diabético: un enfoque hacia la prevención primaria. Rev Colomb Cardiol [Internet]. 2013;20(4):213–22. Disponible en: http://dx.doi.org/10.1016/s0120-5633Test(13)70058-5; Pinilla AE, Barrera M del P, Devia C, Devia D. Actividades de prevención y factores de riesgo en diabetes mellitus y pie diabético. Acta Med Colombiana [Internet]. 2014;39(3):250–7. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0120-24482014000300008&lng=en&nrm=iso&tlng=esTest; Pinilla-Roa AE, Barrera-Perdomo MDP. Prevención en diabetes mellitus y riesgo cardiovascular: enfoque médico y nutricional. Rev Fac Med Univ Nac Colombia [Internet]. 2018;66(3):459–68. Disponible en: http://dx.doi.org/10.15446/revfacmed.v66n3.60060Test; Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Fischl AH, et al. Diabetes self-management education and support in type 2 diabetes: A joint position statement of the American diabetes association, the American association of diabetes educators, and the academy of nutrition and dietetics. J Acad Nutr Diet [Internet]. 2015;115(8):1323–34. Disponible en: http://dx.doi.org/10.1016/j.jand.2015.05.012Test; Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Fischl AH, et al. Diabetes self-management education and support in type 2 diabetes: A joint position statement of the American diabetes association, the American association of diabetes educators, and the academy of nutrition and dietetics. Clin Diabetes [Internet]. 2016;34(2):70–80. Disponible en: http://dx.doi.org/10.2337/diaclin.34.2.70Test; Ortiz-Roa C, Pinilla-Roa AE. Efecto de la lipohipertrofia en el control metabólico de pacientes con diabetes mellitus tipo 2. Rev Fac Med Univ Nac Colombia [Internet]. 2017;65(4):697–701. Disponible en: http://dx.doi.org/10.15446/revfacmed.v65n4.53108Test; Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med [Internet]. 2001;344(1):3–10. Disponible en: http://dx.doi.org/10.1056/NEJM200101043440101Test; Salas-Salvadó J, Bulló M, Estruch R, Ros E, Covas M-I, Ibarrola-Jurado N, et al. Prevention of diabetes with Mediterranean diets: A subgroup analysis of a randomized trial. Ann Intern Med [Internet]. 2014;160(1):1–10. Disponible en: http://dx.doi.org/10.7326/m13-1725Test; Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet [Internet]. 2010;375(9733):2215–22. Disponible en: http://dx.doi.org/10.1016/S0140-6736Test(10)60484-9; Sawada T, Tsubata H, Hashimoto N, Takabe M, Miyata T, Aoki K, et al. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial. Cardiovasc Diabetol [Internet]. 2016;15(1):121. Disponible en: http://dx.doi.org/10.1186/s12933-016-0437Test-y; Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med [Internet]. 2008;359(3):229-41. Disponible en: http://dx.doi.org/10.1056/NEJMoa0708681Test; Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C. Physical activity/exercise and type 2 diabetes. Diabetes Care [Internet]. 2004;27(10):2518–39. Disponible en: http://dx.doi.org/10.2337/diacare.27.10.2518Test; Sigal RJ, Kenny GP, Boulé NG, Wells GA, Prud’homme D, Fortier M, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: A randomized trial. Ann Intern Med [Internet]. 2007;147(6):357. Disponible en: http://dx.doi.org/10.7326/0003-4819-147-6-200709180-00005Test; Sluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Johnsen NF, et al. Physical activity and mortality in individuals with diabetes mellitus: A prospective study and meta-analysis: A prospective study and meta-analysis. Arch Intern Med [Internet]. 2012;172(17):1285–95. Disponible en: http://dx.doi.org/10.1001/archinternmed.2012.3130Test; Steinsbekk A, Rygg L, Lisulo M, Rise MB, Fretheim A. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis. BMC Health Serv Res [Internet]. 2012;12(1). Disponible en: http://dx.doi.org/10.1186/1472-6963-12-213Test; Trento M, Passera P, Bajardi M, Tomalino M, Grassi G, Borgo E, et al. Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial. Diabetologia [Internet]. 2002;45(9):1231–9. Disponible en: http://dx.doi.org/10.1007/s00125-002-0904-8Test; Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet [Internet]. 1998 [citado el 14 de enero de 2023];352(9131):854–65. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9742977Test/; Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9742976Test/; Umpierrez G, Korytkowski M. Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol [Internet]. 2016;12(4):222–32. Disponible en: http://dx.doi.org/10.1038/nrendo.2016.15Test; Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: Analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up: Analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation [Internet]. 2017;136(20):1878–91. Disponible en: http://dx.doi.org/10.1161/CIRCULATIONAHA.117.027966Test; Weisman A, Fazli GS, Johns A, Booth GL. Evolving trends in the epidemiology, risk factors, and prevention of type 2 diabetes: A review. Can J Cardiol [Internet]. 2018;34(5):552–64. Disponible en: http://dx.doi.org/10.1016/j.cjca.2018.03.002Test; Wheeler ML, Dunbar SA, Jaacks LM, Karmally W, Mayer-Davis EJ, Wylie-Rosett J, et al. Macronutrients, food groups, and eating patterns in the management of diabetes. Diabetes Care [Internet]. 2012;35(2):434–45. Disponible en: http://dx.doi.org/10.2337/dc11-2216Test; Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care [Internet]. 2011;34(7):1481–6. Disponible en: http://dx.doi.org/10.2337/dc10-2415Test; Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med [Internet]. 2013;369(2):145–54. Disponible en: http://dx.doi.org/10.1056/NEJMoa1212914Test; Wong Y, Cheung CMG, Larsen M, Sharma S, Simó R. Diabetic retinopathy. Nat Rev Dis Primers [Internet]. 2016;2:16012. Disponible en: http://dx.doi.org/10.1038/nrdp.2016.12Test; Yu Z, Nan F, Wang LY, Jiang H, Chen W, Jiang Y. Effects of high-protein diet on glycemic control, insulin resistance and blood pressure in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr [Internet]. 2020;39(6):1724–34. Disponible en: http://dx.doi.org/10.1016/j.clnu.2019.08.008Test; van Zuuren EJ, Fedorowicz Z, Kuijpers T, Pijl H. Effects of low-carbohydrate- compared with low-fat-diet interventions on metabolic control in people with type 2 diabetes: a systematic review including GRADE assessments. Am J Clin Nutr [Internet]. 2018;108(2):300–31. Disponible en: http://dx.doi.org/10.1093/ajcn/nqy096Test; https://repositorio.unal.edu.co/handle/unal/83208Test; Universidad Nacional de Colombia; Repositorio Institucional Universidad Nacional de Colombia; https://repositorio.unal.edu.coTest/

الإتاحة: https://doi.org/10.1136/bmj.321.7258.41Test
https://doi.org/10.1046/j.1523-1755.2003.00712.xTest
https://doi.org/10.1016/s0140-6736Test(17)32409-1
https://doi.org/10.1016/j.diabet.2013.05.006Test
https://doi.org/10.5888/pcd9.120074Test
https://doi.org/10.1371/journal.pone.0043127Test
https://doi.org/10.1002/dmrr.3269Test
https://doi.org/10.1111/1753-0407.12606Test
https://doi.org/10.1097/HJH.0000000000002506Test
https://doi.org/10.1016/S2213-8587Test(17)30239-5

المؤلفون: Quintero Daza, Carolina

المساهمون: Mercado Pedroza, Manuel Esteban, Casas Del Rio, Gloria Helena

مصطلحات موضوعية: 610 - Medicina y salud::616 - Enfermedades, 610 - Medicina y salud::615 - Farmacología y terapéutica, Calcarea Carbonica/uso terapéutico, Trastornos de Cefalalgia, Terapias Asociadas a la Homeopatía, Estudio Observacional, Calcarea Carbonica/therapeutic use, Headache Disorders, Therapies Associated with Homeopathy, Observational Study, Cefalea crónica, Homeopatía, Calcárea carbónica, Reporte de caso, Unicista, Chronic headache, Homeopathy, Carbonic calcarea, Case report

وصف الملف: 73 páginas; application/pdf

العلاقة: Bireme; Arnold, M. (2018). Headache classification committee of the international headache society (IHS) the international classification of headache disorders. Cephalalgia, 38, 1-211; Avello, M., Avendaño, C., & Mennickent, S. (2009). Aspectos generales de la homeopatía. Revista médica de Chile, 137(1), 115-120.; Barros-St. Pasteur J. Homeopatía: Medicina del Terreno. Ediciones de la Biblioteca. Universidad Central de Venezuela, Caracas, 1977; 17-22; Bustos Sánchez, J. L., Jurado López, S. P., Aroca Posso, A., Márquez Rosales, B. A., Alonso Niño, M. A., Hoyos Gómez, L. K., . & Fernández-Ávila, D. G. 2023). Principales patologías diagnosticadas por el servicio de neurología en urgencias; Demarque, D., Jouanny, J., Poitevin, B., & Jean Y., S. (1997). Farmacología y materia médica. Ediciones CEDH.; Draiman, M. (1999). LAS PERSONALIDADES HOMEOPÁTICAS. Editorial argentina.; Eizayaga, F. X. (1981). Tratado de medicina homeopática. In tratado de medicina homeopática. Marecel; Eizayaga, F. X. (1991). El moderno repertorio de Kent. in El moderno repertorio de kent. Marecel; Fudacion Instituto Colombiano De Homeopatia Luis G. Paez. Fundamentos Toricos De La Homeopatia. Bogota 2014; García, L. R. R., Torres, M. H., Rodríguez, K. C. C., & Orduño, A. C. (2016). Algunas consideraciones sobre miasma y homeopatía. Medisan, 20(12), 6090-7001; Gómez, M. (2008). Cefalea tipo tensional: diagnóstico, fisiopatología y tratamiento. Acta Neurol Colomb. 24(3), S14- S27; Góngora Gómez, O., & Cruz Batista, M. (2020). Importancia de la repertorización en homeopatía. Revista Cubana de Medicina General Integral; González F. Introducción a la Homeopatía. En: Instituto Luis G. Páez. Fundamentos teóricos de la Homeopatia. Bogotá: Comité de Publicaciones de la Fundación Instituto Colombiano de Homeopatía Luis G. Páez; 2014. p. 20-36.; Hahnemann, S. (1845). Las enfermedades crónicas, su naturaleza específica y su tratamiento homeopático. Asturias, Asturias.; Jiménez, M. K. V. (2018) Cefalea cónica diaria y neuralgias craneales. Cuidados paliativos y de soporte 2018; Kent, J. T. (1989). Materia médica homeopática. In maeira médica Homeopática. Albatros.; Lathoud, J. A. (1987). Materia médica homeopática. In Materia Medica Homeopatica. Albatros.; Levin, M. (2013). The international classification of Headache Disorders, (ICHD III)- Changes and Challenges. Headache: The Journal of Head and Face Pain, 1383- 1395.; López-Bravo A., Bellosta-Diago E., Viloria-Alebesque A., Marín-Gracia M., Laguna-Sarriá J., . Santos-Lasaosa S, (2021) Headache as a reason for consultation: the primary care perspective neurología. Volume 36, Issue 8, October 2021, Pages 597-602; Medrano, V., Genovés, A., & Esquembre, R. (2007). ¿Supone la cefalea una sobrecarga asistencial en atención primaria? Kranion, 7, 12- 16.; Ministerio de Salud de Colombia. Lineamientos técnicos para la articulación de las medicinas y las terapias alternativas y complementarias, en el marco del sistema general de seguridad social en salud [Internet]. Documento marco para la acción sectorial e intersectorial Ministerio de Salud y Protección Social. Mesa de Trabajo en Medicinas y las Terapias Alternativas y Complementarias; 2018 p. 73. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/TH/lineamientos-mtac-sgsss.pdfTest; Nash, E. B. (1989). Fundamentos terapéutica homeopática. Buenos Aires. : F.D.T.; Pascual J. (2019), Cefalea y migraña, Medicine - Programa de Formación Médica Continuada Acreditado, Volume 12, Issue 71, 2019, Pages 4145-4153, ISSN 0304-5412; Ortiz M. J. (2016) Cefalea tensional y homeopatía. Monografía. Bogotá Universidad Nacional de Colombia; 2016.; Penié, J. B. (2000). La historia clínica: documento científico del médico. Ateneo, 1, 50-55.; Pérez R, Sanchez F, Jimenez M. (2019) Cefalea Tensional. In: Grupo de Estudio de Cefaleas de la Sociedad Andaluza de Neurología (SANCE). Guía oficial de cefaleas 2019 [Internet]. Madrid: Medea, Medical Education Agency S.L.; 2019. 62–74; Pirra G. (2008) Órganon del Arte de Curar, en búsqueda del pensamiento original de Hahnemann. Edición Argentina. Buenos Aires: 2008 p. 35.; Rosero Paredes, S. J. (2018). Caracterización de la cefalea en pacientes hospitalizados en el Hospital Universitario Nacional de Colombia. Departamento de Medicina Interna.; Santos, A. K. L., Feitosa, H., Silva, S. F., Barros, M. M. M. B., de Oliveira Ferro, J. K., de Oliveira Souza, A. I. S., & de Oliveira, D. A. (2018). Functionality changes of migraine women. Headache Medicine, 183-189.; Schmidt, P. (2001). El arte de interrogar. B. Jain Publishers.; Urrego Mendoza, D. Z. (2010). Abordaje de la Medicina Alternativa como sistema médico complejo en la Universidad Nacional de Colombia. Revista de la Facultad de Medicina, p, 155-156.; Urrego Mendoza, D., Beltran Dussán, E., Martilletti, A., Casas del Río, G. H., Ruiz Díaz, P., & Vega Oviedo, J. A. (2011). La medicina alternativa: una visión desde los sistemas médicos complejos. Bogotá: Universidad Nacional de Colombia.; Vázquez, M. M., Pérez, R. L., Romero, F. V., Cobo, C. J., Parra, M. J., Camello, A. G., & Oria, C. G. (2022). Análisis de la situación actual de la cefalea en Andalucía. Neurología.; Vincent M, Wang S. (2018) The International Classification of Headache Disorders, third edition. Cephalalgia. 2018; 38:1–211.; Vijnovsky B. (1974) Tratado de Materia Medica Homeopatica. Buenos aires: Editorial Provisional; Visens, L. S. (2014). Actualización en la prevención y tratamiento de la migraña. Medicina (Buenos Aires), p, 147-157.; World Health Organization, Lifting the Burden (2011) Atlas of headache disorders and resources in the world 2011. Geneva: WHO; https://repositorio.unal.edu.co/handle/unal/86365Test; Universidad Nacional de Colombia; Repositorio Institucional Universidad Nacional de Colombia; https://repositorio.unal.edu.coTest/

الإتاحة: https://repositorio.unal.edu.co/handle/unal/86365Test
https://repositorio.unal.edu.coTest/

المؤلفون: Carvajal Barbosa, Laura

المساهمون: Aragón Novoa, Diana Marcela, Sistemas Para Liberación Controlada de Moléculas Biológicamente Activas

مصطلحات موضوعية: 540 - Química y ciencias afines::542 - Técnicas, procedimientos, aparatos, equipos, materiales, 610 - Medicina y salud::615 - Farmacología y terapéutica, Carbamazepina/síntesis química, Disolución, Técnicas In Vitro/métodos, Carbamazepine/chemical synthesis, Dissolution, In Vitro Techniques/methods, Correlación in vivo in vitro, Carbamazepina, Método de disolución, Liberación modificada, Aparato de disolución USP 4, Celda de flujo, In vivo in vitro correlation, Carbamazepine, Dissolution method, Modified release, Dissolution apparatus USP 4, Flow-through cell

وصف الملف: x,x, 111 páginas; application/pdf

العلاقة: Bireme; Aguilar Ros, A., Caamaño Somoza, Manuel., Martín Martín, F. R., & Montejo Rubio, M. Consuelo. (2014). Biofarmacia y farmacocinética : ejercicios y problemas resueltos (B. Elsevier, Ed.; 2nd ed.). https://bibliotecadigital.uchile.cl/discovery/fulldisplay?docid=alma991002291699703936&context=L&vid=56UDC_INST:56UDC_INST&lang=es&adaptor=Local%20Search%20Engine&tab=Everything&query=sub,exact,%20Tecnologi%CC%81a%20farmace%CC%81utica,AND&mode=advanced&offset=10Test; Aldenkamp, A. P., Alpherts, W. C. J., Moerland, M. C., Ottevanger, N., & Parys, J. A. P. V. (1987). Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia, 28(5), 507–514. https://doi.org/10.1111/J.1528-1157.1987.TB03679.XTest; Alizadeh, M. N., Shayanfar, A., & Jouyban, A. (2018). Solubilization of drugs using sodium lauryl sulfate: Experimental data and modeling. Journal of Molecular Liquids, 268, 410–414. https://doi.org/10.1016/j.molliq.2018.07.065Test; Alvarado, A. T., Muñoz, A. M., Bendezú, M. R., Palomino-Jhong, J. J., García, J. A., Alvarado, C. A., Alvarado, E. A., Ochoa-Pachas, G., Pineda-Pérez, M., & Bolarte, M. (2021). In Vitro Biopharmaceutical Equivalence of Carbamazepine Sodium Tablets Available in Lima, Peru. Dissolution Technologies, 28(2). https://doi.org/10.14227/DT280221PGC2Test; Ambrósio, A. F., Soares-da-Silva, P., Carvalho, C. M., & Carvalho, A. P. (2002). Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochemical Research, 27(1–2), 121–130. https://doi.org/10.1023/A:1014814924965Test; Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3), 413–420. https://doi.org/10.1023/A:1016212804288Test; Baena, Y., & Ponce D’León, L. F. (2008). Importancia y fundamentación del sistema de clasificación biofarmacéutico, como base de la exención de estudios de biodisponibilidad y bioequivalencia in vivo. Revista Colombiana de Ciencias Químico - Farmacéuticas, 37(1), 18–32. http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0034-74182008000100002Test; Barzegar-Jalali, M., Maleki, N., Garjani, A., Khandar, A. A., Haji-Hosseinloo, M., Jabbari, R., & Dastmalchi, S. (2002). Enhancement of Dissolution Rate and Anti-inflammatory Effects of Piroxicam Using Solvent Deposition Technique. Drug Development and Industrial Pharmacy, 28(6), 681–686. https://doi.org/10.1081/DDC-120003859Test; Bermejo, M., Meulman, J., Davanço, M. G., Carvalho, P. de O., Gonzalez-Alvarez, I., & Campos, D. R. (2020). In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations: Additional Evidence Regarding a Biopredictive Dissolution Medium. Pharmaceutics 2020, Vol. 12, Page 558, 12(6), 558. https://doi.org/10.3390/PHARMACEUTICS12060558Test; Bodhe, R., Deshmukh, R., Gorale, A., Shinde, R., & Bodhe, P. (2019). Formulation, Development and Evaluation of Carbamazepine Extended Release Tablet: Dissolution Apparatus USP IV. World Journal of Pharmaceutical Research, 8(9), 1484–1504. https://doi.org/10.20959/wjpr20199-15588Test; Bondareva, I. B., Jelliffe, R. W., Gusev, E. I., Guekht, A. B., Melikyan, E. G., & Belousov, Y. B. (2006). Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. Journal of Clinical Pharmacy and Therapeutics, 31(3), 211–221. https://doi.org/10.1111/j.1365-2710.2006.00717.xTest; Bruschi, M. L. (2015). Mathematical models of drug release. In Strategies to Modify the Drug Release from Pharmaceutical Systems (pp. 63–86). Elsevier. https://doi.org/10.1016/B978-0-08-100092-2.00005-9Test; Cárdenas Cuadros, P. A. (2015). Estudio de la correlación in vitro/ in vivo de la liberación de 6-metilcumarina a partir de un sistema micropartículado [Tesis doctoral, Universidad Nacional de Colombia]. https://repositorio.unal.edu.co/handle/unal/56673Test; Cárdenas, P. A., Jiménez – Kairuz, Á., Verlindo de Araujo, B., & Aragón, D. M. (2019). Development of a dissolution method based on lipase for preclinical level A IVIVC of oral poly(ε-caprolactone) microspheres. Journal of Drug Delivery Science and Technology, 52, 632–641. https://doi.org/10.1016/j.jddst.2019.05.011Test; Carrión Recio, D., González Delgado, C. A., Olivera Ruano, L., & Correa Fernández, A. (1999). Bioequivalencia: Introducción a la correlación in vivo-in vitro. Parte I. Revista Cubana de Farmacia, 33(2), 137-142. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75151999000200010Test; Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). (2024). Consulta de Registros Sanitarios . https://tramiteselectronicos02.cofepris.gob.mx/BuscadorPublicoRegistrosSanitarios/BusquedaRegistroSanitario.aspxTest; Costa, P., & Sousa Lobo, J. M. (2001). Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences, 13(2), 123–133. https://doi.org/10.1016/S0928-0987Test(01)00095-1; Ding, A., Zhou, Y., Chen, P., & Nie, W. (2017). Ibuprofen-loaded micelles based on star-shaped erythritol-core PLLA-PEG copolymer: effect of molecular weights of PEG. Colloid and Polymer Science, 295(9), 1609–1619. https://doi.org/10.1007/s00396-017-4141-6Test; Dressman, J. B. (Jennifer B. ), & Krämer, J. (2005). Pharmaceutical dissolution testing. Taylor & Francis.; Eichelbaum, M., Köthe, K. W., Hoffmann, F., & von Unruh, G. E. (1982). Use of stable labelled carbamazepine to study its kinetics during chronic carbamazepine treatment. European Journal of Clinical Pharmacology 1982 23:3, 23(3), 241–244. https://doi.org/10.1007/BF00547561Test; EL-Massik, M. A., Abdallah, O. Y., Galal, S., & Daabis, N. A. (2006). Towards a Universal Dissolution Medium for Carbamazepine. Drug Development and Industrial Pharmacy, 32(7), 893–905. https://doi.org/10.1080/03639040600762677Test; European Medicines Agency (EMEA). (2010). Guideline On The Investigation of Bioequivalence Discussion in the Joint Efficacy and Quality Working Group. http://www.ema.europa.euTest; Figueroa, A. I., Gonzalez, M., Merino, V., & Bermejo, M. del V. (2019). Desarrollo de métodos de disolución con capacidad predictiva del rendimiento in vivo de formulaciones farmacéuticas [Tesis doctoral, Universitat de València]. https://hdl.handle.net/10550/70578Test; Food and Drug Administration (FDA). (1997). Guía para la Industria: Pruebas de disolución de formas de dosificación oral sólidas de liberación inmediata. Centro de Evaluación e Investigación de Drogas. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guia-para-la-industria-pruebas-de-disolucion-de-formas-de-dosificacion-oral-solidas-de-liberacionTest; Food and Drug Administration (FDA). (2018). Guía para la Industria: Formas de dosificación oral de liberación prolongada: elaboración, evaluación y aplicación de correlaciones in vitro/in vivo. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guia-para-la-industria-formas-de-dosificacion-oral-de-liberacion-prolongada-elaboracion-evaluacionTest-y; Food and Drug Administration (FDA). (2021). M9 Biopharmaceutics Classification System-Based Biowaivers. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m9-biopharmaceutics-classification-system-based-biowaiversTest; Fotaki, N., & Reppas, C. (2005). The Flow Through Cell Methodology in the Evaluation of Intralumenal Drug Release Characteristics. Dissolution Technologies, 12(2), 17–21. https://doi.org/10.14227/DT120205P17Test; Gao, Z. (2009). In Vitro Dissolution Testing with Flow-Through Method: A Technical Note. AAPS PharmSciTech, 10(4), 1401. https://doi.org/10.1208/s12249-009-9339-6Test; Gohel, M., Parikh, R., Aghara, P., Nagori, S., Delvadia, R., & Dabhi, M. (2009). Application of Simplex Lattice Design and Desirability Function for the Formulation Development of Mouth Dissolving Film of Salbutamol Sulphate. Current Drug Delivery, 6(5), 486–494. https://doi.org/10.2174/156720109789941696Test; Gohel, M., Sarvaiya, K., Shah, A., & Brahmbhatt, B. (2009). Mathematical Approach for the Assessment of Similarity Factor Using a New Scheme for Calculating Weight. Indian Journal of Pharmaceutical Sciences, 71(2), 142. https://doi.org/10.4103/0250-474X.54281Test; González García, I., Mangas Sanjuan, V., Merino Sanjuán, M., Álvarez Álvarez, C., Díaz Garzón, M. J., Rodríguez Bonnín, M. A., Langguth, T., Torrado Durán, J. J., Langguth, P., García Arieta, A., & Bermejo, M. (2017). IVIVC approach based on carbamazepine bioequivalence studies combination. Die Pharmazie, 72(8), 449–455. https://doi.org/10.1691/PH.2017.7011Test; Graves, N. M., Brundage, R. C., Wen, Y., Cascino, G., So, E., Ahman, P., Rarick, J., Krause, S., & Leppik, I. E. (1998). Population Pharmacokinetics of Carbamazepine in Adults with Epilepsy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 18(2), 273–281. https://doi.org/10.1002/j.1875-9114.1998.tb03853.xTest; Grupo SOTAX. (n.d.). CE 7smart Offline: Disolución con celdas de flujo continuo con recogida de muestras.; Hann, E., Malagu, K., Stott, A., & Vater, H. (2022). The importance of plasma protein and tissue binding in a drug discovery program to successfully deliver a preclinical candidate (pp. 163–214). https://doi.org/10.1016/bs.pmch.2022.04.002Test; Höpener, R. J., Kuyer, A., Meijer, J. W. A., & Hulsman, J. (1980). Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia, 21(4), 341–350. https://doi.org/10.1111/J.1528-1157.1980.TB04081.XTest; Hopfenberg, H. B. (1976). Controlled Release from Erodible Slabs, Cylinders, and Spheres (pp. 26–32). https://doi.org/10.1021/bk-1976-0033.ch003Test; Hurtado y de la Peña, M., Vargas Alvarado, Y., Domínguez-Ramírez, A. M., & Cortés Arroyo, A. R. (2003). Comparison of Dissolution Profiles for Albendazole Tablets Using USP Apparatus 2 and 4. Http://Dx.Doi.Org/10.1081/DDC-120021777Test, 29(7), 777–784. https://doi.org/10.1081/DDC-120021777Test; Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA). (2022). Tegretol Retard de 200 mg: Expediente Sanitario 227376, Registro Sanitario INVIMA 2018M-011160-R2. Sistema de Tramites En Linea - Consultas Publicas. https://consultaregistro.invima.gov.co/Consultas/consultas/consreg_encabcum.jspTest; Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA). (2024). Sistema de Tramites en Linea - Consultas Publicas. https://consultaregistro.invima.gov.co/Consultas/consultas/consreg_encabcum.jspTest; Jinno, J. ichi, Kamada, N., Miyake, M., Yamada, K., Mukai, T., Odomi, M., Toguchi, H., Liversidge, G. G., Higaki, K., & Kimura, T. (2008). In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. Journal of Controlled Release, 130(1), 29–37. https://doi.org/10.1016/J.JCONREL.2008.05.013Test; Jung Cook, H., de Anda Jáuregui, G., Rubio Carrasco, K., & Mayet Cruz, L. (2013). Comparación de perfiles de disolución: Impacto de los criterios de diferentes agencias regulatorias en el cálculo de ƒ2. Revista Mexicana de Ciencias Farmacéuticas, 43(3). http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1870-01952012000300007Test; Kassaye, L., & Genete, G. (2013). Evaluation and comparison of in-vitro dissolution profiles for different brands of amoxicillin capsules. African Health Sciences, 13(2). https://doi.org/10.4314/ahs.v13i2.25Test; Katzhendler, I., & Friedman, M. (1999). Zero-order sustained release matrix tablet formulations of carbamazepine (Patent No: US5980942A) (Patent US5980942A). United States Patent. https://patents.google.com/patent/US5980942A/enTest; Kayali, A., Tuglular, I., & Ertas, M. (1994). Pharmacokinetics of carbamazepine Part I: a new bioequivalency parameter based on a relative bioavailability trial. European Journal of Drug Metabolism and Pharmacokinetics, 19(4), 319–325. https://doi.org/10.1007/BF03188858Test; Kiuri, J. N., Maru, S. M., & Ndwigah, S. N. (2020). Product Evaluation of Carbamazepine 200mg Controlled Release Tablets using an in vitro-in vivo Correlation Simulation Model. East and Central African Journal of Pharmaceutical Sciences, 23(2), 60–66. https://www.ajol.info/index.php/ecajps/article/view/200123Test; Kovačević, I., Parojčić, J., Homšek, I., Tubić-Grozdanis, M., & Langguth, P. (2009). Justification of Biowaiver for Carbamazepine, a Low Soluble High Permeable Compound, in Solid Dosage Forms Based on IVIVC and Gastrointestinal Simulation. Molecular Pharmaceutics, 6(1), 40–47. https://doi.org/10.1021/mp800128yTest; Kuo, C. C., Chen, R. S., Lu, L., & Chen, R. C. (1997). Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications. Molecular Pharmacology, 51(6), 1077–1083. https://doi.org/10.1124/MOL.51.6.1077Test; Lake, O. A., Olling, M., & Barends, D. M. (1999). In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. European Journal of Pharmaceutics and Biopharmaceutics, 48(1), 13–19. https://doi.org/10.1016/S0939-6411Test(99)00016-8; Langenbucher, F. (2011). Letters to the Editor: Linearization of dissolution rate curves by the Weibull distribution. Journal of Pharmacy and Pharmacology, 24(12), 979–981. https://doi.org/10.1111/j.2042-7158.1972.tb08930.xTest; Lee, S. L., Raw, A. S., & Yu, L. (2008). Dissolution Testing. In Biopharmaceutics Applications in Drug Development (pp. 47–74). Springer US. https://doi.org/10.1007/978-0-387-72379-2_3Test; Lindenberg, M., Kopp, S., & Dressman, J. B. (2004). Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. European Journal of Pharmaceutics and Biopharmaceutics, 58(2), 265–278. https://doi.org/10.1016/J.EJPB.2004.03.001Test; Lopes, C. M., Lobo, J. M. S., & Costa, P. (2005). Formas farmacêuticas de liberação modificada: polímeros hidrifílicos. Revista Brasileira de Ciências Farmacêuticas, 41(2), 143–154. https://doi.org/10.1590/S1516-93322005000200003Test; Lu, Y., Kim, S., & Park, K. (2011). In vitro–in vivo correlation: Perspectives on model development. International Journal of Pharmaceutics, 418(1), 142–148. https://doi.org/10.1016/j.ijpharm.2011.01.010Test; Mateu López, L., & Herrera LLópiz, A. (2007). Fracturar tabletas de liberación modificada: ¿una práctica adecuada? Revista Cubana de Farmacia, 41(1). http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75152007000100013Test; McLean, M. J., & Macdonald, R. L. (1983). Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. Journal of Pharmacology and Experimental Therapeutics, 227(3).; Medina, J. R., Salazar, D. K., Hurtado, M., Cortés, A. R., & Domínguez-Ramírez, A. M. (2014). Comparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system. Saudi Pharmaceutical Journal, 22(2), 141–147. https://doi.org/10.1016/J.JSPS.2013.02.001Test; Medina Lopez, J. R., & Hurtado Y de la Peña, M. (2009). Dissolution of paracetamol suppositories using the flow-through cell system and their absorption in an animal model %7C Request PDF. Revista Mexicana de Ciencias Farmaceuticas , 40(2), 11–18. https://www.researchgate.net/publication/288673896_Dissolution_of_paracetamol_suppositories_using_the_flow-through_cell_system_and_their_absorption_in_an_animal_modelTest; Resolución 1124 de 2016, 1 (2016).; Minitab LLC. (2023). Model reduction. https://support.minitab.com/en-us/minitab/20/help-and-how-to/statistical-modeling/regression/supporting-topics/regression-models/model-reductionTest/; Mittapalli, P. K., Suresh, B., Hussaini, S. S. Q., Rao, Y. M., & Apte, S. (2008). Comparative In Vitro Study of Six Carbamazepine Products. AAPS PharmSciTech, 9(2), 357. https://doi.org/10.1208/S12249-008-9035Test-Y; Mohamed Rizwan, I., & Damodharan, N. (2020). Mathematical Modelling of Dissolution Kinetics in Dosage forms. Research Journal of Pharmacy and Technology, 13(3), 1339. https://doi.org/10.5958/0974-360X.2020.00247.4Test; Moreno, J., Belmont, A., Jaimes, O., Santos, J. A., López, G., Campos, M. G., Amancio, O., Pérez, P., & Heinze, G. (2004). Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. Archives of Medical Research, 35(2), 168–171. https://doi.org/10.1016/j.arcmed.2003.09.016Test; Okumu, A., DiMaso, M., & Löbenberg, R. (2008). Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharmaceutical Research, 25(12), 2778–2785. https://doi.org/10.1007/S11095-008-9642-ZTest; Olling, M., Mensinga, T. T., Barends, D. M., Groen, C., Lake, O. A., & Meulenbelt, J. (1999). Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharmaceutics and Drug Disposition, 20(1), 19–28. https://doi.org/10.1002Test/(SICI)1099-081X(199901)20:13.0.CO;2-Q; Palma-Aguirre, J. A., & Barreiro Perera, O. (1992). Biodisponibilidad y bioequivalencia de medicamentos. Revista de La Facultad de Medicina, Universidad Nacional Autónoma de México, 35(1). http://revistas.unam.mx/index.php/rfm/article/view/74573Test; Paschal Iwundu, M., & Cosmos, J. (2022). The Efficiency of Seven-Variable Box-Behnken Experimental Design with Varying Center Runs on Full and Reduced Model Types. Journal of Mathematics and Statistics, 18(1), 196–207. https://doi.org/10.3844/jmssp.2022.196.207Test; Podczeck, F. (1993). Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT). International Journal of Pharmaceutics, 97(1–3), 93–100. https://doi.org/10.1016/0378-5173Test(93)90129-4; Polli, J. E., Rekhi, G. S., Augsburger, L. L., & Shah, V. P. (1997). Methods to Compare Dissolution Profiles and a Rationale for Wide Dissolution Specifications for Metoprolol Tartrate tablets†. Journal of Pharmaceutical Sciences, 86(6), 690–700. https://doi.org/10.1021/js960473xTest; Punyawudho, B., Ramsay, E. R., Brundage, R. C., Macias, F. M., Collins, J. F., & Birnbaum, A. K. (2012). Population Pharmacokinetics of Carbamazepine in Elderly Patients. Therapeutic Drug Monitoring, 34(2), 176–181. https://doi.org/10.1097/FTD.0b013e31824d6a4eTest; Rabti, H., Mohammed Salmani, J. M., Elamin, E. S., Lammari, N., Zhang, J., & Ping, Q. (2014). Carbamazepine solubility enhancement in tandem with swellable polymer osmotic pump tablet: A promising approach for extended delivery of poorly water-soluble drugs. Asian Journal of Pharmaceutical Sciences, 9(3), 146–154. https://doi.org/10.1016/J.AJPS.2014.04.001Test; Rane, Y., Mashru, R., Sankalia, M., & Sankalia, J. (2007). Effect of hydrophilic swellable polymers on dissolution enhancement of carbamazepine solid dispersions studied using response surface methodology. AAPS PharmSciTech, 8(2), E1–E11. https://doi.org/10.1208/pt0802027Test; Rawlins, M. D., Collste, P., Bertilsson, L., & Palmér, L. (1975). Distribution and elimination kinetics of carbamazepine in man. European Journal of Clinical Pharmacology 1975 8:2, 8(2), 91–96. https://doi.org/10.1007/BF00561556Test; Riva, R., Albani, F., Ambrosetto, G., Contin, M., Cortelli, P., Perucca, E., & Baruzzi, A. (1984). Diurnal Fluctuations in Free and Total Steady-State Plasma Levels of Carbamazepine and Correlation with Intermittent Side Effects. Epilepsia, 25(4), 476–481. https://doi.org/10.1111/J.1528-1157.1984.TB03446.XTest; Rodriguez, C., Guevara, B. H., & Lobo, G. (2010). Mecanismos de acción de fármacos antiepilépticos. Informe Médico, 12(6), 321–326. https://www.researchgate.net/publication/235769333_Mecanismos_de_accion_de_farmacos_antiepilepticosTest; Roni, M., Kibria, G., & Jalil, R. (2009). Formulation and in vitro Evaluation of Alfuzosin Extended Release Tablets Using Directly Compressible Eudragit. Indian Journal of Pharmaceutical Sciences, 71(3), 252. https://doi.org/10.4103/0250-474X.56019Test; Ruiz, A. M., Restrepo, M. M., Cuesta, F., Giraldo, J., Archbold, R., & Holguín, G. (2001). Estudio de bioequivalencia de dos formulaciones de tabletas de carbamazepina de liberación retardada. Iatreia, 13(3), 131–139.; Sakore, S., & Chakraborty, B. (2011). In Vitro - In Vivo Correlation (IVIVC): A Strategic Tool in Drug Development. Journal of Bioequivalence & Bioavailability, 8(4). https://doi.org/10.4172/JBB.S3-001Test; Sánchez-Dengra, B., González-García, I., González-Álvarez, M., González-Álvarez, I., & Bermejo, M. (2021). Two-step in vitro-in vivo correlations: Deconvolution and convolution methods, which one gives the best predictability? Comparison with one-step approach. European Journal of Pharmaceutics and Biopharmaceutics, 158, 185–197. https://doi.org/10.1016/j.ejpb.2020.11.009Test; Shargel, L., & Yu, A. B. C. (2016). Applied Biopharmaceutics & Pharmacokinetics (7th ed.). McGraw-Hill. https://accesspharmacy.mhmedical.com/book.aspx?bookID=1592Test; Springer Boston, M. (2004). Bioavailability and Bioequivalence. In Foundations of Pharmacokinetics (pp. 171–177). Kluwer Academic Publishers. https://doi.org/10.1007/0-306-47924-9_17Test; Tomson, T. (1984). Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Archives of Neurology, 41(8), 830–834. https://doi.org/10.1001/ARCHNEUR.1984.04050190036011Test; Tunnicliff, G. (1996). Basis of the antiseizure action of phenytoin. General Pharmacology: The Vascular System, 27(7), 1091–1097. https://doi.org/10.1016/S0306-3623Test(96)00062-6; United States Pharmacopeia USP-NF. (2015, May 1). Espectroscopía En El Infrarrojo Medio—Teoría Y Práctica. Online United States Pharmacopeia USP-NF. https://doi.org/10.31003/USPNF_M5512_02_02Test; United States Pharmacopeia USP-NF. (2022a, April 1). Monografía oficial Carbamazepina. Online United States Pharmacopeia USP-NF. https://doi.org/https://doi.org/10.31003/USPNF_M12565_04_02Test; United States Pharmacopeia USP-NF. (2022b, December 1). Capítulo General Espectroscopía Ultravioleta-Visible. Online United States Pharmacopeia USP-NF. https://doi.org/https://doi.org/10.31003/USPNF_M3209_04_02Test; United States Pharmacopeia USP-NF. (2023a, April 1). Monografía oficial Carbamazepina, Tabletas de Liberación Prolongada. https://doi.org/10.31003/USPNF_M12565_04_02Test; United States Pharmacopeia USP-NF. (2023b, May 1). Capítulo General Disolución. https://doi.org/10.31003/USPNF_M99470_03_02Test; United States Pharmacopeia USP-NF. (2023c, August 1). Capítulo General Uniformidad de Unidades de Dosificación. Online United States Pharmacopeia USP-NF. https://doi.org/10.31003/USPNF_M99694_03_02Test; Valbuena Reyes, K. (2018). Estudio de la Cinética de Degradación Bajo Carga Mecánica de un Polímero Implantable [Tesis de maestría]. Universidad Nacional de Colombia .; Veng-Pedersen, P., Gobburu, J. V. S., Meyer, M. C., & Straughn, A. B. (2000). Carbamazepine level-Ain vivo-in vitro correlation (IVIVC): a scaled convolution based predictive approach. Biopharmaceutics & Drug Disposition, 21(1), 1–6. https://doi.org/10.1002/1099-081XTest(200001)21:13.0.CO;2-D; Vinayakrao Barabde, U., Kumar Verma, R., & Singh Raghuvanshi, R. (2009). Carbamazepine formulations (Patent US20090143362A1). United States Patent and Trademark Office. https://patents.google.com/patent/US20090143362A1/enTest; Volonté, M. G., Viñas, M. A., de Buschiazzo, P. M., Piersante, M. v., Escales, M. C., & Gorriti, C. E. (2004). Estudio comparativo de comprimidos con 200 mg de carbamacepina para determinar equivalencia farmacéutica. Acta Farmaceutica Bonaerense, 23(3), 391–397.; Wadher, K., Umekar, M., & Kakde, R. (2011). Formulation and evaluation of a sustained-release tablets of metformin hydrochloride using hydrophilic synthetic and hydrophobic natural polymers. Indian Journal of Pharmaceutical Sciences, 73(2), 208. https://doi.org/10.4103/0250-474X.91579Test; Wei-Qin, T. (Tony). (2008). Molecular and Physicochemical Properties Impacting OralAbsorptionofDrugs. In Biopharmaceutics Applications in Drug Development (pp. 26–46). Springer US. https://doi.org/10.1007/978-0-387-72379-2_2Test; Wennergren, B., Lindberg, J., Nicklasson, M., Nilsson, G., Nyberg, G., Ahlgren, R., Persson, C., & Palm, B. (1989). A collaborative in vitro dissolution study: comparing the flow-through method with the USP paddle method using USP prednisone calibrator tablets. International Journal of Pharmaceutics, 53(1), 35–41. https://doi.org/10.1016/0378-5173Test(89)90358-X; World Health Oranization Collaborating Centre for Drug Statistics Methodology. (2022). ATC/DDD Index: Carbamazepine. Norwegian Institute of Public Health. https://www.whocc.no/atc_ddd_index/?code=N03AF01Test; Zadbuke, N., Khan, A. R., Battase, A., & Shahi, S. (2017). Convolution and Deconvolution Based Approach For Prediction of in-vivo Performance. European Journal of Biomedical and Pharmaceutical Sciences, 4(11), 447–453. https://www.ejbps.com/ejbps/abstract_id/3377Test; Zhang, G. H., Vadino, W. A., Yang, T. T., Cho, W. P., & Chaudry, I. A. (1994). Evaluation of the Flow-Through Cell Dissolution Apparatus: Effects of Flow Rate, Glass Beads and Tablet Position on Drug Release from Different Type of Tablets. Drug Development and Industrial Pharmacy, 20(13), 2063–2078. https://doi.org/10.3109/03639049409050222Test; https://repositorio.unal.edu.co/handle/unal/86344Test; Universidad Nacional de Colombia; Repositorio Institucional Universidad Nacional de Colombia; https://repositorio.unal.edu.coTest/

الإتاحة: https://doi.org/10.1016/B978-0-08-100092-2.00005-910.1208/s12249-009-9339Test-610.1021/bk-1976-0033.ch00310.1111/j.2042-7158.1972.tb08930.x10.1016/0378-5173(93)90129-410.1007/0-306-47924-9_1710.1001/ARCHNEUR.1984.0405019003601110.1016/S0306-3623(96)00062-610.31003/USPNF_M5512_02_0210.31003/USPNF_M12565_04_0210.31003/USPNF_M3209_04_0210.31003/USPNF_M99470_03_0210.31003/USPNF_M99694_03_0210.1007/978-0-387-72379-2_2
https://repositorio.unal.edu.co/handle/unal/86344Test
https://repositorio.unal.edu.coTest/

المؤلفون: Becerra Farieta, Rocío del Pilar

المساهمون: Rodríguez Pulido, María del Pilar

مصطلحات موضوعية: 610 - Medicina y salud::615 - Farmacología y terapéutica, Salud del Anciano Institucionalizado, Musicoterapia/métodos, Ansiedad/terapia, Health of Institutionalized Elderly, Music Therapy/methods, Anxiety/therapy, Musicoterapia, Manifestaciones de ansiedad, Persona mayor, Envejecimiento, Music therapy, Elderly, Aging, Anxiety manifestations

جغرافية الموضوع: Colombia, Cundinamarca, Tenjo, http://vocab.getty.edu/page/tgn/1000583Test

وصف الملف: xiv, 207 páginas; application/pdf

العلاقة: Bireme; Alzate, G., Orozco, S., Ávila C. (2014) Conductas ansiosas. Revista estudiantil Psicoideas N.2, 26-34.; Archivo de la Residència Santa Maria del Tura. (29 de 09 de 2016). Atención a mayores-Instituto de religiosas de san José de Gerona. Obtenido de http://atencionmayores.org/musicoterapia-personas-mayoresTest/; Bruscia, K. (1999). modelos de improvisación en musicoterapia. salamanca: agruparte.; Bruscia, K. (2007). Musicoterapia, métodos y prácticas. Mexico DF: Pax México.; Camacho, P (2019). Musicoterapia:Culto al cuerpo y a la mente. Obtenido de file:///C:/Users/sylvi/Downloads/Dialnet-Musicoterapia-2756902%20(1).pdf; Cano, C. V. (2023). Obtenido de https://www.actualidadenpsicologia.com/enfoque-humanista-psicologiaTest/; CEPAL. (27 de 12 de 2018). NACIONES UNIDAS-CEPAL. Obtenido de COMISIÓN ECONÓMICA PARA AMÉRICA LATINA Y EL CARIBE; Cisneros, G. E., & Ausín, B. (15 de enero de 2019). Prevalencia de los trastornos de ansiedad en las personas mayores de 65 años: una revisión sistemática. Revista Española de Geriatría y Gerontología, 34-48. Obtenido de sciencedirect journal&books: https://www.sciencedirect.com/science/article/abs/pii/S0211139X18305833Test; Denis, E., & Casari, L. (2014). La Musicoterapia y las emociones en el adulto mayor. Revista diáLogos, 75-82.; Díaz, D. (2023, diciembre 29) Menos nacimientos, más vasectomías: la tasa de natalidad de Colombia se desploma. El País.; Elisa Dulcey, R. (2010). Psicología social del envejecimiento y perspectiva del transcurso de la vida: Consideraciones críticas. Fundación Cepsiger para el Desarrollo Humano- Bogotá- Colombia. https://revistas.unal.edu.co/index.php/psicologia/article/download/14521/34435Test; Elisa Dulcey, R. (2010). Psicología social del envejecimiento y perspectiva del transcurso de la vida: Consideraciones críticas. Fundación Cepsiger para el Desarrollo Humano- Bogotá- Colombia. https://revistas.unal.edu.co/index.php/psicologia/article/download/14521/34435Test El Comercio/GDA. (1 del 10 de 2018). La ansiedad en los adultos mayores. Obtenido de Por dentro: http://www.pordentro.pr/salud/nota/la-ansiedad-en-los-adultos-mayoresTest/; Fernández, O.(2006). Salud mental y envejecimiento: una experiencia comunitaria de musicoterapia con ancianos deprimidos. Psicología y Salud, 16(1):93-101.; Ferrari, K. D. (2013). Musicoterapia: Aspectos de la y la evaluación de la práctica clínica. Buenos Aires: Ediciones MTD Karina Daniela Ferrari.; Ferrari, K. (2013). Formas de evaluación de aspectos específicos en una sesión de musicoterapia. En: Aspectos de la y la evaluación de la práctica clínica. Buenos Aires: Ediciones MTD Karina Daniela Ferrari.; Fuentes, C. (25 de mayo de 2016). Revista de Investigación en Musicoterapia. Obtenido de Musicoterapia para el tratamiento de la ansiedad, depresión y somatizaciones, estudio de caso: https://revistas.uam.es/index.php/rim/article/view/7725/8295Test; García, C. (18 de MAYO de 2022). Memoria de trabajo y memoria a corto plazo: definición y diferencias Obtenido de https: https://neuronup.com/neurociencia/neuropsicologia/memoria/memoria-de-trabajoTest-y-memoria-a-corto-plazo-definicion-y-diferencias/; Gobernación de Cundinamarca (Diciembre de 2023). Informe de Rendición de Cuentas- Adulto Mayor Obtenido de https://www.cundinamarca.gov.co/wcm/connect/f540cdc4-da2f-4d87-9306-eda9849a189a/Informe+Adulto+Mayor.pdf?MOD=AJPERES&CONVERT_TO=url&CACHEID=ROOTWORKSPACE-f540cdc4-da2f-4d87-9306-eda9849a189a-oLpSZzeTest; Gobernación de Cundinamarca (Diciembre de 2023). Informe de Rendición de Cuentas- Adulto Mayor Obtenido de https://www.cundinamarca.gov.co/wcm/connect/f540cdc4-da2f-4d87-9306-eda9849a189a/Informe+Adulto+Mayor.pdf?MOD=AJPERES&CONVERT_TO=url&CACHEID=ROOTWORKSPACE-f540cdc4-da2f-4d87-9306-eda9849a189a-oLpSZzeTest Gómez, Jorge (2015). La musicoterapia en procesos de re-significación de la autoconfianza en personas mayores víctimas del conflicto armado en colombia. Tesis de grado, Maestría en musicoterapia. Universidad Nacional de Colombia.; Gómez-Romero, M. (2017). Beneficios de la musicoterapia en las alteraciones conductuales de la demencia. Revisión sistemática. Neurología, 253-263. Obtenido de https://www.elsevier.es/es-revista-neurologia-295-articulo-beneficios-musicoterapia-alteraciones-conductuales-demencia--S0213485314002485Test; González, D. (2014). La Musicoterapia como herramienta para reducir el nivel de depresión en adultos mayores deprimidos e institucionalizados en un hogar de ancianos privado en la ciudad de Guatemala. [Tesis de grado, Guatemala de la Asunción].; González, M. V. (2007). EDUCAR LAS EMOCIONES. Mérida, Venezuela: Producciones Editoriales C. A.; Guevara, N. (2016). Impactos de la institucionalización en la vejez. Análisis frente a los cambios demográficos actuales. entramado, 138-151.; Guzmán, X. S. (2019). Efectos de un programa de musicoterapia en el fortalecimiento de la inteligencia emocional, en un grupo de adultos mayores. Obtenido de Repositorio UNAL: https://repositorio.unal.edu.co/bitstream/handle/unal/75522/Musicoterapia%20e%20Inteligencia%20Emocional%202019%20Ximena%20Sarta.pdf?sequence=1Test; Herdman, T. H. (2013). Diagnósticos enfermeros: definiciones y clasificación. Madrid: Elsevier: Elsevier.; Hernán Feria, M. M. (2019). LA TRIANGULACIÓN METODOLÓGICA COMO MÉTODO DE INVESTIGACIÓN. Revista Didasc@lia: D&E. Publicación del CEPUT- Las Tunas, CUBA, 137-146.; Hidalgo, L. (2009) Confiabilidad y Validez en el Contexto de la Investigación y Evaluación Cualitativas. Obtenido de http://www.ucv.ve/uploads/media/Hidalgo2005.pdfTest.; Instituto Superior de Estudios Sociales y Sociosanitarios (ISESS). (15 de 08 de 2023). Blog Ises ¿Cómo influye la musicoterapia en personas mayores? Obtenido de https://www.isesinstituto.com/noticia/como-influye-la-musicoterapia-en-personas-mayoresTest; Instituto Nacional del Cáncer. INC Obtenido de https://www.cancer.gov/espanol/publicaciones/diccionarios/diccionario-cancer/def/sars-cov-2Test; Kwon M y Gang M. (2013). Effect of the Group Music Therapy on Brain Wave, Behavior, and Cognitive Function among Patients with Chronic Schizophrenia. Asian Nurs Res, 7(4): 168-74.; aínez, S.,Carbonell, A.I., Meléndez, E., Marzal, A.(2022). La influencia de la musicoterapia en personas mayores. Revista de Investigación.; Loroño A. (1996). Esquizofrenia y Musicoterapia. Revista Interuniversitaria de Formación del Profesorado, 26:91-102.; León García, R. G. (s.f.). Clínica de la Ansiedad . Obtenido de Ansiedad y Personalidad.: https://clinicadeansiedad.com/problemas/introduccion/ansiedadTest-y-personalidad/; Lesmes, G. (2018). Promoción de relaciones sociales en el adulto mayor institucionalizado a través de la musicoterapia comunitaria. [Tesis de grado, Maestría en Musicoterapia, Universidad Nacional de Colombia]. https://repositorio.unal.edu.co/handle/unal/69776Test; López, J.P. (2018). Efectos de un programa piloto de musicoterapia basado en la composición de canciones sobre los niveles de depresión en adultos mayores con deterioro cognitivo residentes de un hogar geriátrico privado de la ciudad de Bogotá. [Tesis de grado, Maestría en Musicoterapia, Universidad Nacional de Colombia]. https://repositorio.unal.edu.co/handle/unal/63061Test; Mariela Borda, M. A. (15 de diciembre de 2012). Revista Salud Uninorte. Obtenido de http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-55522013000100008Test; Martinez, F. (2010). Solfeo. Bogotá: Panamericana.; Ministerio de Salud y Protección Social. (Agosto de 2015). Ministerio de Salud y Protección Social . Obtenido de POLITICA COLOMBIANA DE ENVEJECIMIENTO HUMANO Y VEJEZ: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/PS/Pol%C3%ADtica-colombiana-envejecimiento-humano-vejez-2015-2024.pdfTest; Moorhead, S. J. (2014). Clasificación de Resultados de Enfermería (NOC). Madrid: Elsevier.; Muletaber, S. (2019). ¿De qué hablamos cuando hablamos de mediana edad? Anatomía del sujeto envejeciente. https://www.teseopress.com/sociologiadelasedades/chapter/de-que-hablamos-cuando-hablamos-de-mediana-edad-anatomia-del-sujeto-envejecienteTest/; OEA. (2015). Convención Interamericana sobre la protección de los derechos humanos de las personas mayores. Convención Interamericana sobre la protección de los derechos humanos de las personas mayores, (págs. 2,4,8,9). Washington, D.C., Estados Unidos.; OMS. (12 de DICIEMBRE de 2017). ORGANIZACIÓN MUNDIAL DE LA SALUD. Obtenido de https://www.who.int/es/news-room/fact-sheets/detail/la-salud-mentalTest-y-los-adultos-mayores; OMS. (5 de febrero de 2018). Envejecimiento y salud. Obtenido de organización mundial de la salud: https://www.who.int/es/news-room/fact-sheets/detail/envejecimientoTest-y-salud; Pabón, A. (2020). Efecto de la musicoterapia en la autoestima de un grupo de mujeres mayores de 50 años usuarias de la fundación “tu puedes en casa”, de bogotá [Tesis de grado, Maestría en Musicoterapia, Universidad Nacional de Colombia]. Repositorio biblioteca digital universidad nacional de colombia. https://repositorio.unal.edu.co/handle/unal/75939Test; Packer, M. (2018). La ciencia de la Investigación Cualitativa. Bogotá-Colombia: Ediciones Uniandes.; Papalia, D. E. (2009). Desarrollo del adulto y vejez. Ciudad de méxico: McGRAW-HILL.; Romero, C. (23 de JUNIO de 2016). http://www.unife.edu.pe/publicaciones/revistas/psicologia/2015_2/W.Arias.pdfTest. Obtenido de https://recercat.cat/bitstream/id/156101/Cristina_Romero.pdfTest; iveros, E. (2014). La psicología humanista: sus orígenes y su significado en el mundo de la psicoterapia a medio siglo de existencia. http://www.scielo.org.bo/pdf/rap/v12n2/v12n2a1.pdTest; Sampieri, R (2014). Metodología de la Investigación. Ciudad de méxico: McGRAW-HILL. Interamericana Editores S.A; Sarta, X. (2019). Efectos de un programa de Musicoterapia en el fortalecimiento de la Inteligencia Emocional en un grupo de adultos mayores del Centro Día "Tierra de Saberes" de la ciuda de Bogotá. [Tesis de grado, Maestría en Musicoterapia, Universidad Nacional de Colombia]. https://repositorio.unal.edu.co/handle/unal/75522Test; Schapira, D., Ferrari, K., Sánchez, V., & Hugo, M. (2007). Musicoterapia Abordaje plurimodal. Argentina: ADIM ediciones.; Schapira, D. (2007). El trabajo con canciones. En: Musicoterapia Abordaje plurimodal. Argentina: ADIM ediciones.; Sierra, J.C. (2003). Ansiedad, angustia y estrés: tres conceptos a diferenciar. REVISTA MAL-ESTAR E SUBJETIVIDADE / FORTALEZA / V. III / N. 1 /, 10-59. Obtenido de http://pepsic.bvsalud.org/pdf/malestar/v3n1/02.pdfTest; Sepúlveda-Vildósola AC, H. Z. (2014). La musicoterapia para disminuir la ansiedad. Su empleo en pacientes pediátricos con cáncer. Psicoterapia Pediátrica. Revista médica del Instituto Mexicano del Seguro Social, http://biblat.unam.mx/es/revista/revista-medica-del-instituto-mexicano-del-segurosocial/articulo/la-musicoterapia-para-disminuir-la-ansiedad-su-empleo-en-pacientespediatricos-con-cancerTest . Obtenido de http://biblat.unam.mx/es/revista/revista-medica-del-instituto-mexicano-del-segurosocial/articulo/la-musicoterapia-para-disminuir-la-ansiedad-su-empleo-en-pacientespediatricos-con-cancerTest; Solomon, B. y. (2016). Pérdida de memoria, Alzheimer y demencia: Una guía práctica para médicos. Barcelona: Elsevier.; Villamizar, M.J., La Musicoterapia como tratamiento para la conservación de la memoria, el esquema corporal y las nociones espacio-temporales en pacientes con demencia tipo Alzheimer. [Tesis de grado, Maestría en Musicoterapia, Universidad Nacional de Colombia].; https://repositorio.unal.edu.co/handle/unal/86183Test; Universidad Nacional de Colombia; Repositorio Institucional Universidad Nacional de Colombia; https://repositorio.unal.edu.coTest/

الإتاحة: https://repositorio.unal.edu.co/handle/unal/86183Test
https://repositorio.unal.edu.coTest/

المؤلفون: Rivera Garnica, Yuly Stefany

المساهمون: Basabe Rodriguez, Miguel Angel

مصطلحات موضوعية: 360 - Problemas y servicios sociales, asociaciones::361 - Problemas sociales y servicios, 610 - Medicina y salud::615 - Farmacología y terapéutica, Resiliencia Psicológica, Resilience, Psychological, Musicoterapia, Violencia sexual, Resiliencia, Factores protectores, Capacidad de adaptación, Music therapy, Sexual violence, Protective Factors, Adaptability, Acceptance and commitment therapy, Coping with adversity, Abuso sexual, Sexual abuse

وصف الملف: 61 páginas; application/pdf

العلاقة: Barraca, J. (2009). Habilidades Clínicas en la Terapia Conductual de Tercera Generación - Clinical Skills in the Third-Wave of Behavioral Therapy. Clínica y Salud, 20, 109-117.; Becoña Iglesias, E. (2006). Resiliencia: definición, características y utilidad del concepto. Revista de Psicopatología y Psicología Clínica, 11(3), 125–146. https://doi.org/10.5944/rppc.vol.11.num.3.2006.4024Test; Bruscia, K. E. (2007). Musicoterapia, métodos y prácticas. México: Pax Editorial.; Centro Nacional de Memoria Histórica. (2018). Memoria histórica con víctimas de violencia sexual: Aproximación conceptual y metodológica [Informe]. Recuperado de https://centrodememoriahistorica.gov.co/wp-content/uploads/2020/02/memoria-historica-con-victimas-de-violencia-sexual.pdfTest; Cyrulnick, B. (2004). La construcción de la resiliencia en el transcurso de las relaciones precoces. En B. Cyrulnick et al. (Eds.). El realismo de la esperanza (pp. 17-31). Barcelona: Gedisa.; Echeburua, E., Corral, P., & Amor, P. (2018). Evaluación del daño psicológico en las víctimas de delitos violentos. Revista de Psicopatología Clínica Legal y Forense, 4, 227–244.; Folkman, S., & Moskowitz, J. T. (2004). Coping: Pitfalls and Promise. The Annual Review of Psychology, 55, 745-774. https://doi.org/10.1146/annurev.psych.55.090902.141456Test; Grotberg, E. (1995). The International Resilience Project: Promoting Resilience in Children. Wisconsin: Universidad de Wisconsin. Recuperado de https://eric.ed.gov/?id=ED383424Test; Herrera Contreras, J. D., Ramírez Hoyos, G. M., & Ussa Buitrago, K. A. (2019). Secuelas psicológicas en mujeres víctimas de abuso sexual dentro del marco del conflicto armado colombiano [Tesis de pregrado, Universidad Cooperativa de Colombia]. Recuperado de https://repository.ucc.edu.co/server/api/core/bitstreams/bae6d48a-ddea-4960-acaa-c3f2bf230b99/contentTest; Hernández Sampieri, R., Fernández Collado, C., y Baptista Lucio, P. (2010). Nacimiento de un proyecto de investigación cuantitativa o mixta: la idea. En Metodología de la investigación. (pp. 24-30). Recuperado de https://www.esup.edu.pe/descargas/dep_investigacion/Metodologia%20de%20la%20investigaci%C3%B3n%205ta%20Edici%C3%B3n.pdfTest; Hernández Sampieri, Roberto , Fernández Collado, Carlos , Baptista Lucio, María del Pilar (2014). Metodología de la investigación (6° ed.). México: McGraw Hill Interamericana Editores S.A. de C.V.; Larsen, R. J., & Buss, D. M. (2005). Psicología de la personalidad: Dominios del conocimiento sobre la naturaleza humana. McGraw Hill.; Lazarus, R., & Folkman, S. (1984). Stress, Appraisal, and Coping. New York: Springer.; Lozano, M. X., & Caycedo, C. (2008). Terapia de aceptación y compromiso para un caso de trastorno de evitación experiencial [Tesis de especialización]. Pontificia Universidad Javeriana, Bogotá, Colombia.; Luthar, S., Cicchetti, D., & Becker, B. (2000). The construct of resilience: A critical evaluation and guidelines for future work. Child Development, 71(3), 543-562.; Manciaux, Michel et al. (2003). La resiliencia: resistir y rehacerse. Barcelona: Gedisa.; Masten, A. S., & O'Dougherty, M. (2010). Resilience over the lifespan. Developmental perspectives on resistance, recovery and transformation. En J. W. Reich, A. J. Zautra, y J. S. Hall (Eds.), Handbook of adult resilience (pp. 213–237). New York: Guildford Press.; McDonnel, A., Jones, L., & Read, S. (2000). Practical considerations in case study research: The relationship between methodology and process. Journal of Advanced Nursing, 32, 383–390.; Médicos Sin Fronteras. (2017). Colombia: Los impactos olvidados del conflicto armado. Recuperado de https://www.msf.es/sites/default/files/attachments/msf_report-colombia-aug2017.pdfTest; Ministerio de Salud y Protección Social. (2012). Resolución número 000459 de 2012 Por la cual se adopta el Protocolo y Modelo de Atención Integral en Salud para Víctimas de Violencia Sexual [Resolución]. Recuperado de https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/Resolucion-0459-de-2012.PDFTest; Morales Arias, C. (2014). Memorias de un proceso de acompañamiento psicosocial con mujeres víctimas de violencia sexual [Informe]. Corporación Sisma Mujer. Recuperado de https://www.sismamujer.org/wp-content/uploads/2021/08/2016-40.-La-olla-de-Saroma-Yobati.pdfTest; Organización Mundial de la Salud. (2021). Violencia contra las mujeres: estimaciones para 2018. Recuperado de https://iris.who.int/bitstream/handle/10665/349589/9789240027114-spa.pdf?sequence=1Test; Organización Mundial de la Salud y Organización Panamericana de la salud. (2013). Comprender y abordar la violencia contra las mujeres. Recuperado de https://oig.cepal.org/sites/default/files/20184_violenciasexual.pdfTest; Rutter, M. (1990). Psychosocial resilience and protective mechanisms. En J. Rolf, A.S. masten, D. Ciccetti y otros (eds.).Risk and protective factors in the developmental of psychopatology, pp.181-214. Cambridge: Cambridge University Press.; Rutter, M. (1993). Resilience; some conceptual considerations. Journal of Adolescent Health. 14, 8, págs. 626-631; Sistema Integrado de Información de Violencias de Género (SIVIGE) basado en cifras del Instituto Nacional de Medicina Legal y Ciencias Forenses (INML-CF). (2023). Observatorio de Violencias de Género. Recuperado de https://www.sispro.gov.co/observatorios/onviolenciasgenero/Paginas/home.aspxTest; Taylor, S. J., & Bogdan, R. (1987). Introducción a los métodos cualitativos de investigación: La búsqueda de significados (1a ed.). Barcelona.; Tugade, M. M., & Fredrickson, B. L. (2004). Resilient individuals use positive emotions to bounce back from negative emotional experiences. Journal of Personality and Social Psychology, 86, 320–333.; Uriarte Arciniega, J. D., (2005). La resiliencia. Una nueva perspectiva en psicopatología del desarrollo. Revista de Psicodidáctica, 10(2), 61-79.; Unidad para la atención y reparación integral a las víctimas –UARIV-. (2015). Experiencia de la estrategia de recuperación emocional con mujeres víctimas de violencia sexual en Colombia. Recuperado de https://colombia.unfpa.org/sites/default/files/pub-pdf/Mujeres%20V%C3%ADctimas%20de%20Violencia%20Sexual%20Col.pdfTest; Wagnild, G. M. (2009). The Resilience Scale User’s Guide for the US English version of the Resilience Scale and the 14-Item Resilience Scale. Worden, Montana (USA): The Resilience Center.; Werner, E.E. y Smith, R.S. (1992). Overcoming the Odds: Hig-Risk Children from Birth to Adulthood. Ithaca. Nueva York: Cornell University Press.; Werner, E. E. (1993). Risk, Resilience, and Recovery: Perspectives from the Kauai Longitudinal Study.Development and Psychopathology, 5, 503-515. https://doi.org/10.1017/S095457940000612XTest; Werner, E.E. (2003). Prólogo a N. Henderson y M. Milstein: La resiliencia en la escuela. Buenos Aires: Paidós.; Wigram, T. (2004). Improvisation: Methods and techniques for music therapy clinicians, educators, and students. Londres, Inglaterra.; Yin, R. (1994). Case Study Research: Design and Methods. Sage Publications, Thousand Oaks, CA.; https://repositorio.unal.edu.co/handle/unal/86158Test; Universidad Nacional de Colombia; Repositorio Institucional Universidad Nacional de Colombia; https://repositorio.unal.edu.coTest/

الإتاحة: https://doi.org/10.5944/rppc.vol.11.num.3.2006.402410.1017/S095457940000612XTest
https://repositorio.unal.edu.co/handle/unal/86158Test
https://repositorio.unal.edu.coTest/

المؤلفون: Saldaña Peñaloza, Diego Aeljandro

المساهمون: Mahecha Lopez, Daniel Hernán, Rey Buitrago, Mauricio, Castro Rojas, Carlos, Genética clínica

مصطلحات موضوعية: 610 - Medicina y salud::615 - Farmacología y terapéutica, Farmacogenética, Biología Computacional/métodos, Investigación Genética, Pharmacogenetics, Computational Biology/methods, Genetic Research, Dihidropirimidina deshidrogenasa, Valor predictivo de las pruebas, Mutación de cambio de sentido, Análisis In Silico, Dihydropyrimidine dehydrogenase, Predictive value of tests, Missense mutation, In Silico analysis

وصف الملف: 123 páginas; application/pdf

العلاقة: Bireme; Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. diciembre de 1977;74(12):5463-7.; Wake DT, Ilbawi N, Dunnenberger HM, Hulick PJ. Pharmacogenomics: Prescribing Precisely. Med Clin North Am. noviembre de 2019;103(6):977-90.; Verma M, Kulshrestha S, Puri A. Genome Sequencing. En: Keith JM, editor. Bioinformatics: Volume I: Data, Sequence Analysis, and Evolution [Internet]. New York, NY: Springer; 2017 [citado 25 de marzo de 2023]. p. 3-33. (Methods in Molecular Biology). Disponible en: https://doi.org/10.1007/978-1-4939-6622-6_1Test; Petrosino M, Novak L, Pasquo A, Chiaraluce R, Turina P, Capriotti E, et al. Analysis and Interpretation of the Impact of Missense Variants in Cancer. Int J Mol Sci. 21 de mayo de 2021;22(11):5416.; Rodrigues C, Santos-Silva A, Costa E, Bronze-da-Rocha E. Performance of In Silico Tools for the Evaluation of UGT1A1 Missense Variants. Hum Mutat. diciembre de 2015;36(12):1215-25.; Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev [Internet]. 1 de junio de 2020 [citado 25 de marzo de 2023];86. Disponible en: https://www.cancertreatmentreviews.com/article/S0305-7372Test(20)30057-8/fulltext; Morganti S, Tarantino P, Ferraro E, D´Amico P, Achutti B, Curigliano G. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. In: Ruiz-Garcia, E., Astudillo-de la Vega, H. (eds) Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. Advances in Experimental Medicine and Biology [Internet]. Vol. 1168. Switzerland: Springer Nature; [citado 25 de marzo de 2023]. 9–30 p. Disponible en: https://link.springer.com/chapter/10.1007/978-3-030-24100-1_2Test; Micaglio E, Locati ET, Monasky MM, Romani F, Heilbron F, Pappone C. Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine. Front Pharmacol. 2021;12(651720):1-17; Lunenburg CATC, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JHM, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer. 1 de febrero de 2016;54:40-8.; Sharma V, Gupta SK, Verma M. Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs %7C SpringerLink. 4 de septiembre de 2019;84(6):1157-66.; Campbell JM, Bateman E, Peters MD, Bowen JM, Keefe DM, Stephenson MD. Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review ofsystematic reviews and meta-analyses. Pharmacogenomics. marzo de 2016;17(4):435-51.; Lunenburg CATC, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. abril de 2020;28(4):508-17.; Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update - Amstutz - 2018 - Clinical Pharmacology & Therapeutics - Wiley Online Library. 103(2):210-2016.; Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. Int J Mol Sci. 10 de diciembre de 2021;22(24):13302.; Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol. 20 de enero de 2016;34(3):227-34.; Henricks LM, Lunenburg CATC, Man FM de, Meulendijks D, Frederix GWJ, Kienhuis E, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 1 de noviembre de 2018;19(11):1459-67.; Innocenti F, Mills SC, Sanoff H, Ciccolini J, Lenz HJ, Milano G. All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. JCO Oncol Pract. diciembre de 2020;16(12):793-8.; Barin-Le Guellec C, Lafay-Chebassier C, Ingrand I, Tournamille JF, Boudet A, Lanoue MC, et al. Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France. Eur J Cancer. 1 de enero de 2020;124:37-46.; Farinango C, Gallardo-Cóndor J, Freire-Paspuel B, Flores-Espinoza R, Jaramillo-Koupermann G, López-Cortés A, et al. Genetic Variations of the DPYD Gene and Its Relationship with Ancestry Proportions in Different Ecuadorian Trihybrid Populations. J Pers Med. 10 de junio de 2022;12(6):950.; Rodrigues JCG, Fernandes MR, Ribeiro-dos-Santos AM, de Araújo GS, de Souza SJ, Guerreiro JF, et al. Pharmacogenomic Profile of Amazonian Amerindians. J Pers Med. 10 de junio de 2022;12(6):952.; Silgado-Guzmán DF, Angulo-Aguado M, Morel A, Niño-Orrego MJ, Ruiz-Torres DA, Contreras Bravo NC, et al. Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing. Front Pharmacol. 2022;13(931531):1-14.; Danchin A. In vivo, in vitro and in silico: an open space for the development of microbe-based applications of synthetic biology. Microb Biotechnol. 2022;15(1):42-64.; Carvalho C, Varela SAM, Bastos LF, Orfão I, Beja V, Sapage M, et al. The Relevance of In Silico, In Vitro and Non-human Primate Based Approaches to Clinical Research on Major Depressive Disorder. Altern Lab Anim. 1 de julio de 2019;47(3-4):128-39.; Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med. octubre de 2016;16(5):481-5.; Montané E, Santesmases J. Reacciones adversas a medicamentos. Med Clínica. 13 de marzo de 2020;154(5):178-84.; Elzagallaai AA, Carleton BC, Rieder MJ. Pharmacogenomics in Pediatric Oncology: Mitigating Adverse Drug Reactions While Preserving Efficacy. Annu Rev Pharmacol Toxicol. 2021;61(1):679-99.; Lavan AH, O’Mahony D, Buckley M, O’Mahony D, Gallagher P. Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability. The Oncologist. septiembre de 2019;24(9):e968-77.; Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas. Actas Dermo-Sifiliográficas. 1 de enero de 2021;112(1):90-2.; Schütte M, Ogilvie LA, Rieke DT, Lange BMH, Yaspo ML, Lehrach H. Cancer Precision Medicine: Why More Is More and DNA Is Not Enough. Public Health Genomics. 2017;20(2):70-80.; Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 1 de junio de 2018;109(6):952-63.; Grandori C, Kemp CJ. Personalized Cancer Models for Target Discovery and Precision Medicine. Trends Cancer. septiembre de 2018;4(9):634-42.; Low S, Zembutsu H, Nakamura Y. Breast cancer: The translation of big genomic data to cancer precision medicine. Cancer Sci. marzo de 2018;109(3):497-506.; Malki MA, Pearson ER. Drug–drug–gene interactions and adverse drug reactions. Pharmacogenomics J. 2020;20(3):355-66.; Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 4 de mayo de 2019;12(5):407-42.; Rodríguez-Vicente AE, Lumbreras E, Hernández JM, Martín M, Calles A, Otín CL, et al. Pharmacogenetics and pharmacogenomics as tools in cancer therapy. Drug Metab Pers Ther. 1 de marzo de 2016;31(1):25-34.; Mhandire DZ, Goey AKL. The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients. Mol Diagn Ther. marzo de 2022;26(2):137-51.; Kobuchi S, Ito Y. Application of Pharmacometrics of 5-Fluorouracil to Personalized Medicine: A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses. Anticancer Res. 1 de diciembre de 2020;40(12):6585-97.; Sethy C, Kundu CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother. 1 de mayo de 2021;137:111285.; Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 1 de noviembre de 2016;50:9-22.; Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther. 1 de febrero de 2020;206:107447.; ABC Transporter-Mediated Multidrug-Resistant Cancer %7C SpringerLink [Internet]. [citado 24 de abril de 2023]. Disponible en: https://link.springer.com/chapter/10.1007/978-981-13-7647-4_12Test; Varma A, Mathaiyan J, Shewade D, Dubashi B, Sunitha K. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India. J Clin Pharm Ther. 2020;45(4):617-27.; Nishibeppu K, Komatsu S, Imamura T, Kiuchi J, Kishimoto T, Arita T, et al. Plasma microRNA profiles: identification of miR-1229-3p as a novel chemoresistant and prognostic biomarker in gastric cancer. Sci Rep. 21 de febrero de 2020;10:3161.; Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics. abril de 2011;21(4):237-42.; Castro-Rojas C, Ortiz-López R, Rojas-Martínez A. Farmacogenómica del tratamiento de primera línea en el cáncer gástrico: avances en la identificación de los biomarcadores genómicos de respuesta clínica. Investig Clínica. junio de 2014;55(2):185-202.; Wu XP, Dolnick BJ. 5-Fluorouracil alters dihydrofolate reductase pre-mRNA splicing as determined by quantitative polymerase chain reaction. Mol Pharmacol. 1 de julio de 1993;44(1):22-9.; Greenhalgh DA, Parish JH. Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells. Br J Cancer. marzo de 1990;61(3):415-9.; Noordhuis P, Holwerda U, Wilt CLV der, Groeningen CJV, Smid K, Meijer S, et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol. 1 de julio de 2004;15(7):1025-32.; Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero P, et al. Characterization of the Human Dihydropyrimidine Dehydrogenase Gene. Genomics. 1 de agosto de 1998;51(3):391-400.; Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB. Structural Organization of the Human Dihydropyrimidine Dehydrogenase Gene1. Cancer Res. 1 de mayo de 1997;57(9):1660-3.; Dobritzsch D, Ricagno S, Schneider G, Schnackerz KD, Lindqvist Y. Crystal Structure of the Productive Ternary Complex of Dihydropyrimidine Dehydrogenase with NADPH and 5-Iodouracil: IMPLICATIONS FOR MECHANISM OF INHIBITION AND ELECTRON TRANSFER∗. J Biol Chem. 12 de abril de 2002;277(15):13155-66.; Dobritzsch D, Schneider G, Schnackerz KD, Lindqvist Y. Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil. EMBO J. 15 de febrero de 2001;20(4):650-60.; Brutcher E. 5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration. Number 6 Dec 2018. 1 de diciembre de 2018;22(6):627-34.; García-González X, Kaczmarczyk B, Abarca-Zabalía J, Thomas F, García-Alfonso P, Robles L, et al. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine. Cancer Chemother Pharmacol. julio de 2020;86(1):45-54.; White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Ackland S. Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature. Pharmacogenomics Pers Med. 9 de diciembre de 2021;14:1603-17.; Hamzic S, Schärer D, Offer SM, Meulendijks D, Nakas C, Diasio RB, et al. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity. Br J Clin Pharmacol. agosto de 2021;87(8):3234-43.; Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience - PMC [Internet]. [citado 24 de abril de 2023]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018309Test/; Ng PC, Henikoff S. Predicting Deleterious Amino Acid Substitutions. Genome Res. mayo de 2001;11(5):863-74.; Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. abril de 2010;7(4):248-9.; Tang B, Li B, Gao LD, He N, Liu XR, Long YS, et al. Optimization of in silico tools for predicting genetic variants: individualizing for genes with molecular sub-regional stratification. Brief Bioinform. 25 de septiembre de 2020;21(5):1776-86.; Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 1 de julio de 2003;31(13):3812-4.; Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. abril de 2014;11(4):361-2.; Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 1 de septiembre de 2011;39(17):e118.; Reva B, Antipin Y, Sander C. Determinants of protein function revealed by combinatorial entropy optimization. Genome Biol. 1 de noviembre de 2007;8(11):R232.; 67. biocompute.org.uk. fathmm. [citado 22 de agosto de 2023]. Functional Analysis through Hidden Markov Models (v2.3). Disponible en: http://fathmm.biocompute.org.uk/about.htmlTest; Quang D, Chen Y, Xie X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. Bioinformatics. 1 de marzo de 2015;31(5):761-3.; Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. marzo de 2014;46(3):310-5.; Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, et al. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet. 15 de abril de 2015;24(8):2125-37.; Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S. Identifying a High Fraction of the Human Genome to be under Selective Constraint Using GERP++. PLoS Comput Biol. 2 de diciembre de 2010;6(12):e1001025.; Feng BJ. PERCH: A Unified Framework for Disease Gene Prioritization. Hum Mutat. 2017;38(3):243-51.; Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet. 6 de octubre de 2016;99(4):877-85.; Wu Y, Li R, Sun S, Weile J, Roth FP. Improved pathogenicity prediction for rare human missense variants. Am J Hum Genet. 7 de octubre de 2021;108(10):1891-906.; Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the Functional Effect of Amino Acid Substitutions and Indels. PLoS ONE. 8 de octubre de 2012;7(10):e46688.; IONITA-LAZA I, MCCALLUM K, XU B, BUXBAUM J. A SPECTRAL APPROACH INTEGRATING FUNCTIONAL GENOMIC ANNOTATIONS FOR CODING AND NONCODING VARIANTS. Nat Genet. febrero de 2016;48(2):214-20.; Li B, Seligman C, Thusberg J, Miller JL, Auer J, Whirl-Carrillo M, et al. In silico comparative characterization of pharmacogenomic missense variants. BMC Genomics. 20 de mayo de 2014;15(4):S4.; Duzkale H, Shen J, McLaughlin H, Alfares A, Kelly M, Pugh T, et al. A systematic approach to assessing the clinical significance of genetic variants. Clin Genet. noviembre de 2013;84(5):453-63.; Zloh M, Kirton SB. The benefits of in silico modeling to identify possible small-molecule drugs and their off-target interactions. Future Med Chem. febrero de 2018;10(4):423-32.; Masica DL, Karchin R. Towards Increasing the Clinical Relevance of In Silico Methods to Predict Pathogenic Missense Variants. PLoS Comput Biol. 12 de mayo de 2016;12(5):e1004725.; Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes GB. In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat. noviembre de 2008;29(11):1327-36.; Zhou Y, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke VM. An optimized prediction framework to assess the functional impact of pharmacogenetic variants. Pharmacogenomics J. 2019;19(2):115-26.; Lahti JL, Tang GW, Capriotti E, Liu T, Altman RB. Bioinformatics and variability in drug response: a protein structural perspective. J R Soc Interface. 7 de julio de 2012;9(72):1409.; Pandi MT, Koromina M, Tsafaridis I, Patsilinakos S, Christoforou E, van der Spek PJ, et al. A novel machine learning-based approach for the computational functional assessment of pharmacogenomic variants. Hum Genomics. 9 de agosto de 2021;15:51.; Zhou Y, Lauschke VM. Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability. Clin Pharmacol Ther. septiembre de 2021;110(3):626-36.; Farajzadeh-Dehkordi M, Mafakher L, Samiee-Rad F, Rahmani B. Computational analysis of missense variant CYP4F2*3 (V433M) in association with human CYP4F2 dysfunction: a functional and structural impact. BMC Mol Cell Biol. 9 de mayo de 2023;24:17.; Joshi K, Kaur S, Kumar R. Cytochrome P450 2C19 gene polymorphisms (CYP2C19*2 and CYP2C19*3) in chronic myeloid leukemia patients: in vitro and in silico studies. J Biomol Struct Dyn. 2022;40(19):9389-402.; Shrestha S, Zhang C, Jerde CR, Nie Q, Li H, Offer SM, et al. Gene-specific variant classifier (DPYD-Varifier) to identify deleterious alleles of dihydropyrimidine dehydrogenase. Clin Pharmacol Ther. octubre de 2018;104(4):709-18.; Rodrigues-Soares F, Suarez-Kurtz G. Pharmacogenomics research and clinical implementation in Brazil. Basic Clin Pharmacol Toxicol. 2019;124(5):538-49.; Cavalcante GC, Freitas NDSDC, Ribeiro-Dos-Santos AM, Carvalho DCD, Silva EMD, Assumpção PPD, et al. Investigation of Potentially Deleterious Alleles for Response to Cancer Treatment with 5-Fluorouracil. Anticancer Res. 1 de diciembre de 2015;35(12):6971-7.; Zhou Y, Fujikura K, Mkrtchian S, Lauschke VM. Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data. Front Pharmacol. 4 de diciembre de 2018;9:1437.; Pallet N, Hamdane S, Garinet S, Blons H, Zaanan A, Paillaud E, et al. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency. Br J Cancer. septiembre de 2020;123(5):811-8.; Principi N, Petropulacos K, Esposito S. Impact of Pharmacogenomics in Clinical Practice. Pharmaceuticals. noviembre de 2023;16(11):1596.; Frontiers %7C A practical guide for the generation of model-based virtual clinical trials [Internet]. [citado 25 de febrero de 2024]. Disponible en: https://www.frontiersin.org/articles/10.3389/fsysb.2023.1174647/fullTest; Alnasser B. A Review of Literature on the Economic Implications of Implementing Artificial Intelligence in Healthcare. E-Health Telecommun Syst Netw. 15 de septiembre de 2023;12(3):35-48.; Brooks GA, Tapp S, Daly AT, Busam JA, Tosteson ANA. Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based adjuvant chemotherapy for colon cancer. Clin Colorectal Cancer. septiembre de 2022;21(3):e189-95.; Moldrup C. Ethical, social and legal implications of pharmacogenomics: a critical review. Community Genet. 2001;4(4):204-14.; Methods to Develop an in silico Clinical Trial: Computational Head-to-Head Comparison of Lisdexamfetamine and Methylphenidate - PMC [Internet]. [citado 25 de febrero de 2024]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595241Test/; Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper - FullText - Oncology Research and Treatment 2020, Vol. 43, No. 11 - Karger Publishers [Internet]. [citado 24 de abril de 2023]. Disponible en: https://www.karger.com/Article/FullText/510258Test; https://repositorio.unal.edu.co/handle/unal/86050Test; Universidad Nacional de Colombia; Repositorio Institucional Universidad Nacional de Colombia; https://repositorio.unal.edu.coTest/

الإتاحة: https://doi.org/10.1007/978-1-4939-6622-6_1Test
https://repositorio.unal.edu.co/handle/unal/86050Test
https://repositorio.unal.edu.coTest/

المؤلفون: Orjuela Rocha, Adrian Leonardo

المساهمون: Alí Torres, Jorge Isaac, Núñez Zarur, Francisco, Química Cuántica y Computacional, orcid:0000-0003-2789-3948

مصطلحات موضوعية: 540 - Química y ciencias afines::541 - Química física, 610 - Medicina y salud::615 - Farmacología y terapéutica, Hierro/análisis, Placa Amiloide/prevención & control, Enfermedad de Alzheimer/tratamiento farmacológico, Iron/analysis, Plaque, Amyloid/prevention & control, Alzheimer Disease/drug therapy, Alzheimer, DFT, Hierro, Dinámica Molecular, Acoplamiento molecular, Productos naturales, Iron, Molecular dynamics, Molecular docking, Natural products

وصف الملف: xix, 129 páginas; application/pdf

العلاقة: Bireme; J. Lakey-Beitia, Y. González, D. Doens, D. E. Stephens, R. Santamaría, E. Murillo, M. Gutírrez, P. L. Fernández, K. S. Rao, O. V. Larionov, and A. A. Durant-Archibold, “Assessment of novel curcumin derivatives as potent inhibitors of inflammation and amyloid-β aggregation in alzheimer’s disease,” J. Alzheimer’s Dis., vol. 60, pp. S59– S68, 2017; J. Lakey-Beitia, R. Berrocal, K. S. Rao, and A. A. Durant, “Polyphenols as therapeutic molecules in alzheimer’s disease through modulating amyloid pathways,” Molecular Neurobiology, vol. 51, pp. 466–479, 2015; K. P. Kepp, “Bioinorganic chemistry of Alzheimer’s disease,” Chemical reviews, vol. 112, p. 5193–5239, 2012; J. Alí-Torres, “Estudio teóico de la estructura electrónica y molecular de complejos de Cu1+/2+ y Fe2+/3+ relevantes en la enfermedad de Alzheimer,” Tesis Doctoral, 2011; J. Alí-Torres, L. Rodríguez, M. Sodupe, and A. Rauk, “Structures and stabilities of Fe2+/3+ complexes relevant to Alzheimer’s disease: An ab Initio study,” Journal of Phisycal Chemistry, vol. 115, pp. 12523–12530, 2011; A. Kramida, Yu.Ralchenko, and J. Reader, “NIST atomic spectra database ionization energies data,” 2021; A. L. Orjuela, F. Núnez-Zarur, and J. Alí-Torres, “A computational protocol for the calculation of the standard reduction potential of iron complexes: application to Fe2+/3+ − Aβ model systems relevant to alzheimer’s disease,” RSC Advances, vol. 12, pp. 24077–24087, 2022; A. Association, “2021 Alzheimer’s disease facts and figures,” Alzheimers Dement, vol. 13, pp. 325–373, 2021; C. R. de Sanchez, D. M. Nariño, and J. Fernando, “Epidemiologia y carga de la enfermedad de alzheimer,” Acta Neurologica Colombiana, vol. 26, pp. 87–94, 2010.; F. Lopera, M. Arcos, L. Madrigal, K. Kosik, W. Cornejo, and J. Ossa, “Demencia tipo Alzheimer con agregación familiar en Antioquia , Colombia,” Acta Neurológica Colombiana, vol. 10, pp. 173–187, 1994; P. V. Arriagada, J. H. Growdon, E. T. Hedley-Whyte, and B. T. Hyman, “Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease,” Neurology, vol. 42, pp. 631–631, 2012.; A. Mirats, J. Ali-Torres, L. Rodriguez-Santiago, M. Sodupe, and G. L. Penna, “Dioxygen activation in the Cu-amyloid β complex,” Phys. Chem. Chem. Phys., vol. 17, pp. 27270–27274, 2015; G. Waldemar, B. Dubois, M. Emre, J. Georges, I. G. McKeith, M. R. P. Schel-tens, P. Tariska, B. Winblad, , and EFNS, “Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: Efns guideline,” Eur. J . Neurol, vol. 14, pp. 1–26, 2007; A. Rauk, “The chemistry of Alzheimer’s disease,” Chemical Society Reviews, vol. 38, pp. 2698–2715, 2009; J. Kardos, I. Kovfics, F. Haj ́os, M. K ́alaman, and M. Simonyi, “Nerve endings from rat brain tissue release copper upon depolarization. a possible role in regulating neuronal excitability,” Neuroscience Letters, vol. 103, pp. 139–144, 1989; C. J. Maynard, R. Cappai, I. Volitakis, R. A. Cherny, A. R. White, K. Beyreuther, C. L. Masters, A. I. Bush, and Q. X. Li, “Overexpression of alzheimer’s disease amyloid- opposes the age-dependent elevations of brain copper and iron,” Journal of Biological Chemistry, vol. 277, pp. 44670–44676, 2002; M. Lovell, J. Robertson, W. Teesdale, J. Campbell, and W. Markesbery, “Copper, iron and zinc in alzheimer’s disease senile plaques,” Journal of the Neurological Sciences, vol. 158, pp. 47–52, 1998; F.-G. Pajonk, H. Kessler, T. Supprian, P. Hamzei, D. Bach, J. Schweickhardt, W. Herrmann, R. Obeid, A. Simons, P. Falkai, G. Multhaup, and T. A. Bayer, “Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 8, pp. 23–27, 2005; T. Borchardt, J. Camakaris, R. Cappai, C. L. Masters, K. Beyreuther, and G. Multhaup, “Copper inhibits β-amyloid production and stimulates the non- amyloidogenic pathway of amyloid-precursor-protein secretion,” Biochem. J, vol. 344, pp. 461–467, 1999.; J. H. Weiss, S. L. Sensi, and J. Y. Koh, “Zn2+: a novel ionic mediator of neural injury in brain disease,” Trends in Pharmacological Sciences, vol. 21, pp. 395–401, 2000; C. J. Frederickson, S. W. Suh, D. Silva, C. J. Frederickson, and R. B. Thompson, “Importance of zinc in the central nervous system: The zinc-containing neuron,” The Journal of Nutrition, vol. 130, pp. 1471S–1483S, 2000.; L. M. Miller, Q. Wang, T. P. Telivala, R. J. Smith, A. Lanzirotti, and J. Miklossy, “Synchrotron-based infrared and x-ray imaging shows focalized accumulation of cu and zn co-localized with -amyloid deposits in alzheimer’s disease,” Journal of Structural Biology, vol. 155, pp. 30–37, 2006; J. R. Connor, S. L. Menzies, J. R. Burdo, and P. J. Boyer, “Iron and iron management proteins in neurobiology,” Pediatric Neurology, vol. 25, pp. 118–129, 2001.; J. L. Beard, J. R. Connor, and B. C. Jones, “Iron in the brian,” Nutrition Reviews, vol. 51, pp. 157,170, 1993; H. M. Schipper, “Heme oxygenase-1: role in brain aging and neurodegeneration,” Ex- perimental Gerontology, vol. 35, pp. 821–830, 2000; N. Puentes-Díaz, D. Chaparro, D. Morales-Morales, A. Flores-Gaspar, and J. Alí- Torres, “Role of metal cations of copper, iron, and aluminum and multifunctional ligands in Alzheimer’s disease: Experimental and computational insights,” ACS Omega, vol. 8, pp. 4508–4526, 2023.; C. C. Winterbourn, “Toxicity of iron and hydrogen peroxide: the Fenton reaction,” Toxicology Letters, vol. 82-83, pp. 969–974, 1995; A. A. Belaidi and A. I. Bush, “Iron neurochemistry in Alzheimer’s disease and par- kinson’s disease: targets for therapeutics,” Journal of Neurochemistry, pp. 179–197, 2016; A. A. Mamun, M. S. Uddin, B. Mathew, and G. M. Ashraf, “Toxic tau: Structural origins of tau aggregation in Alzheimer’s disease,” Neural Regeneration Research, vol. 15, pp. 1417–1420, 2020; J. T. Rogers, J. D. Randall, C. M. Cahill, P. S. Eder, X. Huang, H. Gunshin, L. Leiter, J. McPhee, S. S. Sarang, T. Utsuki, N. H. Greig, D. K. Lahiri, R. E. Tanzi, A. I. Bush, T. Giordano, and S. R. Gullans, “An iron-responsive element type II in the 5- untranslated region of the Alzheimer’s amyloid precursor protein transcript,” Journal of Biological Chemistry, vol. 277, pp. 45518–45528, 2002; D. J. Pinero and J. R. Connor, “Iron in the brain: An important contributor in normal and diseased states,” Neuroscientist, vol. 6, pp. 435–453, 2000; G. P. Kumar and F. Khanum, “Neuroprotective potential of phytochemicals.,” Pharmacogn Rev, vol. 6, pp. 81–90, 2012; M. Iranshahi, M. G. Chini, M. Masullo, A. Sahebkar, A. Javidnia, M. C. Yazdi, C. Per- gola, A. Koeberle, O. Werz, C. Pizza, S. Terracciano, S. Piacente, and G. Bifulco, “Can small chemical modifications of natural pan-inhibitors modulate the biological selectivity? the case of curcumin prenylated derivatives acting as hdac or mpges-1 inhibitors,” Journal of Natural Products, vol. 78, pp. 2867–2879, 2015; I. Morales, C. Cerda-Troncoso, V. Andrade, and R. B. Maccioni, “The natural product curcumin as a potential coadjuvant in Alzheimer’s treatment,” Journal of Alzheimer’s Disease, vol. 60, pp. 451–460, 2017; M. Dumont and M. F. Beal, “Neuroprotective strategies involving ROS in Alzheimer disease,” Free Radical Biology and Medicine, vol. 51, pp. 1014–1026, 2011; J. Lakey-Beitia, A. M. Burillo, G. L. Penna, M. L. Hegde, and K. S. Rao, “Polyphe- nols as potential metal chelation compounds against Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 82, pp. S335–S357, 2021; D. Chaparro, A. Flores-Gaspar, and J. Alí-Torres, “Computational design of copper ligands with controlled metal chelating, pharmacokinetics, and redox properties for Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 82, pp. S179–S193, 2021; K. Ono, Y. Yoshiike, A. Takashima, K. Hasegawa, H. Naiki, and M. Yamada, “Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer’s disease,” J Neurochem, vol. 87, pp. 172–181, 2003; C. Rivière, T. Richard, X. Vitrac, J. M. Mérillon, J. Valls, and J. P. Monti, “New polyphenols active on β-amyloid aggregation,” Bioorg. Med. Chem. Lett, vol. 18, pp. 828–831, 2008; K. I. Priyadarsini, “The chemistry of curcumin: From extraction to therapeutic agent,” Molecules, vol. 19, pp. 20091–20112, 2014; A. Marchiani, S. Mammi, G. Siligardi, R. Hussain, I. Tessari, L. Bubacco, G. Delogu, D. Fabbri, and P. Ruzza, “Small molecules interacting with alpha -synuclein: antiaggregating and cytoprotective properties,” Amino Acids, vol. 45, pp. 327–338, 2013.; J. Wu, Y. Zhang, Y. Cai, J. Wang, B. Weng, Q. Tang, X. Chen, Z. Pan, G. Liang, and S. Yang, “Discovery and evaluation of piperid-4-one-containing mono-carbonyl analogs of curcumin as anti-inflammatory agents,” Bioorganic and Medicinal Chemistry, vol. 21, pp. 3058–3065, 2013.; F. Arrigoni, T. Prosdocimi, L. Mollica, L. D. Gioia, G. Zampella, and L. Bertini, “Copper reduction and dioxygen activation in Cu-amyloid beta peptide complexes: insight from molecular modelling,” Metallomics, vol. 10, pp. 1618–1630, 2018; D. J. Lane, S. Ayton, and A. I. Bush, “Iron and Alzheimer’s disease: An update on emerging mechanisms,” Journal of Alzheimer’s Disease, vol. 64, pp. S379–S395, 2018; M. Radón, “Benchmarking quantum chemistry methods for spin-state energetics of iron complexes against quantitative experimental data,” Physical Chemistry Chemical Physics, vol. 21, pp. 4854–4870, 2019; G. M. Sandala, K. H. Hopmann, A. Ghosh, and L. Noodleman, “Calibration of dft functionals for the prediction of 57 Fe m ̈ossbauer spectral parameters in iron-nitrosyl and iron-sulfur complexes: Accurate geometries prove essential,” Journal of Chemical Theory and Computation, vol. 7, pp. 3232–3247, 2011; S. Song, M.-C. Kim, E. Sim, A. Benali, O. Heinonen, and K. Burke, “Benchmarks and reliable DFT results for spin-crossover complexes,” arXiv: Chemical Physics, 2017; J. Conradie and A. Ghosh, “DFT calculations on the spin-crossover complex Fe(salen)(NO): A quest for the best functional,” Journal of Physical Chemistry B, vol. 111, pp. 12621–12624, 2007; K. Arumugam and U. Becker, “Computational redox potential predictions: Applications to inorganic and organic aqueous complexes, and complexes adsorbed to mineral surfaces,” Minerals, vol. 4, pp. 345–387, 2014; L. E. Roy, E. Jakubikova, M. G. Guthrie, and E. R. Batista, “Calculation of one- electron redox potentials revisited. is it possible to calculate accurate potentials with density functional methods?,” Journal of Physical Chemistry A, vol. 113, pp. 6745– 6750, 2009.; M. A. Rizvi, M. Mane, M. A. Khuroo, and G. M. Peerzada, “Computational survey of ligand properties on iron(III)–iron(II) redox potential: exploring natural attenuation of nitroaromatic compounds,” Monatshefte fur Chemie, vol. 148, pp. 655–668, 2017.; M. Horch, “Rational redox tuning of transition metal sites: Learning from superoxide reductase,” Chemical Communications, vol. 55, pp. 9148–9151, 2019; K. M. Saravanan, H. Zhang, H. Zhang, W. Xi, and Y. Wei, “On the conformational dynamics of -amyloid forming peptides: A computational perspective,” Frontiers in Bioengineering and Biotechnology, vol. 8, pp. 1–19, 2020; K. Teilum, J. G. Olsen, and B. B. Kragelund, “Protein stability, flexibility and fun- ction,” Biochimica et Biophysica Acta - Proteins and Proteomics, vol. 1814, pp. 969– 976, 2011.; E. Schrödinger, “Quantisierung als eigenwertproblem,” Annalen der Physik, vol. 385, no. 13, pp. 437–490, 1926; A. Szabo and N. S. Ostlund, Modern Quantum Chemistry: : Introduction to Advanced Electronic Structure Theory. Dover Publications, 1 ed., 1996; W. J. Hehre, “Ab initio molecular orbital theory,” Accounts of Chemical Research, vol. 9, pp. 399–406, 1976; B. Nagy and F. Jensen, Basis Sets in Quantum Chemistry, ch. 3, pp. 93–149. John Wiley Sons, Ltd, 2017; M. Dolg, U. Wedig, H. Stoll, and H. Preuss, “Energy-adjusted abinitio pseudopotentials for the first row transition elements,” The Journal of Chemical Physics, vol. 86, no. 2, pp. 866–872, 1987; P. J. Hay and W. R. Wadt, “Ab initio effective core potentials for molecular calcula- tions. Potentials for the transition metal atoms Sc to Hg,” The Journal of Chemical Physics, vol. 82, no. 1, pp. 270–283, 1985; P. Hohenberg and W. Kohn, “Inhomogeneous electron gas,” Phys. Rev., vol. 136, pp. B864–B871, 1964.; W. Kohn and L. J. Sham, “Self-consistent equations including exchange and correlation effects,” Phys. Rev., vol. 140, pp. A1133–A1138, 1965; J. P. Perdew and A. Zunger, “Self-interaction correction to density-functional approxi- mations for many-electron systems,” Phys. Rev. B, vol. 23, pp. 5048–5079; J. P. Perdew and Y. Wang, “Accurate and simple analytic representation of the electron-gas correlation energy,” Phys. Rev. B, vol. 45, pp. 13244–13249; J. P. Perdew, K. Burke, and M. Ernzerhof, “Generalized gradient approximation made simple,” physical review letters, vol. 77, pp. 3865–3868, 1996.; J. Tao, J. P. Perdew, V. N. Staroverov, and G. E. Scuseria, “Climbing the density functional ladder: Nonempirical meta–generalized gradient approximation designed for molecules and solids,” Phys. Rev. Lett., vol. 91, p. 146401; A. V. Arbuznikov, “Hybrid exchange correlation functionals and potentials: Concept elaboration,” Journal of Structural Chemistry, vol. 48, pp. S1–S21, 2007.; J. M. L. Martin and G. Santra, “Empirical double-hybrid density functional theory: A ‘third way’ in between wft and dft,” Israel Journal of Chemistry, vol. 60, no. 8-9, pp. 787–804, 2020; D. Frenkel and B. Smit, Statistical Mechanics. Academic Press, 2 ed., 2002.; C. J. Cramer and D. G. Truhlar, “Implicit solvation models: equilibria, structure, spectra, and dynamics,” Chemical Reviews, vol. 99, pp. 2161–2200, 1999; I. N. Levine, D. H. Busch, and H. Shull, Quantum chemistry. Pearson Prentice Hall Upper Saddle River, NJ, 6 ed., 2009; J. Tomasi, B. Mennucci, and R. Cammi, “Quantum mechanical continuum solvation models,” Chemical Reviews, vol. 105, pp. 2999–3093, 2005; H. M. Senn and W. Thiel, “Qm/mm methods for biomolecular systems,” Angewandte Chemie - International Edition, vol. 48, pp. 1198–1229, 2009; B. Mennucci, J. Tomasi, R. Cammi, J. R. Cheeseman, M. J. Frisch, F. J. Devlin, S. Gabriel, and P. J. Stephens, “Polarizable continuum model (PCM) calculations of solvent effects on optical rotations of chiral molecules,” The Journal of Physical Chemistry A, vol. 106, pp. 6102–6113, 5 2002.; A. V. Marenich, C. J. Cramer, and D. G. Truhlar, “Universal solvation model based on solute electron density and a contiuum model of the solvent defind by the bulk dielectric constant and atomic surface tensions,” J. Phys. Chem. B., vol. 113, pp. 6378–6396, 2009; M. Karplus and J. A. McCammon, “Molecular dynamics simulations of biomolecules,” Nature Structural Biology, vol. 9, pp. 646–652, 2002; R. O. Dror, R. M. Dirks, J. P. Grossman, H. Xu, and D. E. Shaw, “Biomolecular simulation: A computational microscope for molecular biology,” Annual Review of Biophysics, vol. 41, pp. 429–452, 2012.; D. Frenkel and B. Smit, Statistical Mechanics. Academic Press, 2 ed., 2002; A. R. Leach, B. K. Shoichet, and C. E. Peishoff, “Prediction of proteinligand interactions. docking and scoring: successes and gaps,” Journal of Medicinal Chemistry, vol. 49, pp. 5851–5855, 2006; D. B. Kitchen, H. Decornez, J. R. Furr, and J. Bajorath, “Docking and scoring in virtual screening for drug discovery: methods and applications,” Nature Reviews Drug Discovery, vol. 3, pp. 935–949, 2004; R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. Francis, and P. S. Shenkin, “Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy,” Journal of Medicinal Chemistry, vol. 47, pp. 1739–1749, 2004; G. M. Morris, D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart, R. K. Belew, and A. J. Olson, “Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function,” Journal of Computational Chemistry, vol. 19, pp. 1639–1662, 1998; G. Jones, P. Willett, R. C. Glen, A. R. Leach, and R. Taylor, “Development and validation of a genetic algorithm for flexible docking,” Journal of Molecular Biology, vol. 267, pp. 727–748, 1997; M. L. Hegde, P. M. Hegde, K. S. Rao, and S. Mitra, “Oxidative genome damage and its repair in neurodegenerative diseases: Function of transition metals as a double-edged sword,” Journal of Alzheimer’s Disease, vol. 24, pp. 183–198, 2011.; B. J. Tabner, S. Turnbull, R. O. M. El-Agnaf, and D. Allsop, “Production of reactive oxygen species from aggregating proteins implicated in alzheimers disease, parkinsons disease and other neurodegenerative diseases,” Current Topics in Medicinal Chemistry, vol. 1, pp. 507–517, 2005; M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Chee- seman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hrat- chian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. To- yota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. M. Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Mar- tin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, “Gaussian 16 revision D.01,” 2016. Gaussian Inc. Wallingford CT; V. A. Rassolov, J. A. Pople, M. A. Ratner, and T. L. Windus, “6-31G* basis set for atoms K through Zn,” Journal of Chemical Physics, vol. 109, pp. 1223–1229, 1998; F. Weigend and R. Ahlrichs, “Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: Design and assessment of accuracy,” Physical Chemistry Chemical Physics, vol. 7, pp. 3297–3305, 2005; T. H. Dunning, “Gaussian basis sets for use in correlated molecular calculations. i. the atoms boron through neon and hydrogen,” The Journal of Chemical Physics, vol. 90, pp. 1007–1023, 1989; W. J. Stevens, M. Krauss, H. Basch, and P. G. Jasien, “Relativistic compact effective potentials and efficient, shared-exponent basis sets for the third-, fourth-, and fifth-row atoms,” Canadian Journal of Chemistry, vol. 70, pp. 612–630, 1990; N. E. Schultz, Y. Zhao, and D. G. Truhlar, “Density functional for inorganometallic and organometallic chemistry,” Journal of Physical Chemistry A, vol. 109, pp. 11127– 11143, 2005; J. Tomasi and M. Persico, “Molecular interactions in solution: An overview of methods based on continuous distributions of the solvent,” Chemical Reviews, vol. 94, pp. 2027– 2094, 1994; K. Hyungjun, P. Joungwon, and L. Y. Sup, “A protocol to evaluate one electron redox potential for iron complexes,” Journal of Computational Chemistry, vol. 34, pp. 2233– 2241, 2013; S. G. Bratsch, “Standard electrode potentials and temperature coefficients in water at 298.15 k,” Journal of Physical and Chemical Reference Data, vol. 18, pp. 1–21, 1989; M. Cossi, N. Rega, G. Scalmani, and V. Barone, “Energies, structures, and electro- nic properties of molecules in solution with the C-PCM solvation model,” Journal of Computational Chemistry, vol. 24, pp. 669–681, 2003.; A. N. Masliy, T. N. Grishaeva, and A. M. Kuznetsov, “Standard redox potentials of Fe(III) aqua complexes included into the cavities of cucurbit[n]urils (n = 6-8): A DFT forecast,” Journal of Physical Chemistry A, vol. 123, pp. 1341–1346, 2019.; M. D. Tissandier, K. A. Cowen, W. Y. Feng, E. Gundlach, M. H. Cohen, A. D. Earhart, J. V. Coe, and T. R. Tuttle, “The proton’s absolute aqueous enthalpy and gibbs free energy of solvation from cluster-ion solvation data,” vol. 102, pp. 7787–7794, 1998; B. H. Solis and S. Hammes-Schiffer, “Substituent effects on cobalt diglyoxime catalysts for hydrogen evolution,” Journal of the American Chemical Society, vol. 133, pp. 19036–19039, 2011; L. E. Fernandez, S. Horvath, and S. Hammes-Schiffer, “Theoretical analysis of the sequential proton-coupled electron transfer mechanisms for H2 oxidation and production pathways catalyzed by nickel molecular electrocatalysts,” Journal of Physical Che- mistry C, vol. 116, pp. 3171–3180, 2012; D. Chaparro and J. Alí-Torres, “Assessment of the isodesmic method in the calculation of standard reduction potential of copper complexes,” Journal of Molecular Modeling, vol. 23, p. 283, 2017; A. Galstyan and E. W. Knapp, “Accurate redox potentials of mononuclear iron, manganese, and nickel model complexes,” Journal of Computational Chemistry, vol. 30, pp. 203–211, 2009; T. Miura, K. Suzuki, and H. Takeuchi, “Binding of iron(III) to the single tyrosine residue of amyloid beta-peptide probed by raman spectroscopy,” Journal of Molecular Structure, vol. 598, pp. 79–84, 2001; T. Miura, K. Suzuki, N. Kohata, and H. Takeuchi, “Metal binding modes of Alzheimer’s amyloid beta-peptide in insoluble aggregates and soluble complexes,” Biochemistry, vol. 39, pp. 7024–7031, 2000; D. L. Nelson and M. Cox, Lehninger Principles of Biochemistry. W. H Freeman, 2005; E. J. Shin, Y. H. Chung, N. Sharma, B. T. Nguyen, S. H. Lee, S. W. Kang, S. Y. Nah, M. B. Wie, T. Nabeshima, J. H. Jeong, and H. C. Kim, “Glutathione peroxidase- 1 knockout facilitates memory impairment induced by -amyloid (1–42) in mice via inhibition of pkc ii-mediated erk signaling; application with glutathione peroxidase-1 gene-encoded adenovirus vector,” Neurochemical Research, vol. 45, pp. 2991–3002, 12 2020; C. Behl, Oxidative stress in Alzheimer’s Disease: Implications for Prevention and Therapy, pp. 65–78. Boston, MA: Springer US, 2005; M. N. Glukhovtsev, R. D. Bach, and C. J. Nagel, “Performance of the B3LYP/ECP DFT calculations of iron-containing compounds,” Journal of Physical Chemistry A, 1997; P. Pracht, F. Bohle, and S. Grimme, “Automated exploration of the low-energy chemical space with fast quantum chemical methods,” Phys. Chem. Chem. Phys., vol. 22, pp. 7169–7192, 2020; K. A. Wollen, “Alzheimer’s disease: The pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners,” Alternative Medicine Review, vol. 15, pp. 223–244, 2010; E. L. Cooper and M. J. Ma, “Alzheimer disease: Clues from traditional and com- plementary medicine,” Journal of Traditional and Complementary Medicine, vol. 7, pp. 380–385, 2017.; A. A. Starkov and F. M. Beal, “Portal to Alzheimer’s disease,” Nature Medicine, vol. 14, pp. 1020–1021, 2008; V. Calsolaro and P. Edison, “Neuroinflammation in Alzheimer’s disease: Current evidence and future directions,” Alzheimer’s and Dementia, vol. 12, pp. 719–732, 2016; H. Sticht, P. Bayer, D. Willbold, S. Dames, C. Hilbich, K. Beyreuther, R. W. Frank, and P. Rosch, “Structure of amyloid A4-(1-40)-peptide of Alzheimer’s disease,” Eur. J. Biochem, vol. 233, pp. 293–298, 1995; M. Coles, W. Bicknell, a a Watson, D. P. Fairlie, and D. J. Craik, “Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment.,” Biochemistry, vol. 37, pp. 11064–77, 1998; T. Darden, D. Case, I. Ben-Shalom, S. Brozell, D. Cerutti, I. T.E. Cheatham, V. Cru- zeiro, Y. Huang, R. Duke, D. Ghoreishi, M. Gilson, H. Gohlke, A. Goetz, D. Greene, R. Harris, N. Homeyer, D. S. Izadi, A. Kovalenko, T. Kurtzman, T. Lee, S. LeGrand, P. Li, C. Lin, J. Liu, T. L. amd R. Luo, R. Mermelstein, K. Merz, Y. Miao, G. Monard, C. Nguyen, H. Nguyen, I. Omelyan, A. Onufriev, F. Pan, D. York, P. K. Qi, D. Roe, A. Roitberg, C. Sagui, S. Schott-Verdugo, J. Shen, C. Simmerling, J. Smith, R. Sa- lomonFerrer, J. Swails, R. Walker, J. Wang, H. Wei, R. Wolf, X. Wu, and L. Xiao, “Amber 18,” 2018; C. Simmerling, “ff 14sb: Improving the accuracy of protein side chain and backbone parameters from ff 99sb,” J. Chem. Theory Comput, vol. 11, p. 3696–3713, 2015; W. Humphrey, A. Dalke, and K. Schulten, “Vmd: visual molecular dynamics,” Journal of molecular graphics, vol. 14, pp. 33–38, 1996; D. R. Roe and T. E. C. III, “Ptraj and cpptraj: software for processing and analysis of molecular synamics trajectory data,” J Chem Theory Com, vol. 9, pp. 3084–3095, 2013; X. Jin and J. Han, “K-medoids clustering,” Encyclopedia of Machine Learning and Data Mining, pp. 697–700, 2017; L. Schrodinger, “The PyMol molecular graphics system,” 2015; G. Morris and R. Huey, “Autodock4 and autodocktools4: Automated docking with selective receptor flexibility,” Journal of computational chemistry, vol. 30, pp. 2785– 2791, 2009; O. Trott and A. J. Olson, “Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading,” Journal of computational chemistry, vol. 31, pp. 455–461, 2010.; D. R. Koes, M. P. Baumgartner, and C. J. Camacho, “Lessons learned in empirical scoring with smina from the csar 2011 benchmarking exercise,” Journal of Chemical Information and Modeling, vol. 53, pp. 1893–1904, 2013; L. Schrodinger, “Maestro,” 2023; C. N. Cavasotto and R. A. Abagyan, “Protein flexibility in ligand docking and virtual screening to protein kinases,” Journal of Molecular Biology, vol. 337, pp. 209–225, 2004.; K. Palacio-Rodr ́ıguez, I. Lans, C. N. Cavasotto, and P. Cossio, “Exponential consensus ranking improves the outcome in docking and receptor ensemble docking,” Scientific Reports, vol. 9, pp. 1–14, 2019; C. Ritter, M. Adrian, D. Riek-loher, B. Bohrmann, H. Do, D. Schubert, and R. Riek, “3D structure of Alzheimer’s amyloid-beta(1–42) fibrils,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, pp. 17342–17347, 2005; I. Lans, K. Palacio-Rodr ́ıguez, C. N. Cavasotto, and P. Cossio, “Flexi-pharma: a molecule-ranking strategy for virtual screening using pharmacophores from ligand- free conformational ensembles,” Journal of Computer-Aided Molecular Design, vol. 34, pp. 1063–1077, 2020.; I. Lans, E. Anoz-Carbonell, K. Palacio-Rodr ́ıguez, J. A. A ́ınsa, M. Medina, and P. Cossio, “In silico discovery and biological validation of ligands of fad synthase, a promising new antimicrobial target,” PLOS Computational Biology, vol. 16, p. e1007898, 2020; M. Wieder, A. Garon, U. Perricone, S. Boresch, T. Seidel, A. M. Almerico, and T. Langer, “Common hits approach: Combining pharmacophore modeling and molecular dynamics simulations,” Journal of Chemical Information and Modeling, vol. 57, pp. 365– 385, 2017.; P. H. Reddy, M. Manczak, X. Yin, M. C. Grady, A. Mitchell, R. Kandimalla, and C. S. Kuruva, “Protective effects of a natural product, curcumin, against amyloid induced mitochondrial and synaptic toxicities in alzheimer’s disease,” Journal of Investigative Medicine, vol. 64, pp. 1220–1234, 2016; L. O. Tjernberg, J. N ̈aslundt, F. Lindqvist, J. Johansson, A. R. Karlstr ̈om, J. Thyberg, L. Tereniust, and C. Nordstedt, “Arrest of -amyloid fibril formation by a pentapeptide ligand,” Journal of Biological Chemistry, vol. 271, pp. 8545–8548, 1996.; J. Lakey-Beitia, A. M. Burillo, G. L. Penna, M. L. Hegde, and K. Rao, “Polyphe- nols as potential metal chelation compounds against alzheimer’s disease,” Journal of Alzheimer’s Disease, pp. 1–23, 2020; A. Orjuela, J. Lakey-Beitia, R. Mojica-Flores, M. L. Hegde, I. Lans, J. Alí-Torres, and K. Rao, “Computational evaluation of interaction between curcumin derivatives and amyloid- monomers and fibrils: Relevance to alzheimer’s disease,” Journal of Alzheimer’s Disease, pp. 1–13, 2020; J. Lakey-Beitia, A. A. Durant-Archibold, D. Doens, P. L. Fernandez, and E. Murillo, “Anti-amyloid aggregation activity of novel carotenoids: Implications for alzheimer’s drug discovery,” Clinical Interventions in Aging, vol. 12, pp. 815–822, 2017; J. Lakey-Beitia, J. K. D, and M. L. Hegde, “Carotenoids as novel therapeutic molecules against neurodegenerative disorders : Chemistry and molecular docking analysis,” International Journal of Molecular Sciences, vol. 20, pp. 1–22, 2019; S. Katayama, H. Ogawa, and S. Nakamura, “Apricot carotenoids possess potent anti- amyloidogenic activity in vitro,” Journal of Agricultural and Food Chemistry, vol. 59, pp. 12691–12696, 2011.; D. Hornero-Méndez, R. G.-L. de Guevara, and M. I. Mínguez-Mosquera, “Carotenoid biosynthesis changes in five red pepper (capsicum annuum l.) cultivars during ripening. cultivar selection for breeding,” Journal of Agricultural and Food Chemistry, vol. 48, pp. 3857–3864, 2000; G. Maiani, M. J. Periago Castón, G. Catasta, E. Toti, I. G. Cambrodón, A. Bysted, F. Granado-Lorencio, B. Olmedilla-Alonso, P. Knuthsen, M. Valoti, V. Böhm, E. Mayer-Miebach, D. Behsnilian, and U. Schlemmer, “Carotenoids: Actual knowledge on food sources, intakes, stability and bioavailability and their protective role in humans,” Molecular Nutrition & Food Research, vol. 53, no. S2, pp. S194–S218, 2009; E. Murillo, D. Giuffrida, D. Menchaca, P. Dugo, G. Torre, A. J. Meléndez-Martinez, and L. Mondello, “Native carotenoids composition of some tropical fruits,” Food Che- mistry, vol. 140, pp. 825–836, 2013; J. Lakey-Beitia, V. Vasquez, A. L. F. C. Randy Mojica-Flores and, E. Murillo, M. L. Hegde, and K. S. Rao, “Pouteria sapota (red mamey fruit): Chemistry and biological activity of carotenoids,” Comb Chem High Throughput Screen, vol. 25, pp. 1134–1147, 2022; E. Murillo, R. McLean, G. Britton, A. Agócs, V. Nagy, and J. Deli, “Sapotexanthin, an A-provitamin carotenoid from red mamey (Pouteria sapota).,” J Nat Prod, vol. 74, p. 283–285; M. W. Chang, C. Ayeni, S. Breuer, and B. E. Torbett, “Virtual screening for HIV protease inhibitors : A comparison of AutoDock4 and Vina,” PLoS One, pp. 1–9; A. Alhossary, S. D. Handoko, Y. Mu, and C.-K. Kwoh, “Fast, accurate, and reliable molecular docking with quickvina 2,” Bioinformatics, vol. 31, pp. 2214–2216, 2015; N. M. Hassan, A. A. Alhossary, Y. Mu, and C. K. Kwoh, “Protein-ligand blind docking using quickvina-w with inter-process spatio-temporal integration,” Scientific Reports, vol. 7, pp. 15451–15464, 2017; H. K. Tai, S. A. Jusoh, and S. W. Siu, “Chaos-embedded particle swarm optimization approach for protein-ligand docking and virtual screening,” Journal of Cheminformatics, vol. 10, pp. 1–13, 2018; D. R. Lide, G. Baysinger, L. I. Berger, R. N. Goldberg, H. V. Kehiaian, K. Kuchitsu, D. L. Roth, and D. Zwillinger, CRC Handbook of Chemistry and Physics. CRC Press Inc., 1992; A. Cabort, A. Michel, B. Therrien, H. Stoeckli-Evans, K. Bernauer, G. Suss-Fink, A. F. Williams, and G. Stupka, “Iron, cobalt, nickel and ruthenium complexes of 2,6- bis(3,4-dihydro-2h- pyrrol-5-yl)pyridine, a pybox analogue,” Inorganica Chimica Acta, vol. 350, pp. 193–200, 2003; X. Tao, D. W.Stephan, and P. K. Mascharak, “Synthetic analogue approach to metallobleomycins. 2. synthesis, structure, and properties of the low-spin iron(III) complex of N-(2-(4-imidazolyl)ethyl)pyridine- 2-carboxamide,” J. Inorg. Chem., vol. 26, pp. 755– 759, 1986; S. J. Brown, M. M. Olmstead, and P. K. Mascharak, “Iron(II) and iron(III) complexes of N-(2-(4-imidazolyl)ethyl)pyrimidine-4-carboxamide, a ligand resembling part of the metal-binding domain of bleomycin,” Inorg. Chem, vol. 29, pp. 3229–3234, 1990; D. S. Marlin, M. M. Olmstead, and P. K. Mascharak, “Spin states and stability of Fe(III) complexes of ligands with carboxamido nitrogen and phenolato oxygen donors,” European Journal of inorganic chemistry, pp. 859–865, 2002; R. F. Carina, L. Verzegnassi, G. Bernardinelli, and A. F. Williams, “Modulation of iron reduction potential by deprotonation at a remote site,” Chemical Communications, pp. 2681–2682, 1998; P. V. Bernhardt, P. Comba, T. W. Hamble, and G. A. Lawrance, “Coordination of the sexidentate macrocycle 6,13-dimethyl- 1,4,8,11- tetraazacyclotetradecane-6,13-diamine to iron(III),” J inorg Chem, vol. 30, pp. 942–946, 1991; K. Wieghardt, W. Schmidt, W. Herrmann, and H.-J. Kuppers, “Redox potentials of bis(1,4,7-triazacyclononane) complexes of some first transition series metals(II,III). preparation of bis(1,4,7-triazacyclononane)nickel(III) perchlorate,” J Inorg Chem, vol. 22, pp. 2953–2956, 1983; K. Wieghardt, E. Schoffmann, B. Nuber, and J. Weiss2, “Syntheses, properties, and electrochemistry of transition-metal complexes of the macrocycle 1,4,7- tris(2-pyridylmethyl)-1,4,7-triazacyclononane (L). crystal structures of [NiL](Cl04)2, [MnL](Cl04)2, and [PdL](PF6)2 containing a distorted-square-base-pyramidal pdIIN5 core,” Inorg. Chem, vol. 25, pp. 4877–4883, 1986.; B. P. George, G. I. H. Hanania, and D. H. Irvine, “Potentiometric studies of some dipyridyl complexes,” Journal of chemical society, pp. 2548–2554, 1959.; J. Shearer, H. L. Jackson, D. Schweitzer, D. K. Rittenberg, T. M. Leavy, W. Kaminsky, R. C. Scarrow, and J. A. Kovacs, “The first example of a nitrile hydratase model complex that reversibly binds nitriles,” Journal of the American Chemical Society, vol. 124, pp. 11417–11428, 2002; https://repositorio.unal.edu.co/handle/unal/86226Test; Universidad Nacional de Colombia; Repositorio Institucional Universidad Nacional de Colombia; https://repositorio.unal.edu.coTest/

الإتاحة: https://repositorio.unal.edu.co/handle/unal/86226Test
https://repositorio.unal.edu.coTest/

المؤلفون: Moreno Cristancho, Camilo Ernesto

المساهمون: Godoy Silva, Rubén Darío, Gutierrez Triana, José Arturo, Grupo de Investigación en Procesos Químicos y Bioquímicos, orcid:0000-0002-0402-0530

مصطلحات موضوعية: 570 - Biología::576 - Genética y evolución, 660 - Ingeniería química::668 - Tecnología de otros productos orgánicos, 610 - Medicina y salud::615 - Farmacología y terapéutica, Cadenas J de Inmunoglobulina, eucemia-Linfoma Linfoblástico de Células Precursoras, Resistencia a Antineoplásicos, Immunoglobulin J-Chains, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug Resistance, Neoplasm, Leucemia linfoblástica aguda, Genes pronósticos adversos, CRISPRa, Actividad metabólica, Quimioterapia del cáncer, Acute lymphoblastic leukemia, Adverse prognostic genes, Metabolic activity, Cancer chemotherapy

وصف الملف: xviii, 83 páginas; application/pdf

العلاقة: Bireme; M. J. Gacha Garay, V. Akle, L. Enciso, and Z. V. Garavito Aguilar, “La leucemia linfoblástica aguda y modelos animales alternativos para su estudio en Colombia,” Revista Colombiana de Cancerología, vol. 21, no. 4, pp. 212–224, Oct. 2017, doi:10.1016/j.rccan.2016.10.001.; A. Miranda-Filho, M. Piñeros, J. Ferlay, I. Soerjomataram, A. Monnereau, and F. Bray, “Epidemiological patterns of leukaemia in 184 countries: a population-based study,” Lancet Haematol, vol. 5, no. 1, pp. e14–e24, Jan. 2018, doi:10.1016/S2352-3026(17)30232-6.; N. Cruz-Rodriguez et al., “High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-Acute lymphoblastic leukemia,” Journal of Experimental and Clinical Cancer Research, vol. 35, no. 1, 2016, doi:10.1186/s13046-016-0333-z; Instituto Nacional del Cáncer, “Estadísticas del cáncer,” Instituto Nacional del Cáncer. Accessed: Nov. 03, 2022. [Online]. Available: https://www.cancer.gov/espanol/cancer/naturaleza/estadisticasTest; Organización Mundial de la Salud, “Cáncer,” Organización Mundial de la Salud. Accessed: Nov. 03, 2022. [Online]. Available: https://www.who.int/es/news-room/fact-sheets/detail/cancerTest; International Agency for Research on Cancer, “Leukaemia Globocan 2020,” 2020. Accessed: Nov. 03, 2022. [Online]. Available: https://gco.iarc.fr/today/data/factsheets/cancers/36-Leukaemia-fact-sheet.pdfTest; U. Bacher, A. Kohlmann, and T. Haferlach, “Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies,” Cancer Treatment Reviews, vol. 36, no. 8. pp. 637–646, Dec. 2010. doi:10.1016/j.ctrv.2010.05.002.; C. Allemani et al., “Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2),” The Lancet, vol. 385, no. 9972, pp. 977–1010, Mar. 2015, doi:10.1016/S0140-6736(14)62038-9.; C. A. Gómez-Mercado, A. M. Segura-Cardona, D. E. Pájaro-Cantillo, and M. Mesa-Largo, “Incidencia y determinantes demográficos de la leucemia linfoide aguda en pacientes con cáncer pediátrico, Antioquia.,” Univ Salud, vol. 22, no. 2, pp. 112–119, May 2020, doi:10.22267/rus.202202.182.; M. P. Curado, T. Pontes, E. Guerra-Yi, and M. De Camargo Cancela Cancela, “Leukemia mortality trends among children, adolescents, and young adults in Latin America.” Rev Panam Salud Publica, vol. 29, no. 2, pp.96-102, 2011 Feb doi:10.1590/s1020-49892011000200004.; S. Chiaretti, G. Zini, and R. Bassan, “Diagnosis and subclassification of acute lymphoblastic leukemia,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 6, no. 1. Universita Cattolica del Sacro Cuore, 2014. doi:10.4084/mjhid.2014.073.; D. A. Arber et al., “The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia,” Blood, vol. 127, no. 20. American Society of Hematology, pp. 2391–2405, May 19, 2016. doi:10.1182/blood-2016-03-643544.; X. Zhang, P. Rastogi, B. Shah, and L. Zhang, “B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy,” Oncotarget, vol. 8, no. 39, pp. 66728-66741, Jul 15, 2017. doi:10.18632/oncotarget.19271; N. Cruz-Rodriguez et al., “Prognostic stratification improvement by integrating ID1/ID3/IGJ gene expression signature and immunophenotypic profile in adult patients with B-ALL,” Journal of Experimental and Clinical Cancer Research, vol. 36, no. 1, Feb. 2017, doi:10.1186/s13046-017-0506-4.; C. A. O’Brien et al., “ID1 and ID3 Regulate the Self-Renewal Capacity of Human Colon Cancer-Initiating Cells through p21,” Cancer Cell, vol. 21, no. 6, pp. 777–792, Jun. 2012, doi:10.1016/J.CCR.2012.04.036.; P. Sharma, D. Patel, and J. Chaudhary, “Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B,” Cancer Med, vol. 1, no. 2, pp. 187–197, 2012, doi:10.1002/cam4.19.; C. Roschger and C. Cabrele, “The Id-protein family in developmental and cancer-associated pathways,” Cell Communication and Signaling, vol. 15, no. 1, p. 7, 2017, doi:10.1186/s12964-016-0161-y.; C. Larsson et al., “Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer,” NPJ Breast Cancer, vol. 6, no. 1, Dec. 2020, doi:10.1038/s41523-020-0170-2.; J. Padilla, “Evaluación del efecto de la modulación de la firma génica de mal pronóstico ID1/ID3/IGJ en un modelo celular de LLA-B,” Trabajo de Grado para Optar el Título de Magíster en Microbiología, Universidad Industrial de Santander , Bucaramanga.; C. del P. Villalba Toquica, P. A. Martínez Silva, and H. Acero, “Caracterización clínico-epidemiológica de los pacientes pediátricos con leucemias agudas en la Clínica Universitaria Colombia. Serie de casos 2011-2014,” Pediatria (Bucur), vol. 49, no. 1, pp. 17–22, Jan. 2016, doi:10.1016/j.rcpe.2016.01.002.; A. M. Vera, C. Pardo, M. C. Duarte, and A. Suárez, “Análisis de la mortalidad por leucemia aguda pediátrica en el instituto nacional de cancerología,” Biomedica, vol. 32, no. 3, pp. 355–364, Sep. 2012, doi:10.7705/biomedica.v32i3.691.; A. Wojtuszkiewicz et al., “Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia,” J Hematol Oncol, vol. 8, no. 1, May 2015, doi:10.1186/s13045-015-0158-9.; R. Pieters and M. L. Den Boer, “Molecular Pharmacodynamics in,” Int J Hematol, vol. 78:402-413, 2003, doi: https://doi.org/10.1007/BF02983812Test.; S. Paul, H. Kantarjian, and E. J. Jabbour, “Adult Acute Lymphoblastic Leukemia,” Mayo Clinic Proceedings, vol. 91, no. 11. Elsevier Ltd, pp. 1645–1666, Nov. 01, 2016. doi:10.1016/j.mayocp.2016.09.010.; National Cancer Institute, “Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version,” National Cancer Institute.; A. Gaviria, L. Correa, C. Davila, G. Burgos, and G. Escobar, “Guía de práctica clínica. Para la detección, tratamiento y seguimiento de leucemias linfoblástica y mieloide en población mayor de 18 años. Gobierno de Colombia.,” Instituto Nacional de Cancerologia-ESE Colombia, vol. 34. 2017.; D. Dale, “Recuento elevado de glóbulos blancos (leucocitos),” MANUAL MSD Versión para púplico general. Accessed: Oct. 21, 2022. [Online]. Available: https://www.msdmanuals.com/es-co/hogar/trastornos-de-la-sangre/trastornos-de-los-gl%C3%B3bulos-blancos-leucocitos/trastornos-de-los-bas%C3%B3filosTest; M. Vizcaíno, J. E. Lopera, L. Martínez, I. D. los Reyes, and A. Linares, “Guía de atención integral para la detección oportuna, diagnóstico, tratamiento y seguimiento de leucemia linfoide aguda en niños, niñas y adolescentes,” Revista Colombiana de Cancerología, vol. 20, no. 1, pp. 17–27, Jan. 2016, doi:10.1016/j.rccan.2015.08.003.; A. L. Atienza, “PEDIATRÍA INTEGRAL Leucemias. Leucemia linfoblástica aguda,” Madrid, 2016.; C. Ma et al., “Leukemia-on-a-chip: Dissecting the chemoresistance mechanisms in B cell acute lymphoblastic leukemia bone marrow niche,” 2020. doi: doi:10.1126/sciadv.aba5536.; American Cancer Society, “Tratamiento de la leucemia linfocítica aguda,” American Cancer Society. Accessed: Nov. 10, 2022. [Online]. Available: https://www.cancer.org/content/dam/CRC/PDF/Public/9057.00.pdfTest; C. O. Ramos-Peñafiel et al., “Factores pronósticos de remisión en pacientes con leucemia linfoblástica aguda posterior a primer recaída,” Revista Colombiana de Cancerología, vol. 20, no. 4, pp. 159–166, Oct. 2016, doi:10.1016/j.rccan.2016.11.001.; P. Kaaijk et al., “Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia,” Br J Cancer, vol. 88, no. 5, pp. 775–781, Mar. 2003, doi:10.1038/sj.bjc.6600787.; D. Campana, “Role of Minimal Residual Disease Monitoring in Adult and Pediatric Acute Lymphoblastic Leukemia,” Hematology/Oncology Clinics of North America, vol. 23, no. 5. pp. 1083–1098, Oct. 2009. doi:10.1016/j.hoc.2009.07.010.; H. Inaba and C. H. Pui, “Glucocorticoid use in acute lymphoblastic leukaemia,” The Lancet Oncology, vol. 11, no. 11. pp. 1096–1106, Nov. 2010. doi:10.1016/S1470-2045(10)70114-5.; R. A. Chougule, K. Shah, S. A. Moharram, J. Vallon-Christersson, and J. U. Kazi, “Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation,” NPJ Genom Med, vol. 4, no. 1, p. 7, 2019, doi:10.1038/s41525-019-0082-y.; J. M. Nørgaard, L. H. Olesen, and P. Hokland, “Changing picture of cellular drug resistance in human leukemia,” Critical Reviews in Oncology/Hematology, vol. 50, no. 1. pp. 39–49, Apr. 2004. doi:10.1016/S1040-8428(03)00173-2.; J. Styczynski et al., “Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia,” J Cancer Res Clin Oncol, vol. 133, no. 11, pp. 875–893, 2007, doi:10.1007/s00432-007-0274-1.; A. Sociedad Española de Oncología., C. SPARC (Organization), and M. Echenique Elizondo, Oncología., vol. 29, no. 6. Ediciones Cutor, 2006. Accessed: Jan. 03, 2024. [Online]. Available: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0378-48352006000600003&lng=es&nrm=iso&tlng=esTest.; C. Song, M. Reeves, and M. Mcgrath, “IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity inhigh-risk B-cell acute lymphoblastic leukemia,” Blood, 2021, doi:10.1182/blood.2019002655/1729606/blood.2019002655.pdf.; H. Nishida et al., “CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells,” Biochem Biophys Res Commun, vol. 382, no. 1, pp. 57–62, Apr. 2009, doi:10.1016/J.BBRC.2009.02.123.; M. L. Den Boer et al., “A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study,” Lancet Oncol, vol. 10, no. 2, pp. 125–134, Feb. 2009, doi:10.1016/S1470-2045(08)70339-5.; A. Simons et al., “Microarray-based genomic profiling as a diagnostic tool in acute lymphoblastic leukemia,” Genes Chromosomes Cancer, vol. 50, no. 12, pp. 969–981, Dec. 2011, doi:10.1002/gcc.20919.; C. Song et al., “Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia,” Leukemia, vol. 30, no. 6, pp. 1436–1440, 2016, doi:10.1038/leu.2015.331.; G. M. Charles et al., “JAK mutations in high-risk childhood acute lymphoblastic leukemia,” PNAS, Chicago, Nov. 2009. doi: doi:10.1073/pnas.0811761106.; C. G. Mullighan et al., “ Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia ,” New England Journal of Medicine, vol. 360, no. 5, pp. 470–480, Jan. 2009, doi:10.1056/nejmoa0808253.; R. P. Kuiper et al., “High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression,” Leukemia, vol. 21, no. 6, pp. 1258–1266, 2007, doi:10.1038/sj.leu.2404691.; C. K. Gestrich and K. A. Oduro, “Restricted Immunoglobulin Joining Chain (IgJ) Protein Expression in B Lymphoblastic Leukemia (B-ALL) Based on B-ALL Subtype,” Blood, vol. 136, no. Supplement 1, p. 7, Nov. 2020, doi:10.1182/blood-2020-143201.; O. Cristina and L. Camelo, “‘Estudio piloto para la determinación de la expresión de ID1, ID3 e IGJ en Leucemia Linfoblástica Aguda B a partir de muestras de médula ósea,’” 2020. Accessed: Nov. 10, 2022. [Online]. Available: https://repositorio.unal.edu.co/bitstream/handle/unal/79413/1018417049.2020.pdf?sequence=1&isAllowedTest=y; K. Hoffmann et al., “Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index,” Br J Haematol, vol. 140, no. 6, pp. 656–664, Mar. 2008, doi:10.1111/j.1365-2141.2008.06981.x.; E. E. Max, W. MCBRIDEt, C. C. Morton, and M. Ann Robinson, “Human J chain gene: Chromosomal localization and associated restriction fragment length polymorphisms,” 1986. doi: https://doi.org/10.1073/pnas.83.15.5592Test.; S. Khan et al., “Role of recombinant DNA technology to improve life,” International Journal of Genomics, vol. 2016. Hindawi Publishing Corporation, 2016. doi:10.1155/2016/2405954.; Ameera Alsadeq et al., “The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system,” Haematologica, vol. 102, no. 2, pp. 346–355, Feb. 2017, doi:10.3324/haematol.2016.147744.; L. Debaize et al., “Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation,” Nucleic Acids Res, vol. 46, no. 21, pp. 11214–11228, Nov. 2018, doi:10.1093/nar/gky756.; V. M. Chávez-Jacobo and V. M. Chávez-Jacobo, “El sistema de edición genética CRISPR/Cas y su uso como antimicrobiano específico,” TIP. Revista especializada en ciencias químico-biológicas, vol. 21, no. 2, 2018, doi:10.22201/fesz.23958723e.2018.2.5.; J. A. Doudna and E. Charpentier, “The new frontier of genome engineering with CRISPR-Cas9,” Science (1979), vol. 346, no. 6213, p. 1258096, Nov. 2014, doi:10.1126/science.1258096.; L. S. Qi et al., “Repurposing CRISPR as an RNA-γuided platform for sequence-specific control of gene expression,” Cell, vol. 152, no. 5, pp. 1173–1183, Feb. 2013, doi:10.1016/j.cell.2013.02.022.; G. Clouse, “CRISPR Activators: A Comparison Between dCas9-VP64, SAM, SunTag, VPR, and More!,” Addgene. Accessed: Nov. 10, 2022. [Online]. Available: https://blog.addgene.org/crispr-activators-dcas9-vp64-sam-suntag-vprTest; A. Chavez et al., “Comparison of Cas9 activators in multiple species,” Nat Methods, vol. 13, no. 7, pp. 563–567, 2016, doi:10.1038/nmeth.3871.; S. Sajwan and M. Mannervik, “Gene activation by dCas9-CBP and the SAM system differ in target preference,” Sci Rep, vol. 9, no. 1, p. 18104, 2019, doi:10.1038/s41598-019-54179-x.; C. Hunt et al., “Tissue-specific activation of gene expression by the Synergistic Activation Mediator (SAM) CRISPRa system in mice,” Nat Commun, vol. 12, no. 1, p. 2770, 2021, doi:10.1038/s41467-021-22932-4.; E. M. Czekanska, “Assessment of Cell Proliferation with Resazurin-Based Fluorescent Dye,” in Mammalian Cell Viability: Methods and Protocols, M. J. Stoddart, Ed., Totowa, NJ: Humana Press, 2011, pp. 27–32. doi:10.1007/978-1-61779-108-6_5.; A. R. Fernie, F. Carrari, and L. J. Sweetlove, “Respiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport,” Curr Opin Plant Biol, vol. 7, no. 3, pp. 254–261, Jun. 2004, doi:10.1016/J.PBI.2004.03.007.; S. Kamiloglu, G. Sari, T. Ozdal, and E. Capanoglu, “Guidelines for cell viability assays,” Food Front, vol. 1, no. 3, pp. 332–349, Sep. 2020, doi:10.1002/fft2.44.; A. Y. Chang, V. W. Chau, J. A. Landas, and Yvonne, “Preparation of calcium competent Escherichia coli and heat-shock transformation,” Vancouver, Jun. 2017.; P. Thomas and T. G. Smart, “HEK293 cell line: A vehicle for the expression of recombinant proteins,” J Pharmacol Toxicol Methods, vol. 51, no. 3, pp. 187–200, May 2005, doi:10.1016/J.VASCN.2004.08.014.; M. Jordan and F. M. Wurm, “Co-transfer of multiple plasmids/viruses as an attractive method to introduce several genes in mammalian cells,” New Comprehensive Biochemistry, vol. 38, pp. 337–348, Jan. 2003, doi:10.1016/S0167-7306(03)38020-2.; W. Xu, H. Chang, C. K. Qin, and Y. P. Zhai, “Impact of co-transfection with livin and survivin shRNA expression vectors on biological behavior of HepG2 cells,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 9, pp. 5467–5472, 2013, doi:10.7314/APJCP.2013.14.9.5467.; A. J. Heidersbach, K. M. Dorighi, J. A. Gomez, A. M. Jacobi, and B. Haley, “A versatile, high-efficiency platform for CRISPR-based gene activation,” Nat Commun, vol. 14, no. 1, p. 902, 2023, doi:10.1038/s41467-023-36452-w.; F. Cardarelli et al., “The intracellular trafficking mechanism of Lipofectamine-based transfection reagents and its implication for gene delivery,” Sci Rep, vol. 6, no. 1, p. 25879, 2016, doi:10.1038/srep25879.; H. Bai, G. M. S. Lester, L. C. Petishnok, and D. A. Dean, “Cytoplasmic transport and nuclear import of plasmid DNA,” Bioscience Reports, vol. 37, no. 6. Portland Press Ltd, Dec. 22, 2017. doi:10.1042/BSR20160616.; M. Aluigi et al., “Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone Marrow–Derived Mesenchymal Stem Cells,” Stem Cells, vol. 24, no. 2, pp. 454–461, Feb. 2006, doi:10.1634/stemcells.2005-0198.; N. Iversen, B. Birkenes, K. Torsdalen, and S. Djurovic, “Electroporation by nucleofector is the best nonviral transfection technique in human endothelial and smooth muscle cells,” Genet Vaccines Ther, vol. 3, no. 1, p. 2, 2005, doi:10.1186/1479-0556-3-2.; R. Ren et al., “Nucleic acid direct delivery to fibroblasts: a review of nucleofection and applications,” J Biol Eng, vol. 16, no. 1, p. 30, 2022, doi:10.1186/s13036-022-00309-5.; C. Maucksch, B. Connor, and C. Rudolph, “Plasmid DNA Concatemers: Influence of Plasmid Structure on Transfection Efficiency,” in Minicircle and Miniplasmid DNA Vectors, 2013, pp. 59–69. doi: https://doi.org/10.1002/9783527670420.ch5Test.; H. Bruns et al., “A novel immunoregulatory function of beta-2-microglobulin as a promoter of myeloid derived suppressor cell induction,” Leukemia, vol. 33, no. 5, pp. 1282–1287, 2019, doi:10.1038/s41375-018-0345-0.; J. E. Miller et al., “Design of Beta-2 Microglobulin Adsorbent Protein Nanoparticles,” Biomolecules, vol. 13, no. 7, Jul. 2023, doi:10.3390/biom13071122.; M. Yagi and M. E. Koshland, “Expression of the J chain gene during B cell differentiation is inversely correlated with DNA methylation,” 1981. doi: https://doi.org/10.1073/pnas.78.8.4907Test.; C. D. Castro and M. F. Flajnik, “Putting J Chain Back on the Map: How Might Its Expression Define Plasma Cell Development?,” The Journal of Immunology, vol. 193, no. 7, pp. 3248–3255, Oct. 2014, doi:10.4049/jimmunol.1400531.; J. Y. Kim, S. K. Park, H. G. Kim, S. J. Cho, J. Kim, and C. J. Kang, “The HSS3/4 enhancer of Crlz1-IgJ locus is another target of EBF in the pre-B cell stage of B cell development,” Immunol Lett, vol. 107, no. 1, pp. 63–70, Sep. 2006, doi:10.1016/J.IMLET.2006.07.007.; J. H. Lim, H. G. Kim, S. K. Park, and C. J. Kang, “The Promoter of the Immunoglobulin J Chain Gene Receives Its Authentic Enhancer Activity through the Abutting MEF2 and PU.1 Sites in a DNA-Looping Interaction,” J Mol Biol, vol. 390, no. 3, pp. 339–352, Jul. 2009, doi:10.1016/J.JMB.2009.05.040.; Z. X. Chong, S. K. Yeap, and W. Y. Ho, “Transfection types, methods and strategies: A technical review,” PeerJ, vol. 9. PeerJ Inc., Apr. 21, 2021. doi:10.7717/peerj.11165.; M. E. Hystad et al., “Characterization of Early Stages of Human B Cell Development by Gene Expression Profiling,” The Journal of Immunology, vol. 179, no. 6, pp. 3662–3671, Sep. 2007, doi:10.4049/jimmunol.179.6.3662.; J. J. Wallin, J. L. Rinkenberger, S. Rao, E. R. Gackstetter, M. E. Koshland, and P. Zwollo, “B cell-specific activator protein prevents two activator factors from binding to the immunoglobulin J chain promoter until the antigen-driven stages of B cell development,” Journal of Biological Chemistry, vol. 274, no. 22, pp. 15959–15965, May 1999, doi:10.1074/jbc.274.22.15959.; W. E. Stansfield et al., “The Pathophysiology of Cardiac Hypertrophy and Heart Failure,” Cellular and Molecular Pathobiology of Cardiovascular Disease, pp. 51–78, Jan. 2014, doi:10.1016/B978-0-12-405206-2.00004-1.; S. L. Nutt, C. Thévenin, and M. Busslinger, “Essential Functions of Pax-5 (BSAP) in pro-B Cell Development,” Immunobiology, vol. 198, no. 1–3, pp. 227–235, Dec. 1997, doi:10.1016/S0171-2985(97)80043-5.; M. Wang, Y. Wu, X. Li, M. Dai, and S. Li, “IGJ suppresses breast cancer growth and metastasis by inhibiting EMT via the NF κB signaling pathway,” Int J Oncol, vol. 63, no. 3, Sep. 2023, doi:10.3892/ijo.2023.5553.; B. Sprangers, L. Cosmai, and C. Porta, “Conventional chemotherapy,” Onco-Nephrology, pp. 127-153.e11, Jan. 2020, doi:10.1016/B978-0-323-54945-5.00025-4.; Y. Cao et al., “Cyr61 decreases Cytarabine chemosensitivity in acute lymphoblastic leukemia cells via NF-κB pathway activation,” Int J Mol Med, vol. 43, no. 2, pp. 1011–1020, Feb. 2019, doi:10.3892/ijmm.2018.4018.; C. F. Thorn et al., “Doxorubicin pathways: Pharmacodynamics and adverse effects,” Pharmacogenet Genomics, vol. 21, no. 7, pp. 440–446, 2011, doi:10.1097/FPC.0b013e32833ffb56.; Y. Yang, W. Dai, Y. Sun, and Z. Zhao, “Long non coding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K/Akt/mTOR pathway in acute myeloid leukaemia cells,” Oncol Rep, vol. 41, no. 4, pp. 2311–2320, Apr. 2019, doi:10.3892/or.2019.6991.; T. T. T. Vo et al., “mTORC1 inhibition induces resistance to methotrexate and 6-mercaptopurine in Ph+ and Ph-like B-ALL,” Mol Cancer Ther, vol. 16, no. 9, pp. 1942–1953, Sep. 2017, doi:10.1158/1535-7163.MCT-17-0024.; https://repositorio.unal.edu.co/handle/unal/86219Test; Universidad Nacional de Colombia; Repositorio Institucional Universidad Nacional de Colombia; https://repositorio.unal.edu.coTest/

الإتاحة: https://doi.org/10.1016/j.rccan.2016.10.00110.1016/S2352-3026Test(17)30232-610.1186/s13046-016-0333-z10.1016/j.ctrv.2010.05.00210.1016/S0140-6736(14)62038-910.22267/rus.202202.18210.1590/s1020-4989201100020000410.4084/mjhid.2014.07310.1182/blood-2016-03-64354410.18632/oncotarget.1927110.1186/s13046-017-0506-410.1016/J.CCR.2012.04.03610.1002/cam4.1910.1186/s12964-016-0161-y10.1038/s41523-020-0170-210.1016/j.rcpe.2016.01.00210.7705/biomedica.v32i3.69110.1186/s13045-015-0158-910.1007/BF0298381210.1016/j.mayocp.2016.09.01010.1016/j.rccan.2015.08.00310.1126/sciadv.aba553610.1016/j.rccan.2016.11.00110.1038/sj.bjc.660078710.1016/j.hoc.2009.07.01010.1016/S1470-2045(10)70114-510.1038/s41525-019-0082-y10.1016/S1040-8428(03)00173-210.1007/s00432-007-0274-110.1182/blood.2019002655/1729606/blood.2019002655.pdf10.1016/J.BBRC.2009.02.12310.1016/S1470-2045(08)70339-510.1002/gcc.2091910.1038/leu.2015.33110.1073/pnas.081176110610.1056/nejmoa080825310.1038/sj.leu.240469110.1182/blood-2020-14320110.1111/j.1365-2141.2008.06981.x10.1073/pnas.83.15.559210.1155/2016/240595410.3324/haematol.2016.14774410.1093/nar/gky75610.22201/fesz.23958723e.2018.2.510.1126/science.125809610.1016/j.cell.2013.02.02210.1038/nmeth.387110.1038/s41598-019-54179-x10.1038/s41467-021-22932-410.1007/978-1-61779-108-6_510.1016/J.PBI.2004.03.00710.1002/fft2.4410.1016/J.VASCN.2004.08.01410.1016/S0167-7306(03)38020-210.7314/APJCP.2013.14.9.546710.1038/s41467-023-36452-w10.1038/srep2587910.1042/BSR2016061610.1634/stemcells.2005-019810.1186/1479-0556-3-210.1186/s13036-022-00309-510.1002/9783527670420.ch510.1038/s41375-018-0345-010.3390/biom1307112210.1073/pnas.78.8.490710.1016/J.IMLET.2006.07.00710.1016/J.JMB.2009.05.04010.7717/peerj.1116510.4049/jimmunol.179.6.366210.1074/jbc.274.22.1595910.1016/B978-0-12-405206-2.00004-110.1016/S0171-2985(97)80043-510.3892/ijo.2023.555310.1016/B978-0-323-54945-5.00025-410.3892/ijmm.2018.401810.1097/FPC.0b013e32833ffb5610.3892/or.2019.699110.1158/1535-7163.MCT-17-0024
https://repositorio.unal.edu.co/handle/unal/86219Test
https://repositorio.unal.edu.coTest/

المؤلفون: Medellin Olaya, Judith

المساهمون: Gómez Ramírez, Olga Janeth, Cuidado y Práctica en Enfermería, Salud Familiar Enfermería Familiar y Medicion en Salud, orcid:0000-0003-1198-8555, https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000002199Test

مصطلحات موضوعية: 610 - Medicina y salud::615 - Farmacología y terapéutica, Insuficiencia Renal Crónica/enfermería, Automanejo/métodos, Cumplimiento y Adherencia al Tratamiento/estadística & datos numéricos, Renal Insufficiency, Chronic/nursing, Self-Management/methods, Treatment Adherence and Compliance/statistics & numerical data, Enfermedad Renal Crónica, Automanejo, Adherencia, Autoeficacia, Cuidado de Enfermería, Chronic Kidney Disease, Self-management, Adherence, Self-efficacy, Nursing care

وصف الملف: 164 páginas; application/pdf

العلاقة: Bireme; Lopera Medina MM. La enfermedad renal crónica en Colombia: necesidades en salud y respuesta del Sistema General de Seguridad Social en Salud. Rev Gerenc Polít Salud [Internet]. 2016 [cited 2019 Apr 19];15(3):212–33. Available from: http://www.scielo.org.co/pdf/rgps/v15n30/v15n30a15.pdfTest; Fondo Colombiano de Enfermedades de Alto Costo. Situación de la Enfermedad Renal Crónica en Colombia [Internet]. Cuenta de Alto Costo (CAC), editor. Bogotá, D.C.; 2019. Available from: https://cuentadealtocosto.org/site/publicaciones/situacion-erc-hip-art-dmell-colTest/; Zimbudzi E, Lo C, Misso ML, Ranasinha S, Kerr PG, Teede HJ, et al. Effectiveness of self-management support interventions for people with comorbid diabetes and chronic kidney disease: A systematic review and meta-analysis. Syst Rev [Internet]. 2018;7(1). Available from: https://doi.org/10.1186/s13643-018-0748-zTest; Lee MC, Wu SFV, Hsieh NC, Tsai JM. Self-Management Programs on eGFR, Depression, and Quality of Life among Patients with Chronic Kidney Disease: A Meta-Analysis. Asian Nurs Res (Korean Soc Nurs Sci) [Internet]. 2016;10(4):255–62. Available from: http://dx.doi.org/10.1016/j.anr.2016.04.002Test; Lin MY, Liu MF, Hsu LF, Tsai PS. Effects of self-management on chronic kidney disease: A meta-analysis. Int J Nurs Stud [Internet]. 2017 [cited 2019 May 11];74(October 2016):128–37. Available from: https://pubmed.ncbi.nlm.nih.gov/28689160Test/; Havas K, Douglas C, Bonner A. Meeting patients where they are: improving outcomes in early chronic kidney disease with tailored self-management support (the CKD-SMS study). BMC Nephrol [Internet]. 2018 [cited 2019 Oct 5];19:279–92. Available from: https://doi.org/10.1186/s12882-018-1075-2Test; Nieves-Ruiz ER, Ríos-Siordia JM, Oblea-Valdés M, García-Hernández A. Detection of patients susceptible to chronic kidney disease by the family medicine specialist nurse in preventive healthcare service. Rev Enferm Inst Mex Seguro Soc [Internet]. 2017 [cited 2019 Apr 16];25(4):265–70. Available from: https://www.medigraphic.com/pdfs/enfermeriaimss/eim-2017/eim174d.pdfTest; Welch JL, Johnson M, Zimmerman L, Russell CL, Perkins SM, Decker BS. Self-Management Interventions in Stages 1-4 Chronic Kidney Disease: An integrative Review. West J Nurs Res [Internet]. 2015 [cited 2019 Oct 19];37(5):652–78. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364922Test/; Gorostidi M, Santamaría R, Alcázar R, Fernández-Fresnedo G, Galcerán JM. Documento de la Sociedad Española de Nefrología sobre las guías KDIGO para la evaluación y el tratamiento de la enfermedad renal crónica. 2014;302–16.; Fondo Colombiano de Enfermedades de Alto Costo. Situación de la Enfermedad Renal Crónica, la Hipertensión Arterial y la Diabetes Mellitus en Colombia 2022 [Internet]. Vol. 1, Cuenta de Alto Costo (CAC). Bogotá, D.C.; 2022. 90–6 p. Available from: https://cuentadealtocosto.org/wp-content/uploads/2023/10/final-libro-erc-2022-2.pdfTest; Levey AS, Coresh J. Clinical Practice Guidelines K/DOQI [Internet]. New York; 2002 [cited 2019 Nov 24]. Available from: https://www.kidney.org/sites/default/files/docs/ckd_evaluation_classification_stratification.pdfTest; Ministerio de salud y protección social. Resolución 2626 de 2019. Colombia; 2019. p. 1–17.; Havas K, Bonner A, Douglas C. Self-management support for people with chronic kidney disease: Patient perspectives. J Ren Care. 2016;42(1):7–14.; Donald M, Kahlon BK, Beanlands H, Straus S, Ronksley P, Herrington G, et al. Self-management interventions for adults with chronic kidney disease: a scoping review. BMJ Open. 2018;8:19814.; Dwarswaard J, Bakker EJM, van Staa A, Boeije HR. Self-management support from the perspective of patients with a chronic condition: A thematic synthesis of qualitative studies. Health Expectations. 2016;19(2):194–208.; Lopez-Vargas PA, Tong A, Howell M, Craig JC. Educational Interventions for Patients With CKD: A Systematic Review. American Journal of Kidney Diseases [Internet]. 2016;68(3):353–70. Available from: http://dx.doi.org/10.1053/j.ajkd.2016.01.022Test; Peñarrieta MI, Flores-Barrios F, Gutiérrez-Gómez T, Piñones -Martínez S, Resendiz -Gonzalez E, María Quintero-Valle L. Self-management and family support in chronic diseases. J Nurs Educ Pract. 2015;5(11).; León-Hernándeza RC, Peñarrieta-de Córdovab M, Gutiérrez-Gómez T, Banda-Gonzálezd O, Flores-Barriose F, Rivera MC. Self-management behavior predictors among persons with chronic diseases in Tamaulipas. Enfermería Universitaria. 2019;16(2):128–37.; Ponce P, López-Orozco CF, Reyes GEB, Lopez-Caudana E, Parra NM, Molina A. Use of Robotic Platforms as a Tool to Support STEM and Physical Education in Developed Countries: A Descriptive Analysis. Sensors [Internet]. 2022;22(3). Available from: https://doi.org/10.3390Test/ s22031037; Peng S, He J, Huang J, Lun L, Zeng J, Zeng S, et al. Self-management interventions for chronic kidney disease: A systematic review and meta-analysis. BMC Nephrol. 2019;20(1):1–13.; Blakeman T, Blickem C, Kennedy A, Reeves D, Bower P, Gaffney H, et al. Effect of Information and Telephone-Guided Access to Community Support for People with Chronic Kidney Disease: Randomised Controlled Trial. PLoS ONE 9 [Internet]. 2014 [cited 2019 Oct 21];10(e109135.):1–15. Available from: www.plosone.org; GILLIS BP, CAGGIULA AW, CHIAVACCI AT, COYNE T, DOROSHENKO L, MILAS NC, et al. Nutrition Intervention Program of the Modification of Diet in Renal Disease Study. A Self-Management Approach. Vol. 95, Journal of the American Dietetic Association. 1995. p. 1288–94.; Devins GM, Mendelssohn DC, Barré PE, Binik YM. Predialysis psychoeducational intervention and coping styles influence time to dialysis in chronic kidney disease. American Journal of Kidney Diseases. 2003;42(4):693–703.; Devins GM, Mendelssohn DC, Barré PE, Taub K, Binik YM. Predialysis psychoeducational intervention extends survival in CKD: A 20-year follow-up. American Journal of Kidney Diseases. 2005;46(6):1088–98.; Chen SH, Tsai YF, Sun CY, Wu IW, Lee CC, Wu MS. The impact of self-management support on the progression of chronic kidney disease - A prospective randomized controlled trial. Nephrology Dialysis Transplantation. 2011;26(11):3560–6.; Flesher M, Woo P, Chiu A, Charlebois A, Warburton DER, Leslie B. Self-Management and Biomedical Outcomes of a Cooking, and Exercise Program for Patients with Chronic Kidney Disease. Journal of Renal Nutrition [Internet]. 2011;21(2):188–95. Available from: http://dx.doi.org/10.1053/j.jrn.2010.03.009Test; Williams A, Manias E, Walker R, Gorelik A. A multifactorial intervention to improve blood pressure control in co-existing diabetes and kidney disease: A feasibility randomized controlled trial. J Adv Nurs. 2012;68(11):2515–25.; Williams A, Manias E, Liew D, Gock H, Gorelik A. Working with CALD groups: Testing the feasibility of an intervention to improve medication selfmanagement in people with kidney disease, diabetes, and cardiovascular disease. Renal Society of Australasia Journal. 2012;8(2):62–9.; De Brito-Ashurst I, Perry L, Sanders TAB, Thomas JE, Dobbie H, Varagunam M, et al. The role of salt intake and salt sensitivity in the management of hypertension in South Asian people with chronic kidney disease: a randomised controlled trial. Heart [Internet]. 2013 [cited 2020 Jun 20];99:1256–60. Available from: http://dx.doi.org/10.1136Test/; McManus RJ, Mant J, Haque MS, Bray EP, Bryan S, Greenfield SM, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: The TASMIN-SR randomized clinical trial. JAMA - Journal of the American Medical Association. 2014;312(8):799–808.; Park J, Lyles RH, Bauer-Wu S. Mindfulness meditation lowers muscle sympathetic nerve activity and blood pressure in African-American males with chronic kidney disease. Am J Physiol Regul Integr Comp Physiol. 2014;307(1):93–101.; Howden EJ, Coombes JS, Strand H, Douglas B, Campbell KL, Isbel NM. Exercise training in CKD: Efficacy, adherence, and safety. American Journal of Kidney Diseases [Internet]. 2015;65(4):583–91. Available from: http://dx.doi.org/10.1053/j.ajkd.2014.09.017Test; Leehey DJ, Collins E, Kramer HJ, Cooper C, Butler J, McBurney C, et al. Structured exercise in obese diabetic patients with chronic kidney disease: A randomized controlled trial. Am J Nephrol. 2016;44(1):54–62.; Timmerman GM, Tahir MJ, Lewis RM, Samoson D, Temple H, Forman MR. Self-management of dietary intake using mindful eating to improve dietary intake for individuals with early stage chronic kidney disease. J Behav Med [Internet]. 2017;40(5):702–11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996381Test/; Sorait W. The association of self-efficacy and self-management behavior in adult patients with chronic kidney disease: an integrative review. Journal of Kidney Treatment and Diagnosis [Internet]. 2018 Jun 17 [cited 2020 Jul 3];1(1). Available from: https://www.pulsus.com/scholarly-articles/the-association-of-selfefficacy-and-selfmanagement-behavior-in-adult-patients-with-chronic-kidney-disease-an-integrative-review-4587.htmlTest; Tung HH, Lien RY, Wei J, Clinciu DL, Lee JY, Huang HC. The role of adherence in the relationship between self-efficacy and self-management in diabetic patients undergoing CABG in Taiwan. Heart Asia [Internet]. 2014 [cited 2020 Jul 3];4(1):114–9. Available from: /pmc/articles/PMC4832621/?report=abstract; Zhong X, Tanasugarn C, Fisher EB, Krudsood S, Nityasuddhi D. Awareness and practices of self-management and influence factors among individuals with type 2 diabetes in urban community settings in Anhui province, China. Southeast Asian Journal of Tropical Medicine and Public Health [Internet]. 2011;42(1):184–96. Available from: https://pubmed.ncbi.nlm.nih.gov/21323182Test/; Havas K, Douglas C, Bonner A. Person-centred care in chronic kidney disease: a cross-sectional study of patients’ desires for self-management support. BMC Nephrol [Internet]. 2017;18(1):1–9. Available from: http://dx.doi.org/10.1186/s12882-016-0416-2Test; Wembenyui CF. Examining knowledge and self-management of chronic kidney disease in a primary health care setting: Validation of two instruments [Internet] [Thesis degree of Master of Philosophy]. [Queensland]: Queensland University of Technology; 2017 [cited 2020 Jul 3]. Available from: https://eprints.qut.edu.au/114078Test/; Holman H, Lorig K. Patient Self-Management: A Key to Effectiveness and Efficiency in Care of Chronic Disease. Public Health Reports. 2004;119(3):239–43.; Lorig KR, Holman HR. Self-management education: History, definition, outcomes, and mechanisms. Annals of Behavioral Medicine. 2003;26(1):1–7.; De Boer IH, Kovesdy CP, Navaneethan SD, Peralta CA, Tuot DS, Vazquez MA, et al. Pragmatic clinical trials in CKD: Opportunities and challenges. Journal of the American Society of Nephrology. 2016;27(10):2948–54.; Bueno Robles LS. Aspectos Ontológicos Y Epistemológicos De Las Visiones De Enfermería Inmersas En El Quehacer Profesional. Ciencia y enfermería. 2011;17(1):37–43.; Smith MC. Regenerating Nursing’s Disciplinary Perspective. Advances in Nursing Science [Internet]. 2019;42(1):3–16. Available from: https://journals.lww.com/advancesinnursingscience/abstract/2019/01000/regenerating_nursing_s_disciplinary_perspective.3.aspxTest; OPS/OMS. Oficina Regional para las Américas de la Organización Mundial de la Salud. 2015 [cited 2019 Nov 23]. La OPS/OMS y la Sociedad Latinoamericana de Nefrología llaman a prevenir la enfermedad renal y a mejorar el acceso al tratamiento. Available from: https://www.paho.org/hq/index.php?option=com_content&view=article&id=10542:2015-opsoms-sociedad-latinoamericana-nefrologia-enfermedad-renal-mejorar-tratamiento&Itemid=1926&lang=esTest; Ángel Ángel ZE, Duque Castaño GA, Tovar Cortes DL. Cuidados de enfermería en el paciente con enfermedad renal crónica en hemodiálisis: una revisión sistemática. Enfermería Nefrológica. 2016;19(3):202–13.; Eknoyan G, Lameire N. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Vol. 3, Official Journal of the international Society of nephrology. 2013.; Ministerio de Salud y Protección Social. Guía de Práctica Clínica para el diagnóstico y tratamiento de la Enfermedad Renal Crónica (adopción) Sistema General de Seguridad Social en Salud – Colombia. 2016.; Ministerio de Sanidad Servicios Sociales e Igualdad. Documento marco sobre enfermedad renal crónica (ERC) dentro de la estrategia de abordaje a la cronicidad en el SNS. España; 2015.; Paredes MCL, Asensio De La Cruz O, Cortell Aznar I, Carrasco MCM, Barrio Gómez De Agüero MI, Pérez Ruiz E, et al. Fundamentos de la oxigenoterapia en situaciones agudas y cro´nicas: indicaciones, me´todos, controles y seguimiento. An Pediatr (Engl Ed). 2009;71(2):161–74.; Kazawa K, Moriyama M. Effects of a Self-Management Skills-Acquisition Program on Pre-Dialysis Patients with Diabetic Nephropathy. Nephrology Nursing Journal. 2013;40(2).; Tsay SL, Hung LO. Empowerment of patients with end-stage renal disease - A randomized controlled trial. Int J Nurs Stud. 2004;41(1):59–65.; Daker-White G, Rogers A, Kennedy A, Blakeman T, Blickem C, Chew-Graham C. Non-disclosure of chronic kidney disease in primary care and the limits of instrumental rationality in chronic illness self-management. Soc Sci Med. 2015 Apr 1;131:31–9.; Lin CC, Wu CC, Anderson RM, Chang CS, Chang SC, Hwang SJ, et al. The chronic kidney disease self-efficacy (CKD-SE) instrument: Development and psychometric evaluation. Nephrology Dialysis Transplantation. 2012;27(10):3828–34.; Donald M, Beanlands H, Straus S, Ronksley P, Tam-Tham H, Finlay J, et al. Identifying Needs for Self-management Interventions for Adults With CKD and Their Caregivers: A Qualitative Study. American Journal of Kidney Diseases. 2019;1–9.; Luyckx VA, Tonelli M, Stanifer JW. OMS %7C La carga global de la insuficiencia renal y los objetivos de desarrollo sostenible. WHO. World Health Organization; 2018. (96). Report No.: 6.; Bandura A. Self-efficacy: Toward a Unifying Theory of Behavioral Change. Vol. 84, Psychological Review. 1977.; Resnick B, Luisi D, Vogel A. Testing the Senior Exercise Self-efficacy Project (SESEP) for use with Urban dwelling minority older adults. Public Health Nurs. 2008;25(3):221–34.; Zimbudzi E, Lo C, Kerr PG, Zoungas S. A need-based approach to self-management education for adults with co-morbid diabetes and chronic kidney disease. [cited 2020 Jun 11]; Available from: https://doi.org/10.1186/s12882-019-1296-zTest; Zimbudzi E, Lo C, Misso M, Ranasinha S, Zoungas S. Effectiveness of management models for facilitating self-management and patient outcomes in adults with diabetes and chronic kidney disease. 2015; Donald M, Kahlon BK, Beanlands H, Straus S, Ronksley P, Herrington G, et al. Self-management interventions for adults with chronic kidney disease: a scoping review. BMJ Open [Internet]. 2018 [cited 2019 Sep 28];8:19814. Available from: https://bmjopen.bmj.com/content/8/3/e019814Test; Dilla T, Valladares A, Lizán L, Sacristán JA. Treatment adherence and persistence: Causes, consequences and improvement strategies. Aten Primaria. 2009;41(6):342–8.; Soria Trujano R, Vega Valero CZ, Nava Quiroz C. Escala de adherencia terapéutica para pacientes con enfermedades crónicas, basada en comportamientos explícitos. Alternativas en Psicología [Internet]. 2009 [cited 2020 Jun 13];14(20):89–103. Available from: http://pepsic.bvsalud.org/scielo.php?script=sci_arttext&pid=S1405-339X2009000100008&lng=pt&nrm=iso&tlng=esTest; Padilla JL, Acosta B, Guevara M, Gómez J, González A. Propiedades psicométricas de la versión española de la escala de autoeficacia general aplicada en Méxco y España. Revista Mexicana de Psicología [Internet]. 2006 [cited 2021 Apr 24];23(2):245–52. Available from: http://www.redalyc.org/articulo.oa?id=243020649010Test; Olivari Medina C, Urra Medina E. Autoeficacia y Conductas de Salud. Ciencia y Enfermería. 2007;III(1):9–15.; Schunk DH, DiBenedetto MK. Motivation and social cognitive theory. Contemp Educ Psychol [Internet]. 2020;60(December 2019):101832. Available from: https://doi.org/10.1016/j.cedpsych.2019.101832Test; Smith MJ, Liehr PR. Middle range theory for nursing. Third Edit. Michael O, editor. New York: Springer Publishing Company, LLC; 2014. 1–487 p.; Sritarapipat P, Pothiban L, Panuthai S, Lumlertgul D, Nanasilp P. Causal Model of Elderly Thais’ Self-Management Behaviors of Pre-dialysis Chronic Kidney Disease. Pacific Rim Int J Nurs Res. 2012;16(164):277–93.; Chen YC, Chang LC, Liu CY, Ho YF, Weng SC, Tsai TI. The Roles of Social Support and Health Literacy in Self-Management Among Patients With Chronic Kidney Disease. Journal of Nursing Scholarship. 2018 May 1;50(3):265–75.; Ministerio de la Protección Social. Resolución No. 2565 de 2007. 2007.; Ministerio de la Protección Social, Ministerio de Hacienda y Crédito Público. Resolución 5394 de 2009. 2009.; Ministerio de Salud y Protección Social, Salud SN de. Circular No. 038 de 2016. 2016.; Sidani S. Principles of outcome measurement and analysis. In Health intervention research. SAGE Publications Ltd. 55 City Road, London: SAGE Publications Ltd; 2015. 197–211 p.; American Nephrology Nurses Association [Internet]. 2019 [cited 2020 Apr 11]. Available from: https://www.annanurse.org/download/reference/association/strategicPlan.pdfTest; Bruce 2011. El automanejo en personas con enfermedades crónicas: el caso de México y Perú. Vol. 53, Journal of Chemical Information and Modeling. 2013.; Johnson ML, Zimmerman L, Welch JL, Hertzog M, Pozehl B, Plumb T. Patient activation with knowledge, self-management and confidence in chronic kidney disease. J Ren Care. 2016;42(1):15–22.; Kao YH, Huang YC, Chen PY, Wang KM. The effects of exercise education intervention on the exercise behaviour, depression, and fatigue status of chronic kidney disease patients. Health Educ. 2012;112(6):472–84.; Bartlett Ellis RJ, Welch JL, Ellis B. Medication-taking Behaviors in CKD with Multiple Chronic Conditions: A meta-ethnographic synthesis of qualitative studies.; Murali S, Arab L, Vargas R, Rastogi A, Ang A, Shetty N. Internet-Based Tools to Assess Diet and Provide Feedback in Chronic Kidney Disease Stage IV: A Pilot Study. Journal of Renal Nutrition. 2013;23(2):e33–42.; Vann JCJ, Hawley J, Wegner S, Falk RJ, Harward DH, Kshirsagar A V. Nursing Intervention Aimed at Improving Self-Managementfor Persons with Chronic Kidney Disease in North Carolina Medicaid: A Pilot Project. Nephrol Nurs J. 2015;42(3):239–56.; Byrne J, Khunti K, Stone M, Farooqi A, Carr S. Feasibility of a structured group education session to improve self-management of blood pressure in people with chronic kidney disease: an open randomised pilot trial. BMJ open accesible medical research [Internet]. 2011 [cited 2019 Oct 22];1(e000381.):1–8. Available from: http://bmjopen.bmj.comTest/; Choi ES, Lee J. Effects of a Face-to-face Self-management Program on Knowledge, Self-care Practice and Kidney Function in Patients with Chronic Kidney Disease before the Renal Replacement Therapy. J Korean Acad Nurs. 2012;42(7):1070.; Forero Villalobos Doctor Ramón Rubio J, Ciprés Rengo E, Forero Villalobos J, Barrios Araya S, Revisión A DE. Nursing role in predialysis visit in patients with advanced chronic kidney disease.; Bardón Otero E, Marti Monros A, Vila Paz ML. Enfermería en la consulta de enfermedad renal crónica avanzada (ERCA). Nefrología. 2008;3:53–6.; Ibarra O, Ramón B, Verdugo M. Lo que debes saber sobre la Adherencia al tratamiento. 2017.; Reyes-Flores E, Trejo-Alvarez R, Arguijo-Abrego S, Jímenez-Gómez A, Castillo-Castro A, Hernández-Silva A, et al. Therapeutic adherence: concepts, determinants and new strategies. Vol. 84, REV MED HONDUR. 2016.; Rodriguez Cladero MC. Adherencia terapéutica al estilo de vida saludable en personas con diabetes tipo 2 de Castilla y León en el ámbito de la atención primaria. Universidad Miguel Hernández de Elche; 2015.; Dilla T, Valladares A, Lizán L, Sacristán JA. Adherencia y persistencia terapéutica: causas, consecuencias y estrategias de mejora. Aten Primaria. 2009;41(6):342–8.; Periz DA, Antonio J, Guerrero S, Périz DA. Farmacoterapia en la Enfermedad Renal. Adherencia terapéutica. BMC Nephrol. 2017;18:42.; Ha Dinh TT, Bonner A, Clark R, Ramsbotham J, Hines S. The effectiveness of the teach-back method on adherence and self-management in health education for people with chronic disease: a systematic review. JBI Database System Rev Implement Rep. 2016;14(1):210–47.; Saturni S, Bellini F, Braido F, Paggiaro P, Sanduzzi A, Scichilone N, et al. Randomized controlled trials and real life studies. Approaches and methodologies: A clinical point of view. Pulm Pharmacol Ther. 2014;27(2):129–38.; Lam Díaz RM, Hernández Ramírez P. Los términos: eficiencia, eficacia y efectividad ¿son sinónimos en el área de la salud? Rev Cubana Hematol Inmunol Hemoter. 2008;24(2).; Tristán-López a. Modificación al modelo de Lawshe para el dictamen cuantitativo de la validez de contenido de un instrumento objetivo. Avances en medición. 2008;6:37–48.; Lloret-Segura S, Ferreres-Traver A, Hernández-Baeza A, Tomás-Marco I. El análisis factorial exploratorio de los ítems : una guía práctica , revisada y actualizada Introducción Determinación de la adecuación del Análisis. Anales De Psicología. 2014;30(3):1151–69.; Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the reporting of pragmatic trials: An extension of the CONSORT statement. Bmj [Internet]. 2008;337(7680):1223–6. Available from: https://www.bmj.com/content/337/bmj.a2390Test; Hernandez Sampieri R, Fernández Collado C, Baptista M del P. Metodología de la Investigación. Sexta edic. Bogotá: Mc Graw Hill Education; 2014. 1–589 p.; Higgins J [Ed], Green S [Ed]. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. The Cochrane Collaboration. 2011. 1–639 p. Available from: www.cochrane-handbook.org; Gaitán Duarte HG, Rojas Reyes MX, Feliciano-Alfonso J. Búsqueda, evaluación y síntesis de la evidencia de efectividad y seguridad en evaluaciones de tecnología : Manual metodológico [Internet]. Banco Interamericano de Desarrollo; 2017. 110 p. Available from: https://publications.iadb.org/es/busqueda-evaluacionTest-y-sintesis-de-la-evidencia-de-efectividad-y-seguridad-en-evaluaciones-de; Consejo Superior Universitario. Acuerdo 035. Colombia: Universidad Nacional de Colombia; 2012.; Meneses J. Introducción al análisis multivariante [Internet]. Primera. Universidad de Catalunya, editor. Barcelona: FUOC; 2019. 1–52 p. Available from: https://femrecerca.cat/meneses/publication/introduccion-analisis-multivariante/introduccion-analisis-multivariante.pdfTest; Ministerio de Salud. Resolución Número 8430 de 1993. República de Colombia; 1993.; Colombia C de. Ley 911 De 2004. LEY 911 DE 2004 (octubre 5) Diario Oficial No 45693 de 6 de octubre de 2004. 2004;15.; Duque D. Consideraciones para la promoción de la conducta responsable en ciencia, tecnología e innovación. Bogotá, Colombia: Departamento Administrativo de Ciencia, Tecnología e Innovación –Colciencias; 2017. 43 p.; Cobos-Carbó A, Augustovski F. Declaración CONSORT 2010: actualización de la lista de comprobación para informar ensayos clínicos aleatorizados de grupos paralelos. Med Clin (Barc) [Internet]. 2011;137(5):213–5. Available from: https://www.elsevier.es/es-revistaTest-medicina-clinica-2-articulo-declaracion-consort-2010-actualizacion-lista-S0025775310009899; Tripepi G, Chesnaye NC, Dekker FW, Zoccali C, Jager KJ. Intention to treat and per protocol analysis in clinical trials. Nephrology [Internet]. 2020;25(7):513–7. Available from: https://pubmed.ncbi.nlm.nih.gov/32147926Test/; Guía-Yanes MA. Enfermería: evolución, arte, disciplina, ciencia y profesión. Revista Vive [Internet]. 2019;2(4):33–41. Available from: https://doi.org/10.33996/revistavive.v2i4.22Test; Triviño Vargas ZG. Enfermería como ciencia disciplina - profesión y práctica. In: Guerrero Arango L, Gallego Cortes L, Triviño Vargas Z, editors. Fundamentos en los procesos básicos de los cuidados de enfermería Tomo I [Internet]. Cali - Colombia: Editorial Universidad Santiago de Cali; 2017. p. 21–35. Available from: orcid:0000-0001-6968-9334; Cabal E VE, Guarnizo T M. Nursing as a discipline. Revista Colombiana de Enfermería [Internet]. 2016;6:73–81. Available from: https://doi.org/10.18270/rce.v6i6.1436Test; Blanco Balbeito N, Betancourt Roque Y. La enfermería: ciencia constituida. Revista Eugenio Espejo [Internet]. 2021 Jun 1 [cited 2023 Dec 7];15(2):3–5. Available from: https://www.redalyc.org/articulo.oa?id=572866949002Test; Haugan G, Eriksson M. Health Promotion in Health Care – Vital Theories and Research [Internet]. Department of Public Health and Nursing NTNU Norwegian University of Science and Technology, editor. Vol. 38, Springer. Norway; 2023. 852–852 p. Available from: https://doi.org/10.1007/978-3-030-63135-2%0ATest©; Manjarres-Posada NI, Onofre-Rodríguez DJ, Benavides-Torres RA. Social Cognitive Theory and Health Care: Analysis and Evaluation. Int J Soc Sci Stud. 2020;8(4):132.; Thojampa S, Sarnkhaowkhom C. The Social Cognitive Theory with Diabetes: Discussion. Int J Caring Sci [Internet]. 2019;12(2):1–4. Available from: www.internationaljournalofcaringsciences.org; Lin CC, Tsai FM, Lin HS, Hwang SJ, Chen HC. Effects of a self-management program on patients with early-stage chronic kidney disease: A pilot study. Applied Nursing Research [Internet]. 2013;26(3):151–6. Available from: http://dx.doi.org/10.1016/j.apnr.2013.01.002Test; Carroll DL, Robinson E, Buselli E, Berry D, Rankin SH. Activities of the APN to enhance unpartnered elders self-efficacy after myocardial infarction. Clin Nurse Spec. 2001;15(2):60–6.; Savioni L, Triberti S. Cognitive Biases in Chronic Illness and Their Impact on Patients’ Commitment. Front Psychol. 2020;11(October):1–6.; Belil FE, Alhani F, Ebadi A, Kazemnejad A. Self-efficacy of people with chronic conditions: A qualitative directed content analysis. J Clin Med. 2018;7(11).; Jang Y, Yoo H. Self-management programs based on the social cognitive theory for Koreans with chronic diseases: A systematic review. Contemp Nurse. 2012;40(2):147–59.; Cueto-Manzano AM, Martínez-Ramírez HR, Cortés-Sanabria L. Management of chronic kidney disease: Primary health-care setting, self-care and multidisciplinary approach. Clin Nephrol. 2010;74(SUPPL.1):99–104.; Meleis AI. THEORETICAL NURSING: DEVELOPMENT AND PROGRESS. 5th Editio. Vol. 53, Journal of Chemical Information and Modeling. Pennsylvania: Wolters Kluwer, Lippincott Williams & Wilkins; 2013. 1689–1699 p.; Martínez-Castelao A, Górriz JL, Bover J, Segura-De La Morena J, Cebollada J, Escalada J, et al. Documento de consenso para la detección y manejo de la enfermedad renal crónica. Revista Nefrología [Internet]. 2014 [cited 2019 Nov 3];34(2):243–62. Available from: http://www.revistanefrologia.comTest; Suarilah I, Lin CC. Factors influencing self-management among Indonesian patients with early-stage chronic kidney disease: A cross-sectional study. J Clin Nurs. 2022;31(5–6):703–15.; Joboshi H, Oka M, Takahashi S, Onbe H, Hara Y, Murase C, et al. Efects of the EASE Program in Chronic Kidney Disease Education: A Randomized Controlled Trial to Evaluate Self-Management. J Jpn Acad Nurs Sci [Internet]. 2012;32(1):21–9. Available from: https://www.jstage.jst.go.jp/article/jans/32/1/32_1_1_21/_articleTest; Zheng J, Jing YJ, Guo AH, Wu SY, Liu R, Zhai LJ. Effect of New Nursing Team Management Mode on Self-Efficacy, Compliance, and Quality of Life of Patients with Chronic Kidney Disease and Its Chain Mediating Effect. Contrast Media Mol Imaging. 2022;2022.; Blickem C, Blakeman T, Kennedy A, Bower P, Reeves D, Gardner C, et al. The clinical and cost-effectiveness of the BRinging Information and Guided Help Together (BRIGHT) intervention for the self-management support of people with stage 3 chronic kidney disease in primary care: study protocol for a randomized controlled trial. Trials [Internet]. 2013;14(1):1. Available from: Trials; Lin MY, Cheng SF, Hou WH, Lin PC, Chen CM, Tsai PS. Mechanisms and Effects of Health Coaching in Patients With Early-Stage Chronic Kidney Disease: A Randomized Controlled Trial. Journal of Nursing Scholarship. 2021;53(2):154–60.; Mega Noviana C, Zahra AN. Social support and self-management among end-stage renal disease patients undergoing hemodialysis in Indonesia. Vol. 11, Journal of Public Health Research. 2022.; Dinh TTH, Bonner A. Exploring the relationships between health literacy, social support, self-efficacy and self-management in adults with multiple chronic diseases. BMC Health Serv Res. 2023 Dec 1;23(1).; Paes-Barreto JG, Barreto Silva MI, Qureshi AR, Bregman R, Cervante VF, Carrero JJ, et al. Can Renal Nutrition Education Improve Adherence to a Low-Protein Diet in Patients With Stages 3 to 5 Chronic Kidney Disease? Journal of Renal Nutrition. 2013 May;23(3):164–71.; Matteson ML, Russell C. Interventions to improve hemodialysis adherence: A systematic review of randomized-controlled trials. Hemodialysis International. 2010 Oct;14(4):370–82.; Novak M, Costantini L, Schneider S, Beanlands H. Approaches to Self-Management in Chronic Illness. Semin Dial. 2013 Mar;26(2):188–94.; Peek K, Carey M, Mackenzie L, Sanson-Fisher R. Characteristics associated with high levels of patient-reported adherence to self-management strategies prescribed by physiotherapists. Int J Ther Rehabil. 2020 Jan 2;27(1):1–15.; Wierdsma JM, van Zuilen A, van der Bijl J. Self-efficacy and long-term medication use in patients with chronic kidney disease. J Ren Care. 2011;37(3):158–66.; León Hernández RC, Arriaga Martínez JL, Rodríguez Pérez AC, Peñarrieta de Córdova MI, Cosme Mendoza MF, Vejarano Campos G. Resultados de “Tomando Control de su Salud” online, en personas con enfermedades no transmisibles de México y Perú durante COVID-19. Horiz Enferm [Internet]. 2023 Dec 6 [cited 2024 Apr 29];(NE). Available from: https://ojs.uc.cl/index.php/RHE/article/view/67067/56075Test; Peñarrieta De Córdova MI, Leon R, Gutierrez T, Mier N, Banda O, Delabra M. Effectiveness of a chronic disease self-management program in Mexico: A randomized controlled study. Journal ofNursing Education and Practice. 2017;7(7):87–94.; Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 2011;13(2):217–24.; Ford I, Norrie J. Pragmatic Trials. New England Journal of Medicine. 2016;375(5):454–63.; Gitlin LN, Czaja SJ. Behavioral Intervention Research: Designing, Evaluating, and Implementing [Internet]. Sheri W. Sussman, editor. New York: Springer Publishing Company, LLC; 2016 [cited 2024 Jan 15]. 1–524 p. Available from: https://connect.springerpub.com/content/book/978-0-8261-2659-7Test; De Boer IH, Kovesdy CP, Navaneethan SD, Peralta CA, Tuot DS, Vazquez MA, et al. Pragmatic clinical trials in CKD: Opportunities and challenges. Journal of the American Society of Nephrology [Internet]. 2016;27(10):2948–54. Available from: https://doi.org/10.1681/ASN.2015111264Test; Grisales Romero H. Usos y limitaciones de los métodos de análisis multivariados en la Investigación epidemiológica. Investigaciones Andina [Internet]. 2006 [cited 2024 Jan 15];8(13):81–4. Available from: http://www.redalyc.org/articulo.oa?id=239017515007Test; de Arenaza DP. Multivariate Analysis. Vol. 52, Acta Gastroenterologica Latinoamericana. Sociedad Argentina de Gastroenterologia; 2022. p. 115–9.; Bonner A, Gillespie K, Campbell KL, Corones-Watkins K, Hayes B, Harvie B, et al. Evaluating the prevalence and opportunity for technology use in chronic kidney disease patients: A cross-sectional study. BMC Nephrol. 2018;19(1):4–11.; Smith SR, Rublein JC, Marcus C, Brock TP, Chesney MA. A medication self-management program to improve adherence to HIV therapy regimens. Patient Educ Couns [Internet]. 2003 [cited 2023 Jan 28];50:187–99. Available from: https://pubmed.ncbi.nlm.nih.gov/12781934Test/; Schunk DH, Zimmerman B. Handbook of Self-Regulation of Learning and Performance [Internet]. Taylor & Francis, editor. 2011 [cited 2023 May 1]. 1–500 p. Available from: https://books.google.com.co/books/about/Handbook_of_Self_Regulation_of_Learning.html?id=XfOYV0lwzGgC&redir_escTest=y; https://repositorio.unal.edu.co/handle/unal/86193Test; Universidad Nacional de Colombia; Repositorio Institucional Universidad Nacional de Colombia; https://repositorio.unal.edu.coTest/

الإتاحة: https://doi.org/10.1186/s13643-018-0748-z10.1016/j.anr.2016.04.00210.1186/s12882-018-1075-210.1053/j.ajkd.2016.01.02210.1053/j.jrn.2010.03.00910.1053/j.ajkd.2014.09.01710.1186/s12882-016-0416-210.1186/s12882-019-1296-z10.1016/j.cedpsych.2019.10183210.33996/revistavive.v2i4.2210.18270/rce.v6i6.143610.1007/978-3-030-63135-2%0A10.1016/j.apnr.2013.01.00210.1681/ASN.2015111264Test
https://repositorio.unal.edu.co/handle/unal/86193Test
https://repositorio.unal.edu.coTest/